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Steroids are a class of important polycyclic compounds which exhibit diverse biological 
activities. Except for the naturally occurring substances, most of steroidal pharmaceuticals 
are semi-synthetic compounds. It is proved that a number of biologically important properties 
of modified steroids are dependent upon structural features of the steroid ring system or side 
chain so this chemical modification of the steroid skeleton provides a way to alter the 
functional groups and numerous structure-activity relationships have been established by 
such synthetic alterations. 
Steroids have always attracted considerable attention in bio-organic research because 
of being a fundamental class of biologically active molecules. Their profound physiological 
and clinical importance is now well validated. They can regulate a variety of biological 
processes and thus have the potential to act as drugs for the treatment of a number of diseases 
including cardiovascular, autoimmune, brain tumour, breast cancer, prostate cancer and 
osteoarthritis. The diversity in the biological action might be due to the presence of different 
functional groups located around the tetracyclic core which serve as substrates for different 
targets. The advantage of employing hydrophobic steroid units is their ability to interact with 
cell membranes and thus pave the way for biological activity of such hybrid molecules. 
Previous work from our laboratory described the synthesis of number of unknown steroidal 
derivatives in the cholestane series. These include azasteroids, oxasteroids, thiadiazoles, 
oxadiazolines, pyrrolidine, pyrazolines etc. 
In continuation of the above work, an attempt has been made to synthesize new 
heterosteroids with probable biological activities like antimicrobial, anticancer, antioxidant 
and simultaneously study their DNA binding behavior. The newly synthesized heterosteroids 
have been characterized by IR, 'H NMR, 13C NMR, MS and analytical data. In some cases, 
abnormal products have been obtained and this has offered scope for some mechanistic and 
stereochemical studies also. The whole work of the thesis is divided into five chapters 
namely, 
Chapter I Synthesis of steroidal pyrimidines 
Chapter 2 • Synthesis of steroidal pyrans 
Chapter 3 Synthesis of steroidal pyrazoles and pyrazolones 
Chapter 4 Synthesis of steroidal benzothiazines and thiazoles 
Chapter 5 Biological activity (antimicrobial, anticancer and 
antioxidant) and DNA binding studies of newly 
synthesized heterosteroids 
Chapter 1 
Synthesis of steroidal pyrimidines 1,2 
Pyrimidine moiety containing molecules have been reported to exhibit a broad spectrum of 
biological activities such as anticancer, antiviral, antibacterial, antioxidant, anxiolytic, etc. As 
far as literature is concerned, little attention has been paid to the synthesis of steroidal based 
pyrimidine derivatives. This prompted us to carry out the synthesis of some steroidal 
pyrimidines and with this aim two series of reactions were carried out. First series involves 
the reactions of 5a-cholestan-6-one thiosemicarbazone (I), 3fl-acetoxy-5a-cholestan-6-one 
thiosemicarbazone (II) and 3/3-chloro-5a-cholestan 6-one thiosemicarbazone (III) with 
diethyl malonate to yield [4', 6'-dioxo-2'-thioxo-lH-pyrimidin-1-yl] 6-imino-5a-cholestane 
(IV), 3,6-acetoxy [4', 6'-dioxo-2'-thioxo-1H-pyrimidin-1-yl] 6-imino-5a-cholestane (V) and 
3fl-chloro[4', 6'-dioxo-2'-thioxo-1H-pyrimidin-1-yl] 6-imino-5a-cholestane (VI), respectively 
while as the second series includes reactions of 5a-cholestan-6-one thiosemicarbazone and its 
analogues (I-III) with ethyl cyanoacetate to provide [6'-amino-2'-thioxo-4'-oxo dihydro-lH-
pyrimidin-1-yl] 6-imino-5a-cholestane (VII), 3/3-acetoxy [6'-amino-2'-thioxo-4'-oxo dihydro-
1H-pyrunidin-1-yl] 6-imino-5a-cholestane (VIII) and 3fl-chloro [6'-amino-2'-thioxo-4'-oxo 
dihydro-lH-pyrimidin-1-yl] 6-imino-5a-cholestane (IX), respectively. 
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1. Shamsuzzaman, Ayaz Mahmood Dar, Z. Yaseen, K. Alain, A. Hussain, M. A. Gatoo, 
Steroidal pyrimidines: Synthesis, characterization, molecular docking studies with DNA and in vitro 
cytotoxicity. Journal of Mokcular Structure 1045 (2013) 62-71 
2. Shamsuzzaman, Ayaz Mahmood Dar, S. Tabassum, M. Zaki, Y. Khan, A. Sohail, M. A. Gatoo 
DNA binding, docking studies, artificial nuclease activity and in vitro cytotoxicity of newly synthesized 
steroidal 1H-pyrimidines. Comptes Rendus Chinile http:l/dx.doi.org/10.10161j.crei.2013.07.001 (in press) 
Chapter 2 
Synthesis of steroidal pyrans 3'  4 
Pyran derivatives represent an important class of organic compounds with wide number of 
applications. They are not only used in cosmetics, pigments and biological agrochemicals but 
also constitute a structural unit of many natural products. These compounds have been 
reported to possess various pharmacological activities such as antiallergic, antitumor and 
antibacterial. The diversity in the biological action might be due to the presence of different 
functional moieties located around the pyran core which serve as substrates for different 
targets. Keeping this in consideration, the synthesis of some steroidal 4H-pyrans has been 
carried out and with this aim two series of reactions were done. First series involves the 
reactions of cholest-5-en-7-one (X), 3fl-acetoxycholest-5-en-7-one (XI) and 3fl-chlorocholest-
5-en-7-one (XII) with ethyl cyanoacetate to yield 2'-amino-3'-carboethoxycholest-6-eno [5, 
7- d e] 4H-pyran (XIII), 3/3-acetoxy-2'-amino-3'-carboethoxycholest-6-eno [5, 7 - d e] 4H-
pyran (XIV) and 3fl-chloro-2'-amino-3'-carboethoxycholest-6-eno [5, 7 - d e] 4H -pyran (XV) 
while as the second series includes reactions of cholest-5-en-7-one and its analogues (X-XII) 
with malononitrile to provide 2'-amino-3'-cyanocholest-6-eno [5, 7 - d e] 4H-pyran (XVI), 3l-
acetoxy-2'-amino-3'-cyanocholest-6-eno [5, 7 - d el 4H-pyran (XVII) and 3/3-chloro-2'-amino 
-3'-cyanocholest-6-eno [5, 7 - d e] 4H-pyran (XVIII), respectively. 
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Chapter 3 
Synthesis of steroidal pyrazoles and pyrazolones 5,6 
Pyrazoles have played a vital role in the development of theory in heterocyclic chemistry and 
are also used extensively as useful synthons in organic synthesis. Pyrazole derivatives also 
show number of biological activities like antimicrobial, anticancer, antioxidant, analgesic, 
anti-inflammatory, antipyretic, etc. This prompted us to carry out the synthesis of some of the 
steroidal pyrazoles and with this aim two series of reactions were done. First series involves 
the reactions of 5a-cholestan-6-ore thiosemicarbazone (I), 3fl-acetoxy-5a-cholestan-6-one 
thiosemicarbazone (II) and 3/J-chloro-5a-cholestan-6-one thiosemicarbazone (III) with 
phosphorus oxychloride and acetamide to yield 5a-cholestano [6, 7- c] 5'-methyl-l'-carbo-
thioic acid amido pyrazole (XIX), 3f-acetoxy-5a-cholestano [6, 7 - c] 5'-methyl-1'-carbo-
thioic acid amido pyrazole (XX) and 3Q-chloro-5a-cholestano [6, 7 - c] 5'-methyl-1'-carbo 
thioic acid amido pyrazole (XXI), respectively while as second series includes the reactions 
of 5a-cholestan-6-one (XXII), 3fl-acetoxy-5a-cholestan-6-one (XXIII) and 3f-chloro-5a-
cholestan-6-one (XXIV) with cyanoacetohydrazide to yield cholest-6 [5'-amino-l', 2'-dihydro 
pyrazol-3-one-1'-yl] 5-ene (XXV), 3/l-acetoxycholest-6 [5'-amino-1', 2'-dihydropyrazol-3-one 
-l'-yl] 5-ene (XXVI) and 3fl-chlorocholest-6 [5'-amino-l', 2'-dihydropyrazol-3-one-1'-yl] 5-
ene (XXVII), respectively_ 
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5. Shamsuzzaman, Ayaz Mahmood Dar, S. Shervani, I. Bhat, M. A. Gatoo, Structural, optical and 
antimicrobial studies of 3fl-acetoxycholest-5-ene, 3fl-acetoxy-6-nitrocholest-5-ene and newly synthesized 
steroidal pyrazolones. J.  Taibah University for Science httpJ/dx.doi.org/l0.10161j.jtusci.2013.08.003, 
(in press) Elsevier 
6. Shamsuzzaman, Ayaz Mahmood Dar, 1. A. Bhat, Y. Khan, DNA binding studies and in vitro cytotoxicity of 
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Chapter 4 
Synthesis of steroidal benzothiazines and thiazoles 7,8 
Benzothiazines represent an important class of compounds in medicinal chemistry because 
the presence of nitrogen-sulphur axis is one of the features responsible for their biological 
activity; hence they show bioactivities like anticancer, vasorelaxant, antidiabetic, 
antihypertensive, antimicrobial, etc. On the other hand, thiazole derivatives have also 
attracted continuing interest over the years because of their varied biological activities. They 
have been reported as antiallergic, antihypertensive, anti-inflammatory, antischizophrenic, 
antibacterial, anti-HIV, hypnotics and selective COX-2 inhibitors, fibrinogen receptor 
antagonists with antithrombotic activity and new inhibitors of bacterial DNA gyrase B. With 
this enthusiasm, an attempt for the synthesis of these compounds was made and hence two 
series of reactions were carried out. First series involves the one pot synthesis of 5a-
cholestano [5, 6 - b] benzothiazine (XXVIII), 3/l-acetoxy-5a-cholestano [5, 6 - b] 
benzothiazine (XXIX) and 3fl-chloro-5a-cholestano [5, 6 - b] benzothiazine (XXX) by 
reacting 5a-cholestan-6-one and its analogues (XXII-XXIV) with iodine/ 2-aminothiophenol 
while as the second series involves the one pot synthesis of 2'-hydrazinocholest-6-eno [4, 5 -
d] thiazole (XXXI), 3f3-acetoxy-2'-hydrazinocholest-6-eno [4, 5 - ci] thiazole (XXXII) and 
313-chloro-2'-hydrazinocholest-6-eno [4, 5 - d] thiazole (XXXIII) by reacting 5a-cholestan-6-
one and its analogues (XXII-XXIV) with iodine/ thiosemicarbazide. 
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7. Shamsuzzaman, Ayaz Mahmood Dar, H. Khanam, M. A. Gatoo, Anticancer and antimicrobial evaluation of 
newly synthesized steroidal 5, 6 fused benzothiazines. Arabian Journal of Chemistry httpa/dx.doi.org/10.10 
16 /j.arabjc.2013.06.027, in press 
8. Shamsuzzaman, Ayaz Mahmood Dar, H. Khanam, M. A. Gatoo, Synthesis, Characterization and In Vitro 
Anticancer Activity of Newly Synthesized Steroidal 6, 7-Fused Thiazoles. Journa! of Chemistry (Accepted) 
(2013) 
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Chapter 5 
Biological activities (antimicrobial, anticancer and antioxidant) and DNA 
binding studies of newly synthesized heterosteroids 
Antimicrobial activity 
In antimicrobial screening, the newly synthesized steroidal compounds showed moderate to 
potential behavior against different bacterial as well as fungal strains. During antimicrobial 
testing of steroidal pyrimidines (IV-VI), compound IV was found to be almost equally active 
as compared to the standard drug, Griseofulvin against Candida albicans. In case of screening 
of steroidal pyrans (XIII-XV) and steroidal pyrazolones (XXV-XXVII)5 against different 
microbial strains, the activity of the compound XIII and XXVI was found to be almost same 
as the standard drugs, Ciprofloxacin and Chloramphenicol, respectively against the 
Streptococcus pyogenes. When steroidal benzothiazines (XXVIII-XXX)7 were allowed to 
undergo the antimicrobial screening, all the three compounds showed moderate to good 
antibacterial activity but the compound XXVIII showed influential zone of inhibition i.e. 
19.4 mm against the E-coli strain which is almost equal to the inhibition zone of 
Chloramphenicol i.e. 20.0 mm against the same strain. 
Anticancer activity 
During in vitro anticancer screening of steroidal pyrimidines (IV-VI), compound IV and V 
showed effective IC50 against A545, A549, HeLa and HepG2 cell lines hence showed 
potential cytotoxicity. In comet assay, compound V revealed maximum DNA damage against 
MCF7 cells_ The nucleolytic experiment showed that reactive oxygen species ROS ('OH) are 
responsible for cell death.' In case of cytotoxicity assay of steroidal pyrimidines (VII-IX), 
compound VIII and IX showed IC50 against A549, HeLa, HepG2 and A545 cell lines close to 
that of Cisplatin, hence also show endowed cytotoxicity. Compound VIII allowed maximum 
DNA degradation in comet assay.2 
During the cytotoxic screening of steroidal pyrans (XIII-XV), IC50 for XIII against 
HeLa and MCF7 was found to be 13.73 p.mol L' and 11.18 µmol L' in comparison with 
Doxorubicin (IC50 = 11.53 gmol L 1 and 12.41 µmol L'), respectively. Hence these 
compounds also have cytotoxic potency and thus presented maximum DNA damage against 
MCF7 cells in the comet assay. The nucleolytic experiments showed that ROS ('OH) are 
responsible for cell death.3 During the cytotoxic screening of steroidal pyrans (XVI-XVIII), 
VI 
compound XVII was found to be potentially cytotoxic with its IC5o against MCF7 found to be 
13.21 pmol L' (close to the IC50 of Doxorubicin 12.41 µcool L) and hence presented 
maximum DNA degradation of MCF7 cells in comet assay. Microscopic examination of 
cancer cells and compound XVXI-treated cancer cells also showed the inhibition of growth by 
compound XVII.4 
In case of the in vitro cytotoxic screening of steroidal pyrazoles (XIX-XXI), 
compounds XX and XXI showed potential cytotoxicity against SW480, HL-60 and MCF-7 
cell lines by showing IC5o close to that ofDoxorubicin. Compound XXI showed IC50 same as 
that of Doxorubicin against HL-60 cell line. Microscopic examination of cancer cells and 
compound XX and XXI-treated cancer cells showed the cytotoxic nature of these compounds. 
In comet assay, compound XX presented higher DNA damage against MCF7 cells.6 
} 
	
	 During the cytotoxic screening of steroidal benzothiazines (XXVIII-XXX), compound 
XXVIII showed effective IC50 =13.73 pmol L' against HeLa cell line. Compounds XXIX 
and XXX also showed minimum ICso of 15.83 }cmol L 1 (HepG2) and 16.89 µmol L' 
(A549), respectively.7 When the steroidal thiazoles (XXXI-XXXIII) were screened for the in 
vitro cytotoxicity, compound XXXII was found to be active against SW480, A549, HepG2, 
HeLa and HL-60 cells in comparison with the standard drug, Cisplatin.8 
Antioxidant activity 
2, 2-Diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging assay of new heterosteroids was 
studied during which the steroidal pyrimidines (IV-VI) exhibited potential antioxidant 
activity. DPPH assay of the steroidal pyrans (XIII-XV) was also carried out which showed 
that compounds were not significantly active. During the hydrogen peroxide (H202) 
scavenging assay, steroidal pyrazolones (XVI-XVIII) showed significantly active antioxidant 
behavior. When the nitric oxide radical scavenging assay of steroidal thiazoles (XXXI-
XXXIII) was carried out, all the compounds showed potential nitric oxide radical scavenging 
behavior. 
DNA binding studies 
The DNA-binding studies included gel electrophoresis, W-vis absorption and fluorescence 
spectroscopy and molecular docking technique. The binding constants (Kb) for the steroidal 
pyrimidines (IV-IX) were found to be 4.63 x 10"3 NT', 2.12 x 10-3 Nf', 2.43 x 10-3 Mf', 9.34 
x 103 M-', 6.56 x 103 M"' and 1.54 x 104 M'', respectively. It was found that the absorption 
intensity in the compounds (IV-IX) increased with gradual addition of DNA and hence 
vii 
showed hyperchromism, revealing the fact of exposure of more bases of DNA which is the 
indication of strong binding of compounds to CT DNA.'' 2 
The binding constants (Kb) for the steroidal pyrans XIV and XV were found to be 
5.3 x 103 and 3.7 x 103 M-' and for the steroidal pyrans (XVI-XVIII) Kb was found to be 2.2 
x 103 M-', 5.37 x 103 M' and 2.51 x 103 M, respectively. The absorption spectra of these 
compounds also revealed strong hyperchromism implying their higher DNA binding 
propensity which results in partial uncoiling of DNA helix structure, exposing more bases of 
DNA which is the indication of strong binding of compounds to CT DNA.3' 4 
The gel electrophoresis also revealed the interaction of these compounds with DNA 
by showing the disappearance of the original band of DNA in gel plate. In molecular docking 
study, it was found that these type of compounds interacted with DNA through major as well 
as minor groove and their hetereocyclic moiety (pyrimidine or pyran) shows electrostatic 
interaction between the nucleotide base pairs of DNA.'4  
OR 
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Steroids are a group of chemical substances which are found abundant in nature and show 
wide range of characteristics. They include cholesterol, sex hormones, adrenal cortex 
hormones, bile salts, oestrogens, vitamin-D, sapogenin and some other important metabolites. 
These steroids have a close association or rather indispensable for various physiological 
phenomena of the living world thus making themselves the focus of attention in the field of 
organic chemistry. The incentive feature of steroids is that they can be easily synthesized in 
the laboratory on a large scale. The wide implication of these compounds and their 
association with life has made the field of steroids as an important research area. The 
discovery of testosterone which showed marked biological properties is the most striking 
feature of this field. Scientists diverted their attention towards the steroids and the work on 
isolation as well as on synthesis started with great enthusiasm. Thereafter, researchers 
1 	diversified their efforts to evaluate the structural and stereochernical problems of steroidal 
skeleton because the stereochemistry is the primary factor responsible for the physiological 
activity of the steroids. Later on the structure elucidation and the reaction mechanism of the 
steroids became a matter of immense importance. 
The fusion of any heterocyclic ring system to steroid core or to introduce any hetero 
atom such as sulfur, oxygen, nitrogen or any of the halogen group members, was found to 
augment the biological and industrial revolution. Hence, innumerable methods started 
developing across the world to fmd the better substitutes for already existing steroids. As a.  
matter of fact, steroid chemistry has always proved to be much inviting to chemists and 
industries and also fascinated us to undertake the work in the field. Our laboratory is mainly 
concerned with the synthesis of steroidal compounds and their identification by chemical and 
spectral studies, has reported the preparation of a number of heterosteroids. 
In the present work an attempt has been made to synthesize some modified steroids of 
biological interest like pyrimidines, pyrans, pyrazoles, pyrazolones, benzothiazines and 
thiazoles. First chapter is dealing with the synthesis of steroidal pyrimidines, second chapter 
is concerned with synthesis of steroidal pyrans, third chapter is attributed to the synthesis of 
steroidal pyrazoles and pyrazotones while as the fourth chapter is associated with the 
synthesis of steroidal benzothiazines and thiazoles. The fifth chapter is concerned with the 
biological activities (antimicrobial, anticancer and antioxidant) and DNA binding studies of 
these newly synthesized heterosteroid compounds. 
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Pyrimidine or 1, 3-diazine (1) is a 6-membered aromatic heterocycle with two nitrogen atoms 
in the ring at 1, 3-positions.' It may be regarded as being derived from benzene by the 
replacement of two meta "CH" groups by "N". The pyrimidine ring system has wide 
occurrence in nature as substituted and fused ring derivatives, Iike the nucleotides, thiamine 
and alloxan (2).' It is also found in many synthetic compounds such as barbiturates and the 
HIV drug, zidovudine. 
0 
	
N 	 HNNH 
L) O o 
N 	 O 
(1) (2) 
Although pyrimidine derivatives such as uric acid and alloxan were known in the early 
19th century, a laboratory synthesis of a pyrimidine was not carried out until 1879,2 when 
Grimaux3 reported the preparation of barbituric acid (3) from urea and malonic acid in the 
presence of phosphorus oxychloride. 
0 	~; 0 
NH2 
HO 	OH 
0 
POC13 	HN 	NH 
_ H2O 0" 
0 
(3) 
The systematic study of pyrimidines began in 1884 with Pinner4 who synthesized 3, 5-
dimethyl-5H-pyrazin-2-one (4) by condensing ethyl acetoacetate with acetamidine. Pinner5 
first proposed the name "pyrimidin" in 1885 which later got modified as "pyrimidine". 
O p 	NH 
+ 	NH,  
0 
w3C 	N ------~ 	~~INJJJ 
CH3 
(4) 
Gabriel and Colman in 1900 reported the conversion of barbituric acid (3) into 
trichloropyrimidine (5) by POC13. The compound (5) upon selective reduction yielded 
dichloropyrimidine (6). 
:i: 	cl (3) 	CI ~~ \ Zu dust N C1 	N 	C1 
Cl 
(5) 	(6) 
2 
t 
Benhard7 reported the reaction of ethyl acetoacetate with urea that yielded a 
pyrimidine derivative (4-methyluracil) (7). 
0 O 	 CH3  
per\ + 	
f'.oOLOH 
N 
H2N NH,
HO N 
(7) 
Hussain and co-workers$ reported that heating the mixture of methyl cyanoacetate, S-
methyl isothiourea and aldehydes (8 a-d) yielded corresponding 4-aryl-5-cyano-2-methylthio-
6-oxopyrimidine derivatives (9 a-d). 
0 	+ 	NH 
NC-C2 C-OCH3 	H2N-11--S-CH3  + Ar-CHO 
(8) 
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(a) C6H5 
(b) p-NO2-C6H4 
(c) o-CH3O-C6H4 
(d) o-NO2-C6H4 
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(9) 
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(a) C6H5 
(b) p-NO2-C6H4 
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(d) o-NO--C6H4 
Soto and co-workers9 reported the reaction of thiobenzamide with 3-ethoxy-3-phenyl-
2-cyanoacrylonitrile (10) in presence of sodium isopropoxide in 2-propanol to afford 5-cyano-
2, 6-diphenyl-4-thioxo-3, 4-dihydropyrimidine (11) through formation of the 3-phenyl-2-
cyano-3-thiobenzamide acrylonitrile as an intermediate-. 
r 	CN 	 Ph S 	 Ph 
	
+ Ph 	 P N
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HZN 	Ph 	EcO 	CN 	HPh Ph I 	NH 	ph' i 
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(10) 
Taylor and Morrison16 reported the synthesis of 1, 4, 6-triamino-2(2H)-pyrimidine-2-
thione (12) by reacting malononitrile with thio.Semicarbazide in presence of sodium-ethoxide 
in ethanol. 
3' 
CN 
+ H2N )N.. 	
NaOEt 	H2N ~N~S 
CN 	 N 	NH2 
	EtOH 	 N NH2 
NH2 
(12) 
Botta and co-workers" reported the synthesis of 2-methoxy-6-methyl-3(2H)- 
pyrimidin-4-one (13) after reacting ethyl acetoacetate and 0-methylisourea in an aqueous 
medium. 
0 NHH3C.. /~ ~OC2H5 
 ,,_iL 
+ 
H3C~0 
 
NH2 	
0 0 	
H3C N~ OCH; 
(13) 
Andereichikov and co-workers'2 reported the synthesis of uracil derivatives (15 a-d) 
by the reaction of aryl substituted bromopyruvate esters (14 a-d) with urea. 
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(14) 	 (15) 
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E1-Subbagh13 reported the synthesis of pyrimidine derivative (17 a, b) by reacting 
thiazolyl thiourea derivatives (16 a, b) with masonic acid in the presence of acetyl chloride. 
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4 
Bowman and co-workers14 reported that. acetyl acetone condensed with acetamidine 	.4 
derivatives (18 a-e) and gave corresponding pyrimidine derivatives (19 a-e) in good yields. 
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(18) 	 (19) 
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Yossef and co-workers's reported the reaction of 1, 1-cycloalkane dicarboxylic acid 
diethyl esters (20 a-c) with thiourea which gave spiro-barbituric acid derivatives (21 a-c). 
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Mohamed16 reported the reaction of 1, 2-dihydro-4-hydroxy-l-methyl-2-oxoquinoline-
3-carbaldehyde (22) with thiosemicarbazides to yield desired thiosemicarbazones (23 a-d). 
These thiosemicarbazones then reacted with diethyl malonate which resulted into 
corresponding pyrimidine derivatives (24 a-d) in good yields. 
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Eldin and Attaby" reported the reaction of pyrazole [3, 2 - b] pyrimidine derivatives 
(25 a-p) with diethyl oxalate which yielded imidazo [1, 2:3', 4'] pyrazole [3, 2 - b] pyrimidine 
derivatives (26 a-p) in good yields. 
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Stadlbauer and co-workers'5 reported the reaction of diethyl malonate with urea and 2- 
aminopyridine which gave barbituric acid derivative (27) and pyrido [1, 2 - a] pyrimidine-2, 
4-dione derivative (28), respectively in better yields. 
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Peseke and co-workers19 reported the reaction of androstenolone acetate (29).with CS2 
and CH3I that yielded 3fl-acetoxy-16-[bis(methylthio) methylene] androst-5-en-17-one (30) 
which later reacted with different amidines in presence of sodium methoxide to provide 
corresponding steroidal pyrimidinc derivatives (31 a-e). 
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Semenov et al.,20 reported the reaction of J-phenyl tryptamine (32) with formic acid 
under Bischler-Napieralski conditions that yielded 4-phenyl-3, 4-dihydro-fl-carbo line (33) 
which upon reaction with 1, 3-dimethylbarbituric acid provided two diastereomers of 
substituted pyrimidinones [34 (RR), 35 (RS)]. 
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Bawazir and co-workers2' reported the reaction of phenylisothiocyanate (36) with 
sulfa drugs (37 a-c) in 1, 4-dioxane that yielded N, N'-disubstituted thiourea derivatives (38 a-
c) which later on reaction with dimethyl malonate in presence of sodium methoxide provided 
corresponding 1, 3-disubstituted thiobarbituric acid derivatives (39 a-c). 
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Parashar and co-workers2' reported the reaction of isonicotinohydrazide (40) with 
ethyl cyanoacetate, diethyl malonate, diethyl malonate with acetic acid and phenylisothio-
cyanate, which gave 3-amino-I-isonicotinoyl-IH-pyrazol-5(4H)-one (41), 1-isonicotinoyl 
pyrazolidine-3, 5-dione (42), 1-acetyl-2-isonicotinoylpyrazolidine-3, 5-dione (43), 1-isonic-
otinoyl-4-phenylthiosemicarbazide (44), respectively. The compound (44) on further reaction 
with ethyl chloroacetate gave N-(4-oxo-2-(phenylimino) thiazolidin-3-yl) isonicotinamide 
(45). 
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Hassan23 reported the reaction of methyl anthranilate (46) with hydrazine hydrate that 
gave 2-aminobenzhydrazide (47) which in tarn on reaction with methyl acetoacetate, acetyl 
acetone and diethyl malonate, yielded (2-amino benzoyl)-3-methyl-IH-pyrazole-5-(4H)-one 
(48), (2-aminobenzoyl)(3, 5-dimethyl-1H-pyrazole-1-yl) methanone (49) and (2-amino 
benzoyl) pyrazolidine-3, 5-dione (50), respectively in good amounts. 
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Abbas and co-workers24 reported - the reaction of 3-amino-2-(pyridin-3-yl)-4-quina-
zolinone (51) withp-hydroxy phenylisocyanate and phenylisothiocyanate provided 1-(4-oxo-
2-(pyridin-3-yl)-quinazolin-3(4H)-yl)-3-phenylurea (52a) and 1-(4-oxo-2-(pyridin-3-yl)-
quinazolin-3(4H)-yl)-3-phenylthiourea (52b). The compounds (52a and 52b) upon reaction 
with diethyl malonate and after keto-enoI tautomerism, yielded 6-hydroxy-3-(4-oxo-2-
(pyridin-3-yl)-quinazolin-3-(4H)-yl)-l-phenyl pyrimidine-2, 4-(1H, 3H)-dione (53a) and 3-(4-
hydroxy-6-oxo-3-phenyl-2-thioxo-2, 3-dihydropyrimidin-1(6H)-yl)-2-(pyridin-3-yl)-quinazol-
in-4(3H)-one (53b). 
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Naganagowda and co-workers25 reported the synthesis of 3-chloro-l-benzothiophene-
2-carbonylchloride (55) from cinnamic acid (54). The compound (55) reacted with hydrazine 
and gave 3-chloro-1-benzo [b] thiophene-2-carboxylic acid hydrazide (56) which on reaction 
with potassium thiocyanate provided 2-[(3-chloro-1-benzo [b] thiophen-2-yl) carbonyl] 
hydrazine carbothioamide (57) which on reaction with diethyl malonate yielded 3-chloro-N(4, 
6-dioxo-2-thioxotetrahydropyrimidin- 1 (2H)-yl)- I -benzothiophene-2-carboxamide (58). 
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El-zahar and co-workers26 reported the reaction of 2-hydrazino-6-oxo-4-phenyl-1, 6- 
dihydropyrimidine-5-carbonitrile (59) with diethyl oxalate, diethyl malonate, methyl 
acetoacetate and ethyl cyanoacetate that provided corresponding 3, 4, 6-trioxo-8-phenyl-
tetrahydro-2H-pyrimido[2, 1 - c][1, 2, 4] triazine-7-carbonitrile (60), 2-(3, 5-dioxo-pyrazo 
Iidin-l-yl)-6-oxo-4-phenyl-1, 6-dihydropyrimidine-5-carbonitrile (61), 2-(3-methyl-5-oxo-2, 
5-dihydro-pyrazol-1-yl)-6-oxo-4-phenyl-1, 6-dihydropyrimidine carbonitrile (62) and 2-(5-
amino-3-oxo-2, 3-dihydro-pyrazol-1-yl)-6-oxo-4-phenyl-1, 6-dihydropyrimidine-5-carbonitri 
-ile (63), respectively in good yields. 
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Dabholkar and Gavande 7 reported the reaction of 2H, 4H-2-ethoxycarbonyl-3, 4- 
dihydro-3-oxo-1, 4-benzoxazine (64) with hydrazine and provided 2H, 4H-2-hydrazino 
carbonyl-3, 4-dihydro-3-oxo- 1, 4-benzoxazine (65) which upon reaction with 
arylisothiocyanate derivatives yielded 2H, 4H-2-[(4'-substituted)-arylthiosemicarbazino]-
carbonyl-3, 4-dihydro-3-oxo-1, 4-benzoxazine derivatives (66 a-d). The compounds (66 a-d) 
later on reaction with diethyl malonate and gave 2H, 4H-2-[5'H-5'-dihydro-2'-thioxo-3'-aryl-
4', 6'-dioxo-1, 3-diazine]-aminocarbonyl-3, 4-dihydro-3-oxo-1, 4-benzoxazines (67 a-d). 
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Wahab and Mohamed28 reported the reaction of N-[3-amino-4-(benzoxazol-2-yl) 
pyrazol-5-yl] phenylamine (68) with diethyl malonate which provided 3-benzoxazol-2-yl-2- 
phenylamino-4H-pyrazolo [1, 5 - a] pyrimidine-5, 7-dione (69) in 80% yield. 
H2N 	 0 
(:::Coo 
/ NH HN 
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HN—Ph  
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(68) 	 (69) 
Abodi and co-workers29 reported the reaction of 3-amino-5-(benzylidene)-2-(pyridin-
3-yl)-3, 5-dihydro-4H-imidazol-4-one (70) with p-hydroxybenzaldehyde which gave 5-
(benzylidene)-3-[(p-hydroxybenzylidene) amino]-2-(pyridin-3-yl) dihydro-4H-imidazo1-4-one 
(71). The compound (71) reacted with benzoyl chloride and provided N-[chloro (4'-phenyl) 
methyl]-N-[4` p-hydroxybenzylidene-5'-oxo-2-(pyridin-3-yl)-4, 5-dihydro-IH-imidazol-1-yI] 
benzamide (72). The compound (72) later upon reacted with thiourea yielded 4'-phenyl {[4'-
(4'-benzylidene-5'-oxo-2-(pyridin-3-yl)-4, 5-dihydro- 1 H-imidazol- l-yl] (p-hydroxybenzoyl) 
amino} methyl carbamimidothioate (73). The compound (73) in turn reacted with diethyl 
malcq nate yielded N- { 1-[(4", 6 "-dioxo-tetrahydropyrimidin-2-yl) sulfanyl] benzyl} -N-[4 p-
hydroxybenzylidene-5'-oxo-2-(pyridin-3-yl)-4, 5-dihydro-1H-imidazol-1-yl-benzamide (74). 
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Drea and co-workers30 reported the reaction of 5-amino-3-mercaptopyrazole (75) with 
4-dimethylaminobenzaldehyde (76) which gave 5-(4'-dimethylamino) benzylidene) amino-3-
mercaptopyrazole (77). The compound (77) on reaction with benzoyl chloride provided 5-(4'-
dimethylamino)-chlorobenzylidene) N-(benzoyI) amino-3-mercaptopyrazole (78). The 
compound (78) reacted with guanidine hydrochloride and yielded 5-{(4'-dimethylamino)-
benzylidene) N-(benzoyl) N-(guanidino)} amino-3-mercaptopyrazole (79) which later on 
reaction with diethyl malonate gave 5-((4'-dimethylamino)-benzylidene) N-(benzoyl) (4, 6-
dioxotetrahydropyrimidin-2-yl amino)-methyl)} amino-3-mercaptopyrazole (80). 
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Hasanen31 reported the reaction of 3-acetylcoumarin (81) with thiosemicarbazide that 
provided 3-acetylcoumarin thiosemicarbazone (82) which reacted with diethyl malonate, 
chloro ethylacetate and ethyl acetoacetate to yield corresponding 4, 6-dihydroxy-l-(coumarin-
3-ylethylidene) aminopyrimidin-2-thione (83), 3-(coumarin-3-ylethylidene) amino-2-thioxo-
imidazolidin-4-one (84) and 6-methyl-l-(coumarin-3-ylethylidene) amino-2-thioxo-
pyrimidin-4-one (85) in better yields. 
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Hafez and co-workers32 reported the reaction of 5-acetyl-3-ethyl (2-amino-4-methyl 
thiophene) carboxylate (86) with CS2 which gave methyl N-(4-methyl-5-acetyl-3-
carboxyethyl-thiophene) dithiocarbamate (88). The compound (88) reacted with hydrazine 
and yielded methyl N-(4-methyl-5-.acetyl-3-carboxyethyl-thiophene) thiosemicarbazide (89). 
The compound (89) in warmed ethanolic sodium hydroxide solution cyclized and gave 3-
amino-6-acetyl-5-methyl-2-thioxo-thieno [2, 3 - d] pyrimidin-4-one (90). 
H3C 	COOEt 
H3COC ' I NH2 
S 
(86) 
H3C 	COOEt 	 H3C 	COOEt 
H3COC ' 	NH -+ 
S 	CAS Na 
($7) 	S' 
H3COC 	NH S-CH , 	3 
(S8) 	S. 
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Heterosteroids have been accredited with a great amount of attention over the years by 
medicinal chemists for drug discovery. The interesting structural and stereochemical features 
of the steroid nucleus provide additional fascination to the researchers and thereby alterations 
in the steroidal skeleton have been envisaged to discover new chemical entities with a 
potential to afford some promising drugs of the future. The incorporation of a heterocyclic 
ring like pyrimidine, thiazole or a heteroatom in the steroid backbone affects the chemical 
properties of a steroid and often results in useful alterations in its biological activities 33  
Therefore, researchers are on a continuous pursuit to design and produce better 
heterosteroids, by following natural models. 
From last few years, numerous molecules possessing pyrimidine moiety have been 
reported to exhibit a broad spectrum of biological activities such as anticancer, antiviral, 
antibacterial, antioxidant, anxiolytic and antidepressant. Furthermore, they possess anti-
inflammatory 344' and analgesic activities which are well documented in the literature.43, as 
Besides this, pyrimidine derivatives have been explored for use as histamine and adenosine 
receptor antagonists as well as among several other biological receptors and modulators 45 
The biological importance of these steroidal pyrimidines3445  and study of interesting 
behavior of diethyl malonate and ethyl cyanoacetate with simple thiosemicarbazones giving 
pyrimidines encouraged us to make similar studies with steroidal thiosemicarbazones. The 
substrates selected for synthesizing the new steroidal pyrimidines include 5a-cholestan-6-one 
thiosemicarbazone (91)46, 3fl-acetoxy-5a-cholestan-6-one thiosemicarbazone (92)46 and 3fl-
chloro-5a-cholestan-6-one thiosemicarbazone (93)•46  The products obtained have been 
characterized on the basis of spectral (IR,'H NMR, 13C NMR, MS) and elemental analyses. 
M 
N—NH-C—NH2 
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Reaction of 5a-cholestan-6-one thiosemicarbazone (91) with diethyl malonate. 
The 5a-cholestan-6-one thiosemicarbazone (91) in 1, 4-dioxane was allowed to react 
with diethyl malonate. After completion of the reaction, the reaction mixture was taken in 
diethyl ether, washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvents gave an oil which was crystallized from methanol to give compound 94, m.p. 134 °C. 
EtOOC-CH2-COOEt 
N—NH -C — NH2 
S 
I,4-D ioxane 
J NH 
O 	 ` 
(91) 	 (94) 
Characterization of the compound, m.p. 134 °C as 14', 6'-dioxo-2'-thioxo-1H-pyrimidin-
1-y1] 6-imino-5a-cholestane (94): 
The elemental analysis of compound 94 corresponded to the molecular formula 
C31H49N302S. Its IR spectrum showed a band at 3322 cm' which could be assigned to NH 
group while as the bands at 1677, 1670, 1651, 1232 and 1025 cm 1 were attributed to CONH, 
CON, C=N, C=S and C-N group, respectively. These values supported the presence of 
pyrimidine moiety47 in the product molecule. The structure 94 was well supported by its 'H 
NMR spectrum which displayed a singlet integrating for one proton at J 7.6 (exchangeable 
with D20) indicating the presence of NH while as another singlet integrating for two protons 
at 5 4.0 showed the presence of C5'-H2. Other prominent peaks for angular and side-chain 
methyl protons were observed at J 1.22, 0.97, 0.98 and 0.74. The 13C NMR spectrum of 
compound 94 displayed characteristic signals at 6 182 (C2'.), 172.1 (C4'), 171.2 (Co'), 153.3 
(C6), 52.2 (C5') and 26 (C3). Remaining carbon atoms were seen in accordance to the 
cholestane series. The structure of compound 94 was further supported by its mass spectrum 
in which the distinct molecular ion peak (M+  527) was found. 
On the basis of foregoing discussion and the mechanism proposed (Scheme 1.1), this 
compound can be best characterized as [4', 6'-dioxo-2'-thioxo-1H-pyrimidin-1-yl] 6-imino-
5a-cholestane (94). 
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Reaction of 3/I-acetoxy-5a-cholestan-6-one thiosemicarbazone (92) with diethyl malonate. 
The 3j3-acetoxy-5a-cholestan-6-one thiosemicarbazone (92) in 1, 4-dioxane was 
allowed to react with diethyl malonate. After completion of the reaction, the reaction mixture 
was taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 95, m.p. 167 °C. 
EtOOC-CI,-COOEI 
1,4-Dioxane N — NH- C--NH, 
II 	-  
S 
NH 
O 
0 
(92) 	 (95) 
Characterization of the compound, m.p. 167 °C as 3/1-acetoxy-14', 6'-dioxo-2'-thioxo-1H-
pyrimidin-1-yl] 6-imino-5a-cholestane (95): 
The compound 95 was correctly analyzed for the molecular formula C33H51N304S. Its 
IR spectrum showed a band at 3342 cm' which could be assigned to NH group. The strong 
absorption bands at 1734 and 1080 cm ' indicated the presence of acetate group, while as the 
bands at 1679, 1674, 1643, 1269 and 1025 cm"' were attributed to CONH, CON, C N, C=S 
and C-N group, respectively. These values supported the presence of pyrimidine moiety 7 in 
the product molecule. The structure 95 was well supported by its 'H NMR spectrum which 
displayed the singlet integrating for one proton at d 8.3 (exchangeable with D2O) indicating 
the presence of NH while as the singlet integrating for two protons at 4.2 showed the 
presence of C5 '-Hz. A broad multiplet (W1,' = 15 Hz, axial) for one proton was observed at a 
4.7 which could be assigned to C3a-H. Three acetoxy group protons appeared at o 2.04 as a 
sharp singlet. The prominent peaks for angular and side-chain methyl protons were observed 
at d 1.22, 0.97, 0.98 and 0.74. The 13C NMR spectrum of compound 95 displayed 
characteristic signals at 6 183 (C2'), 176.1 (OCOCH3), 171.6 (C4'), 170.2 (C6'), 158.3 (C6), 
52.2 (C$') and 70.4 (C3). Remaining carbon atoms were seen in accordance to the cholestane 
series. The structure of compound 95 was further supported by its mass spectrum in which the 
distinct molecular ion peak (M"' 585) was found. 
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On the basis of above studies and its analogy with earlier compound 94, this 
compound can be best characterized as 3/3-acetoxy-[4`, 6'-dioxo-2'-thioxo-1H-pyrimidin-1-yl] 
6-imino-5a-cholestane (95). 
Reaction of 3fl-cliloro-5a-cholestan-6-one thiosemicarbazone (93) with diethyl malonate. 
The 3fl-chloro-5a-cholestan-6-one thiosemicarbazone (93) in 1, 4-dioxane was 
allowed to react with diethyl malonate. After completion of the reaction, the reaction mixture 
was taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 96, m.p. 151 °C. 
C) EIOOC-CH,-COOEt C 
I,4-Dioxane 
 
N—NH-C—NH2 
S 
H 
0 
O 
(93) 	 (96) 
Characterization of the compound, m.p. 151 °C as 3Q-chloro-[4', 6'-dioxo-2'-thioxo-1H-
pyrimidin-1-yl] 6-imino-5a-cholestane (96): 
The compound 96 was correctly analyzed for the molecular formula C31H48CIN302S 
(Beilstein positive). Its IR spectrum showed a band at 3315 cm 1 which could be assigned to 
NH group while as the bands at 1675, 1671, 1637, 1254, 1025 and 740 cm I were attributed to 
CONH, CON, C=N, C=S, C-N and C-Cl group, respectively. These values suggested the 
presence ofpyrimidine moiety47 in the product molecule. The structure 96 was well supported 
by its I H NMR spectrum which displayed the singlet integrating for one proton at S 7.9 
(exchangeable with D20) indicating the presence of NH while as the singlet integrating for 
two protons at b 4.0 showed the presence of C5'-H2. A broad multiplet (Wi/z = 17 Hz, axial) 
for one proton was observed at 53.9 which could be assigned to C3a-H. The prominent peaks 
for angular and side-chain methyl protons were observed at 6 1.22, 0.97, 0.98 and 0.74. The 
13C NMR spectrum of compound 96 displayed characteristic signals at 5 184 (C21), 172.1 
(C4'), 171.2 (CO,  157.3 (C6), 59.6 (C51) and 52.2 (C3). Remaining carbon atoms were seen in 
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accordance to the cholestane series. The structure of compound 96 was further supported by 
its mass spectrum in which the distinct molecular ion peak (M+  561/563) was observed. 
The above data led to the structure of compound 96 as, 3/J-chloro-[4', 6'-dioxo-2'- 
thioxo-lH-pyrimidin-1-yl] 6-imino-5a-cholestane. 
Formation of steroidal pyrimidines (94-96) under the condition case and in the light 
of available literature10, 13. 15, 16, 22 may be shown according to the proposed mechanism 
(Scheme 1.1). 
• 0 C2H50  
0 
" N—N=C 
C2H50. 	NH 
0 
 
 
N-N- \ 
0 H 0 
(94) H 
(95) OAc 
(96) Cl 
Scheme I.1. Mechanism for the formation of [4','• 6'-dioxo-2'-thioxo-1H-pyrimidin-1-yl] 6- 
imino-5a-cholestane derivatives (94-96) 
Work published; 
Steroidal pyrimidines: Synthesis, characterization, molecular docking studies with DNA and 
in vitro cytotoxicity, Shamsuzzaman, Ayaz Mahmood Dar, et al., Journal of Molecular 
Structure 1045 (2013) 62-71 
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Reaction of 5a-cholestan-6-one thiosemicarbazone (91) with ethyl cyanoacetate. 
The 5a-cholestan-6-one thiosemicarbazone (91) in 1, 4-dioxane was allowed to react 
with ethyl cyanoacetate. After completion of the reaction, the reaction mixture was taken in 
diethyl ether, washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvents gave an oil which was crystallized from methanol to give compound 97, m.p. 123 °C. 
NC-CH,-COOEI 
1,4-Dioxane N—NH-C—NH2 
S 
 
N — N— NH 
H,N 
O 
(91) 	 (97) 
Characterization of the compound, m.p. 123 °C as [6'-amino-2'-thioxo-4'-oxo dihydro-
1H-pyrimidin-1-yll 6-imino-5a-cholestane (97): 
The elemental analysis of compound 97 corresponded to the molecular formula 
C31H5oN4OS. Its IR spectrum showed bands at 3349 and 3284 cm 1 which could be assigned 
to NH and NH2 groups while as the bands at 1670, 1653, 1620, 1264 and 1027 cm I were 
attributed to C=O, C=N, C=C, C=S and C-N group, respectively. These values supported the 
presence of pyrimidine moiety47 in the product molecule. The structure 97 was well supported 
by its 'H NMR spectrum which showed a singlet at 6 7.8 (exchangeable with D20) indicating 
the presence of NH while as a broad singlet at d 3.2 (exchangeable with D20) integrating for 
two protons (NH2). Another singlet for one proton appeared at 6 5.6 depicting the presence of 
an olefinic proton (C5'-H) in the compound. The prominent peaks for angular and side-chain 
methyl protons were observed at d 1.17, 0.98, 0.94 and 0.72. The '3C NMR spectrum of 
compound 97 displayed characteristic signals at 6185 (C2'), 173.6 (C6', 167.3 (C47, 154 (C6), 
81.4 (C5') and 26 (C3). Remaining carbon atoms were seen in accordance to the cholestane 
series. The structure of compound 97 was further supported by its mass spectrum in which the 
distinct molecular ion peak (11  526) was observed. 
On the basis of foregoing discussion and the mechanism proposed (Scheme 1.2), this 
compound can be best characterized as [6'-amino-2'-thioxo-4'-oxo dihydro-IH-pyrimidin-l-
y1] 6-imino-5a-cholestane (97). 
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Reaction of 3/1 acetoxy-5a-cholestan-6-one thiosemicarbazone (92) with ethyl cyanoacetate. 
The 3,8-acetoxy-5a-cholestan-6-one thiosemicarbazone (92) in 1, 4-dioxane was 
allowed to react with ethyl cyanoacetate. After completion of the reaction, the reaction 
mixture was taken in diethyl ether, washed with water and dried over anhydrous sodium 
sulfate. Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 98, m.p. 154 °C. 
NC-CI z-COOEt 
1,4-Dioxane N--NH- C —NH, u 	` 
S 
N —N\ NH 
HZN 
O 
(92) 	 (98) 
Characterization of the compound, m.p. 154 °C as 3/I-acetoxy-[6'-amino-2'-thioxo-4'-oxo 
dihydro-1H-pyrimidin-1-yl] 6-imino-5a-cholestane (98): 
The compound 98 was correctly analyzed for the molecular formula C33H52N403S. Its 
IR spectrum showed bands at 3345 and 3290 cn ' which could be assigned to NH and NH,, 
groups. The strong absorption bands at 1714 and 1080 cm-1 indicated the presence of acetate 
group, while as the bands at 1671, 1645, 1622, 1269 and 1025 cni ' were attributed to C=O, 
C=N, C=C, C=5 and C-N group, respectively. These values suggested the presence of 
pyrimidine moiety47 in the product molecule. The structure 98 was weII supported by its 'H 
NMR spectrum which showed a singlet at 5 8.2 (exchangeable with D20) indicating the 
presence of NH while as a broad singlet at 6 2.9 (exchangeable with D20) integrating for two 
protons (NHZ). Another singlet for one proton appeared at d 5.7 depicting the presence of an 
olefmic proton (Cs'-17) in the compound. A broad multiplet (Wiz = 15 Hz, axial) for one 
proton was observed at 6 4.7 which could be assigned to C3a-H. Three acetoxy group protons 
appeared at 6 2.03 as a sharp singlet. Other prominent peaks for angular and side-chain 
methyl protons were observed at 6 1.18, 0.97, 0.83 and 0.70. The 13C NMR spectrum of 
compound 98 displayed characteristic signals at 6 185 (CZ'), 173.2 (C61), 171.6 (OCOCH3), 
168.3 (C4'), 155.3 (C6), 85.8 (C5') and 70 (C3). Remaining carbon atoms were seen in 
accordance to the cholestane series. The structure of compound 98 was further supported by 
its mass spectrum in which the distinct molecular ion peak (M+- 584) was found. 
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On the basis of above studies and its analogy with earlier compound 97, this 
compound can be best characterized as 3,6-acetoxy-[6'-amino-2'-thioxo-4'-oxo dihydro-lH-
pyrimidin-1-yl] 6-imino-5a-cholestane (98). 
Reaction of 3Q-chloro-5a-cholestan-6-one thiosemicarbazone (93) with ethyl cyanoacetate. 
The 3fl-chloro-5a-cholestan 6-one thiosemicarbazone (93) in 1, 4-dioxane was 
aIIowed to react with ethyl cyanoacetate. After completion of the reaction, the reaction 
mixture was taken in diethyl ether, washed with water and dried over anhydrous sodium 
sulfate. Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 99, m.p. 138 C. 
NC-CH-,-COOEt 
1,4-Dioxane 	C1  
N— NH-  C — NH2 
S 
N--N —\ 
NH 
H,N 
0 
(93) 	 (99) 
Characterization of the compound, m.p. 138 °C as 3p-chloro-[6'-amino-2'-thioxo-4'-oxo 
dihydro-1H-pyrimidin-1-yl] 6-imino-5a-cholestane (99): 
The compound 99 was correctly analyzed for the molecular formula C3!H44CIN4OS 
(Beilstein positive). Its IR spectrum showed bands at 3353 and 3286 cm' which could be 
assigned to NH and NH2 groups while as the bands at 1669, 1654, 1618, 1251, 1019 and 742 
cm 1 were attributed to C=O, C=N, C=C, C=S, C-N and C-Cl group, respectively. These 
values supported the presence of pyrimidine moiety47 in the product molecule. The structure 
99 was well supported by its 'H NMR spectrum which showed a singlet at S 7.6 
(exchangeable with D20) indicating one proton (NH) while as a broad singlet at 6 3.1 
(exchangeable with D20) integrating for two protons (NH2). Another singlet for one proton 
appeared at J 5.5 depicting the presence of an olefmic proton (Cs'-H) in the compound. A 
broad multiplet (W1z = 17 Hz, axial) for one proton was observed at 6 3.9 which could be 
assigned to (C3a-H). The peaks for angular and side-chain methyl protons were observed at d 
1.17, 0.96, 0.84 and 0.72. The 13C NMR spectrum of compound 99 displayed characteristic 
signals at 6183 (CZ'), 171.6 (CO,  168.3 (C41), 155.3 (C6), 79.8 (C5') and 52.6 (C3). Remaining 
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carbon atoms were seen in accordance to the cholestane series. The structure of compound 99 
was further supported by its mass spectrum in which the distinct molecular ion peak (M}' 
5601562) was observed. 
The above data led to the structure of compound 99 as, 3f-chloro-[6'-amino-2'-thioxo-
4'-oxo dihydro-1 H-pyrimidin- 1-yl] 6-imino-5a-cholestane. 
Formation of steroidal pyrimidines (97-99) under the condition case and in the light of 
available literature""' 26 may be shown according to the proposed mechanism (Scheme 1.2). 
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Scheme 1.2. Mechanism for the formation of [6'-amino-2'-thioxo-4'-oxo dihydro-lH-
pyrimidin-1-yl] 6-imino-5a-cholestane derivatives (97-99) 
Work published; 
DNA binding, docking studies, artificial nuclease activity and in vitro cytotoxicity of newly 
synthesized steroidal 1H-pyrimidines, Shamsuzzaman, Ayaz Mahmood Dar, et al., Comptes 
Rendus Chimie, http://dx.doi.org/10.1016/j.crci.2013.07.001 (in press) 
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All the melting points were determined in degrees Celsius on a Koler apparatus and are 
uncorrected. The IR spectra were recorded on KBr pellets with Perkin Elmer RXI 
Spectrophotometer and values are given in cm. 'H and '3C NMR spectra were run in CDC13 
on a JEOL Eclipse (400 MIiz) instrument with TMS as internal standard and values are given 
in ppm (6). Mass spectra were recorded on a JEOL SX 102/DA-6000 Mass Spectrometer. 
Thin layer chromatography (TLC) plates were coated with silica gel G and exposed to iodine 
vapors to check the homogeneity as well as the progress of reaction. Petroleum ether refers to 
a fraction of boiling point 60-80 °C. Sodium sulfate (anhydrous) was used as a drying agent. 
3Q- Chlo rocho test-5-ene: 
Freshly purified thionyl chloride (40 mL) was added gradually to cholesterol (50 g) at 
room temperature. A vigorous reaction ensured with evolution of gaseous products. When the 
reaction slackened, the mixture was gently heated at temperature 50-60 °C on water bath for 1 
h and then poured into crushed ice-water with stirring. The yellow solid thus obtained was 
filtered under suction and washed several times with ice-cold water and air dried. 
Recrystallization of crude product from acetone gave 3J3-chlorocholest-5-ene (42 g), m.p. 95-
96 °C (reported m.p. 96-97 °C).4$ It gave positive Beilstein test and a yellow color with tetra-
nitromethane in chloroform. 
Cholest-5-ene: 
3fl-Chlorocholest-5-ene (10 g) was dissolved in warm amyl alcohol (230 mL) and 
sodium metal (20 g) was added in small portions to the solution with continuous stirring over 
the period of 8 h. The reaction mixture was warmed occasionally. When all the sodium metal 
was dissolved, the reaction mixture was poured into water, acidified with dilute hydrochloric 
acid and allowed to stand overnight. A white crystalline solid thus obtained was filtered under 
suction, washed thoroughly with water and air dried. Recrystallization of the crude material 
from acetone gave cholest-5-ene (8.3 g) in cubes, mp. 92 °C (reported m.p. 89-91 °C).A9 
6-Nitrocholest-5-ene: 
A suspension of finely powdered cholest-5-ene (6 g) in glacial acetic acid (50 rhL) 
was stirred at room temperature for 5 min. and nitric acid (15 mL; d, 1.52 g/cm3) was rapidly 
added followed by the addition of sodium nitrite (3 g) and stirring was continued for further 2 
h. The temperature of a reaction mixture was controlled between 20-25 °C by external 
cooling. The reaction mixture was then poured into cold water and the yellow solid thus 
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obtained was filtered under suction, washed thoroughly with water and air dried. 
Recrystallization of the crude material from methanol furnished 6-nitrocholest-5-ene (4.5 g), 
m.p. 119-120 °C (reported m.p. 120l21 °C).'0 
5a-Cholestan-6-one: 
6-Nitrocholest-5-ene (6 g) was dissolved in glacial acetic acid (120 mL) by heating 
and to this solution; zinc dust (12 g) was gradually added in small portions with shaking. 
After the initial exothermic reaction was subsided, the suspension was heated under reflux for 
4 h and water (12 mL) was added during the course of reaction. The solution was then filtered 
and the residue was washed with two (10 mL) portions of warm acetic acid. To the filtrate, a 
few mL of water was added till turbidity developed and it was allowed to stand overnight at 
room temperature. The crystalline material thus separated was filtered under suction and 
washed thoroughly with water in order to remove zinc acetate. The organic solid was air dried 
and then recrystallized from methanol (3.6 g), m.p. 96-98 °C (reported m.p. 98-100 0C).48  
5u-Cholestan-6-one thiosemicarbazone (91): 
To a boiling solution of 5a-cholestan-6-one (3.85 g) in ethanol (20 mL), a few drops 
of concentrated hydrochloric acid were added followed by the addition of solution of 
thiosemicarbazide (1.01 g) in ethanol (10 mL) with stirring. The reaction mixture was 
reffuxed for I h and then cooled. The precipitate thus obtained was separated by filtration and 
purified by recrystallization from methanol to give 5a-cholestan-6-one thiosernicarbazone 
(91) (3.2g) as shinning needles, m.p. 1 12-1 I4 °C (reported m.p. 113 °C).46 
3Q-Acetoxycholest-5- en e: 
A mixture of cholesterol (50 g), pyridine (75 mL freshly distilled over KOH) and freshly 
distilled acetic anhydride (50 mL) was heated on a water bath for 2 h. The resulting brown 
colored reaction mixture was poured into crushed ice-water mixture with stirring. A light 
brown solid thus obtained was filtered under suction, washed with water until free from 
pyridine and air dried. The crude product on crystallization from acetone gave pure 3/-
acetoxycholest-5-ene (45 g), m.p. 113-114 °C (reported m.p. 115-116 0C).51  
3/1-Acetoxy-6-nitrocholest-5-en e: 
To a cooled mixture of 3/3-acetoxycholest-5-ene (10 g) and nitric acid (250 mL; d, 
1.42 g/cm3), sodium nitrite (10 g) was gradually added over a period of 45 min. with constant 
stirring. Slight cooling was also affecting during the course of reaction and stirring was 
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continued for additional 2 h and then cold water (350 mL) was added to reaction mixture. The 
yellow solid material thus separated was extracted with diethyl ether and the ethereal Iayer 
was washed with water, sodium bicarbonate solution (5%) (until washing was pink), again 
with water and finally dried by anhydrous sodium sulfate. Removal of solvents provided the 
compound as an oil which was crystallized from methanol (40 mL) to give 3/3-acetoxy-6-
nitrocholest-5-ene (7.0 g), m.p. 104 °C (reported m.p. 102-104 °C).52 
3/3-Acetoxy-5a-cholestan-6-one: 
3,8-Acetoxy-6-nitrocholest-5-ene (6 g) was dissolved in hot glacial acetic acid (250 
mL) and zinc dust (12 g) was added in small portions with shaking. The suspension was 
heated under reflux for 4 h and water (12 mL) was added during the course of reaction. Zinc 
dust was removed by filtration and the filtrate was diluted with large excess of water. Usual 
work up of the reaction mixture afforded the ketone, which was crystallized from methanol 
(3.9 g), m.p. 128 °C (reported m.p. 127-128 °C).s3  
3/1-Acetoxy-5a-cholestan-6-one thiosemicarbazone (92): 
To a boiling solution of 3fl-acetoxy-5a-cholestan-6-one (4.44 g) in ethanol (20 mL), a 
few drops of concentrated hydrochloric acid were added followed by the addition of solution 
of thiosemicarbazide (1.01 g) in ethanol (10 mL) with stirring. The reaction mixture was 
refluxed for 1 h and then cooled. The precipitate was separated by filtration and purified by 
recrystallization from methanol to give 3,6-acetoxy-5a-cholestan-6-one thiosemicarbazone 
(92) as shinning needles (3.3 g), m.p. 128-129 °C (reported m.p. 128 °C).46 
3/1-Chloro-6-nitrocholest-5-ene: 
To a stirred mixture of 3fl-chlorocholest-5-ene (14 g), glacial acetic acid (100 mL) and 
nitric acid (28 mL; d, 1.52 g/cm3) at temperature below 20 °C was added sodium nitrite (3.5 
g) gradually added over a period of 1 h. After complete addition of sodium nitrite, the reaction 
mixture was stirred for an additional period of 2 h. Ice cold water (200 mL) was added and the 
yellowish solid separated was filtered and air dried. The desired product was crystallized from 
methanol as needles (8.9 g), m.p. 151-152 °C (reported m.p. 153 0C).54  
3/1-Chloro-5a-cholestan-6-one: 
A solution of 3fl-chloro-6-nitrocholest-5-ene (12 g) and glacial acetic acid (240 mL) 
was heated to get a clear solution. The zinc dust (24 g) was added gradually in small portions 
with constant shaking. The suspension was heated under reflux for 4 h and water (24 mL) was 
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added at regular intervals during the course of reaction. The hot solution was poured into ice 
cold water. The organic matter was extracted with diethyl ether and the ethereal layer was 
successively washed with water, sodium bicarbonate solution (5 %) and again with water and 
dried over anhydrous sodium sulfate. Evaporation of the solvent furnished the product as an 
oil which was crystallized from methanol (8.7 g), imp. 128-129 °C (reported imp. 129 °C).55 
3/3-Chloro-5a-cho]estan-6-one thiosemicarbazone (93): 
To a boiling solution of 3/3-chloro-5a-cholestan-6-one (4.2 g) in ethanol (20 mL), few 
drops of concentrated hydrochloric acid were added followed by the addition of solution of 
thiosemicarbazide (1.01g) in ethanol (10 rnL) with stirring. The reaction mixture was refluxed 
for 1 h and cooled. The precipitate thus obtained was separated by filtration and purified by 
recrystallization from methanol to give 3/3-chloro-Sa-cholestan-6-one thiosemicarbazone (93) 
as crystalline solid (3.3 g), m.p. 135-136 °C (reported m.p. 136 °C).46 
Reaction of 5a-cholestan-6-one- thiosemicarbazone derivatives (91-93) with diethyl 
malonatelethyl cyanoacetate: 
To a solution of 5a-cholestan-6-one thiosemicarbazone derivatives (91-93) (1.5 mmol) 
in 1, 4-dioxane (20 mL), an equimolar amount of diethyl malonate/ ethyl cyanoacetate was 
added. The reaction mixture was refluxed for 10-11 h. The progress and completion of the 
reaction was monitored by TLC. After completion of reaction, the excess solvent was reduced 
to three fourths of the original volume under reduced pressure. The reaction mixture was then 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Evaporation of solvents and crystallization of the oily residue from methanol afforded the 
corresponding products (94-99). 
[4', 6'-Dioro-2! thioxo-1H pyrimidiir-1 yl]6-imino-5a-cholestane (94): 
Yield 70%; m.p. 134 °C; Analysis found: C 70.58, H 9.29, N 7.96%. C31H49N302S requires: 
C 70.54, H 9.35, N 7.96%; 1R (KBr): v max  3322 (NH), 1677 (CONH), 1670 (CON), 1651 
(C=N), 1232 (C=S), 1025 (C-N); 'H NMR (CDCI3): 6 7.6 (s, 1H, NH, exchangeable with 
D20), 4.0 (s, 2H, C5'-H2), 1.22 (s, 3H, C,o-CH3), 0.74 (s, 3H, C13-CH3), 0.97 and 0.98 (other 
methyl protons); '3C NMR (CDC13): 6 I82 (C2'), 172.1 (C4'), 171.2 (C61), 153.3 (C6), 52.2 
(C5'), 48 (C17), 46.7 (C,4), 42.1 (Cio),  40.1 (Cs),  37 (c20), 35 (Cis), 26 (C3), 24 (C2), 22 (C4), 
20 (C16); MS: m/z 527 [M}']. 	 i 
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3f Acetoxy-[4', 6' dioxo-2! thioxo-lI pyriniidin-I ylf 6-imino-Sa-cl:olestane (95): 
Yield 78%; m.p. 167 °C; Analysis found: C 67.69, H 8.71, N 7.17%. C33H51N304S requires: 
C 67.65, H 8.77, N 7.17%; IR (KBr): v max 3342 (NH), 1734 (OCOCH3), 1679 (CONH), 1674 
(CON), 1643 (C=N), 1269 (C=S), 1080 (C-O), 1025 (C-N);'H NMR (CDC13): 6 8.3 (s, 1H, 
NH, exchangeable with D20), 4.7 (m, IH, C3a-H, W%z = 15 Hz), 4.2 (s, 2H, C5'-H2), 2.04 (s, 
3H, OCOCH3), 1.22 (s, 3H, Clo-CH3), 0.74 (s, 3H, C,3-CH3), 0.97 and 0.98 (other methyl 
protons); 13C NMR (CDCl3): d 183 (C2'), 176.1 (CH3COO), 171.6 (C47, 170.2 (C6'), 158.3 
(C6), 70.4 (C3), 52.2 (C5'), 48 (Cis), 46.7 (C14),  42.1 (Cio), 40.1 (C5), 37 (G0), 35 (C18), 24 
(C.), 22 (C4), 20 (C16); MS: m/z 585 [Mi. 
3/J-Chloro-[4, 6' dioxo-2'-thioxo-IH-pyrimidin-1 yl]6-imino-5a-cliolestane (96): 
Yield 80%; m.p. 151 °C; Analysis found: C 66.31, H 8.55, N 7.48%. C31HggCIN302S requires: 
C 66.22, H 8.60, N 7.47%; IR (KBr): v max  3315 (NH), 1675 (CONH), 1671 (CONS), 1637 
(C=N), 1254 (C=S), 1025 (C-N), 740 (C-Cl); 'H NMR (CDC13): 6 7.9 (s, 1H, NH, 
exchangeable with D20), 4.0 (s, 2H, C5'-H2), 3.9 (m, 1H, C3a-H, W% = 17 Hz), 1.22 (s, 3H, 
Cio-CH3), 0.74 (s, 3H, C13-CH3), 0.97 and 0.98 (other methyl protons); '3C NMR (CDC13): S 
184 (C2'), 172.1 (C4'), 171.2 (CO,  157.3 (C6), 59.6 (C5'), 52.2 (C3), 46.7 (C14), 42.1 (CIO), 40.1 
(C5), 37 (CZO), 35 (C,8), 24 (C1), 22 (C4), 20 (C16); MS: m/z 561/563 [Mt]. 
[6'Anino-2'-ih oxo-4'-ovo dihydro-1H pyrunidin-Y ylj6-inrino-5a-cliolestane (97): 
Yield 70%; m.p. 123 °C; Analysis found: C 70.66, H 9.45, N 10.61%. C31H50N40S requires: 
C 70.57, H 9.39, N 10.58%; IR (KBr): v .x 3349, 3284 (NH, NH2), 1670 (C=O), 1653 
(C=N), 1620 (C=C), 1264 (C=S), 1027 (C-N); 'H NMR (CDCI3): d 7.8 (s, 1H, NH, 
exchangeable with D2O), 5.6 (s, 1H, C5'-H), 3.2 (s, 2H, NH2, exchangeable with D20) 1.17 
(s, 3H, C10-CH3), 0.72 (s, 3H, C13-CH3), 0.98 and 0.94 (other methyl protons); '3C NMR 
(CDC13): 6 185 (C21), 173.6 (C61), 167.3 (C4'), 154.3 (C6), 81.4 (CAA, 39 (C5), 35 (C,o), 26 
(C3), 24 (C7), 22 (C,6), 20 (C15); MS: m/z 526 [M{']. 
3/i -A etoxy-[6'-amino-2'-tliioxo-4'-orodil:ydro-IH pyriniidin-I y1J6-in:ino-5a-cholestane (98): 
Yield 80%; m.p. 154 °C; Analysis found: C 67.80, H 8.90, N 9.53%. C33H52N403S requires: 
C 67.69, H 8.84, N 9.49%; IR (KBr): v ma. 3345, 3290 (NH, NH-,), 1714 (OCOCH3), 1671 
(C=O), 1645 (C=N), 1622 (C=C), 1269 (C=S), 1080 (C-O), 1025 (C-N);'H NMR (CDC13): S 
8.2 (s, 1H, NH, exchangeable with D20), 5.7 (s, 1H, C51-I1), 4.7 (m, 111, C3a-H, WY2 =15 Hz), 
2.9 (s, 2H, NH2, exchangeable with D20), 2.03 (s, 3H, OCOCH3), 1.18 (s, 3H, Cio-CH3), 0.70 
27 
(s, 3H, C13-CH3), 0.97 and 0.83 (other methyl protons); '3C NMR (CDC13): 6185 (C2'), 173.2 
(C6'), 171.6 (OCOCH3), 168.3 (C41), 155.3 (C6), 85.8 (C5'), 70 (C3), 39 (C5), 35 (Cio), 24 (C7), 
22 (C16), 20 (C15); MS: m/z 584 [M}'].. 
3/!-Chloro [6'-amino-2'-thioxo-4'-oro dihydro-JH pyriinidin-I yl]6-iminro-Sa-cliolestane (99): 
Yield 75%; m.p. 138 °C; Analysis found: C 66.42, H 8.75, N 9.9%. C31H49C1N40S requires: C 
66.34, H 8.64, N 9.87%; IR (KBr): v 	3353, 3286 (NH, NH2), 1669 (C-0), 1654 (C=N), 
16I8 (C=C), 1251 (C=S), 1019 (C-N), 742 (C-Cl); 'H NMR (CDCI3): 6 7.6 (s, 1H, NH, 
exchangeable with D20), 5.5 (s, 1H, C5'-H), 3.9 (m, 1H, C3a H, W % = 17 Hz), 3.1 (s, 2H, 
NH2, exchangeable with D2O) 1.17 (s, 3H, C10-CH3), 0.72 (s, 3H, C13-CH3), 0.96 and 0.84 
(other methyl protons); 13C NMR (CDC13): 6 183 (C27, 171.6 (C6'), 168.3 (C4'), 155.3 (C6), 
79.8 (C5'), 52.6 (C3), 39 (C5), 35 (Cio), 24 (C7), 22 (C,6), 20 (Cis); MS: m/z 560/562 [Mt]. 
28 
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Pyran is a six membered non-aromatic ring consisting of five carbon atoms, one oxygen atom 
and two double bonds. The molecular formula is C5H60. The term pyran is also often applied 
to the saturated ring analog, which is more properly referred to as tetrahydropyran (oxane). 
There are two isomers of pyran that differ by the location of the double bonds. In 2H-pyran 
(1), the saturated carbon is at position 2 while as in 4H-pyran (2), the saturated, carbon is at 
position 4. 
0(T) 
Masamune and Castelluccil in 1962 first isolated and characterized 4H-pyran by 
the pyrolysis of 2-acetoxy-3, 4-dihydro-2H-pyran (3). It was found too unstable, particularly 
in the presence of air and easily disproportionated to the corresponding dihydropyran (4) and 
the pyrylium ion (5). 
cI:J Pyrolysis 	 Air 	 O 
	
1 	I Disproportion 
a 	OAc  
(3) 	 (2) 	 (4) 	 (5) 
Dormant in 1967 reported the reaction of acetyl acetone (6) with ethylene glycol 
which gave 2-methyl-2-acetonyl-1, 3-dioxolan (7). The compound (7) was acylated with 
diethyl oxalate in presence of sodium methoxide formed methyl 5-(2-methyl-[1, 3] dioxolan-
2-yl)-2, 4-dioxopentanoic acid methyl ester (8). The compound (8) was treated with 0.5 N 
HC[ to give intermediate triketone (9). The compound (9) was refluxed to complete ring 
closure forming 6-methyl-4H-pyran-4-one-2-carboxylic acid (10) which on subsequent 
decarboxylation yielded 2-methyl-4H-pyran-4-one (11). 
32 
0 0 	 O 	 (COOEt)2 
{ 	H~ 0 0 O NaOCH3 - 0 0 0  
	
H3C 	CHa HQ OH ~ f~ -H20 H3C ~!\CH CH3OH H3C 
3 	 COOMe 
(6) (7) (8) 
0 	 0 
0.5 N HCI 	0 	0 	0 	Reflux 	 Ph2O 
R T H3C 	 COQEt~ 	I 	23Q-245 
H3C 0 COON 	H3C 0 
(9) 	(10) 
Lingaiah and co-workers 3 reported an efficient synthesis of polyfunctionalized 4H-
pyrans (14 a-h) which involved one pot condensation of active methylenic diketo compounds 
(12 a-h), aldehydes (13 a-h) and malononitrile using basic Mg/La mixed oxide as catalyst. 
O R2 
0 	0 R2 O + 
<CN
CN Mg/Lamixedoxide 	 EtO 	 CN 
EtO 	Rt 	H 	CH30H, 63 C R' 0 NHz 
(12) (13) (14) 
Ri Rz Rt R2 
(a) C,H4Br (a) C6Hs (a) C2H4Br C6H5 
(b) C21-15 (b) 4 NO2-C6H4 (b) C2H5 4-NO2-C6114 
(c) C31-17 (c) 3-NO2-C6H4 (c) C3H7 3-NO2-C6Ha 
(d) CHZCI (d) 4-Cl-C6H4 (d) CH,CI 4-Cl-C6 
(e) CH2Br (e) 4-CN-C6H4 (e) CH2Br 4-CN-C6H4 
(I) C6114C1 (i) 4-OH-C6 (t) C6114C1 4-OH-C6H4 
(g) C6HhBr (g) 4-Me-C6H4 (g) C6H4Br 4-Me-C6H4 
(h) CH2I (h) 4-OMe-C6H4 (h) CH2,I 4-OMe-C6H4 
Tyvorskii and co-workers4 reported the reaction of oxiranes (15 a-e) with ethyl 
perfluoroalkanoate in presence of sodium iso-propoxide or potassium tert-butoxide that gave 
hydroxypyranones (16 a-e). The hydroxypyranones upon reaction with thionyl chloride in dry 
pyridine yielded chlorosulfites (17 a-e). These sulphites upon refluxing in presence of 
pyridine provided chlorosubstituted pyranones (18 a-e) which on reaction with triethyl amine 
yielded 2-perfluoroalkyl-4H-pyran-4-ones (19 a-e). 
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R2 
R' 	0 	CF3 
(19) 
R' Rz 
(a) H CH3 
(b) H Ph 
(c) CH3 CH3 
(d) CH2CI CH3 
(e) CH2I Ph 
0 	 0 	 0 
RZ Rz R2 
t 	CH3 
O} 	 r-B OK 
I 
	HO~t 	I 	SOC12 	CI-05-01t Ri + CF3CO2Et 	~ l  
Pyridine 
R 	0 	CF3 	 R1 	O 	CF3 
(15) 
	
(16) 
	 (17) 
R' R2 R' R2 R' R2 
(a) H CH3 (a) H CH3 (a) H CH3 
(b) H Ph (b) H Ph (b) H Ph 
(c) CH3 CH3 (c) CH3 CH3 (c) CH3 CH3 
(d) CH2CI CH3 (d) CH2CI CH3 (d) CH,CI CH3 
(e) CH2I Ph (e) CH2I Ph (e) CH2I Ph 
O 
Ci 
Pyridine 	R2 	I 	 Et3N 
R' 	0 	CF3 
(18) 
R' RZ 
(a) H CH3 
(b) H Ph 
(c) CH3 CH3 
(d) CH2CI CH3 
(e) CH2I Ph 
Ivanov and co-workers reported the reaction of 4-hydroxy-6-methyl-pyranone and 
pyridinone derivatives (20 a-c) with Knoevenagel products (21 a-c) in presence of piperidine 
in methanol to yield substituted 2-amino-4H, 5H-pyrano [4, 3 - b] pyran-5-ones (22 a-c). 
OH
0 NH, 
	
NC Y 	 ~i3 C ~ 
Piperidias 
+ 	I 	CH .	x 	Y,CLH3C X 0 Ar O Ar H 
(20) 	 (21) 	 (22) 
X Ar Y X Ar Y 
(a) 0 	(a) Ph 	COOCH3 	(a) 0 	Ph 	COOCH3 
(b) NH (b) Ph 	CN 	 (b) NH Ph 	CN 
(c) NCH1Ph 	(c) NO2Ph COOC1H5 	(c) NCH2Ph NO2Ph COOC2115 
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Yavari and Bayat6 reported that dialkylacetylenedicarboxylates (23 a-d) reacted 
smoothly with triphenylphosphine and ethyl oxo-(2-oxocycloalkyl)-ethanoates (24 a-d) via 
intramolecular Wittig reaction to produce spirocyclobutene derivatives (25 a-d). These Spiro 
systems underwent electrocyclic ring-opening reaction to produce electron-deficient 1, 3-
dienes which spontaneously cyclized to 2H-pyran derivatives (26 a-d). 
COOR 
COOK O O 	0 COOEt  COOK 
Ph3P + 	=C + 	 OEt 	\ COOR 	O 
ROOC 	L 
(C z)n 0 	 (CH2)n 	 COOEt COOR  
(CFi2)n 
(23) 	(24) 	 (25) 	 (26) 
R 	 n 	 R 	n 	 R 	n 
(a) Me 	(a) 3 (a) Me 	3 (a) Me 	3 
(b) Et (b) 4 	 (b) Et 4 	 (b) Et 4 
(c) iPr 	(c) 5 (c) iPr 	5 (c) iPr 	5 
(d) iBu (d) 9 	 (d) iBu 9 	 (d) iBu 9 
Arseneva and Arsenev7 reported that 8-hydroxy-1, 3-dimethyl-4H-cyclohepta [c] 
furan-4-one (27) on reaction with arylidenemalononitriles (28 a-h) gave the corresponding 
condensed 2-amino-4H-pyrans (29 a-h) in good yields. 
Ar 
1. 
F 
H3 
Ar 	CN OH ~/ 
CN 
O 	CH3 
Et3N 
CH3CN / 60 °C 
;N 
NH2 
(27) (28) 
	
(29) 
	
Ar Ar 
(a) C12-C6H3 	 (a) C12-C6H3 
(b) F-C6H4 (b)F-C6Ha 
(c) C1-C6H4 	 (c) Cl-CfiH4 
(d) Br-C6H4 (d) Br-C6H4 
(e) EtO-C6H4 	 (e) EtO-C6H4 
(f) MeO-C6H4 (f) MeO-C6H4 
(g) MeS-C6H4 	 (g) MeS-C6H4 
(h) Thienyl (h) ThienyI 
35 
R 
O^ Cli,Cl 
(35) 
R 
L 
Bobrov and Tyvorskii8 reported the synthesis of 6-methyl-2-(2-pyridyl)-4H-pyran-4- 
one (32). The pyranone precursor (5-ethoxy-1-hydroxy-l-pyridin-2-yl hexa-1, 4-dien-3-one) 
(31) was prepared by Claisen condensation of acetylacetone enol ether (30) with ethyl 
pica linate. 
0 	OC2H5 
II I Ethyl picoliriate  
H3C~ r-BuOK, Et,O 
Q OH 
/ N\ 
&0 CH3 
0 
HCI / i-PrOH 	 ` 	N— 
H3C 
(30) 
	
(31) 
	
(32) 
Yan and co-workers9 reported the reaction of aromatic aldehydes (33 a-j) with 3-oxo-
butyric acid-2-chloroethyl ester (34) in acetic anhydride in presence of zinc chloride, which 
was irradiated by an ultrasonic processor at 50 °C and 100 W to yield substituted 4-aryl-4H-
pyran-3, 5-dicarboxylates (35 a-j). 
CHO 
O 	0 	ZnCI, / Ac,O 
O ~CH2CI U. S. 
R 
(33) 	(34) 
R 
(a) 2-F 	 (a) 2-F 
(b) 2, 4-(CH3)2 	 (b) 2, 4-(CH3)2 
(c) 4-Br 	 (c) 4-Br 
(d) 4-OC2H5 	 (d) 4-OC2H5 
(e) 2, 4-Cl, Br (e) 2, 4-Cl, Br 
(1)2, 4-Cl, I 	 (1)2,4-Cl,I 
(g) 4—F 
	
(g) 4-F 
(h) 2, 4-NO2, CH3 	 (h) 2,4-NO2, CH3 
(i) 2, 4-(OH)2 (i) 2, 4-(OH)2 
6) 3-Br 	 (j) 3-Br 
Heravi and co-workers1° reported one-pot, three component reaction of aromatic 
aldehydes (36 a-e), malononitrile and a-naphthol (37) in presence of methanesulfonic acid to 
yield two isomers of 2-amino-4H-chromenes 38 (a-e) and 39 (a-e) in very good yields. 
NH2 	 CN 
OH O 	CN N H2 
Methanesulfonic acid 	 ~ 
Ar-CHO + NC-CHz-CN 	 Ar + 
CH3CN , i 	
Ar 
(36) 
	
(37) 
	
(38) 	(39) 
Ar 	 Ar 	 Ar 
(a) C12C6H3  
(b) (NO2)2C6H3 
(c) (MeO)2C6H3  
(d) FC1C6H3  
(e) CIN02 C6H3  
(a) C12C6H3 
(b) (NO2)2CGH3 
(c) (MeO)2C6H3 
(d) FCIC6H3  
(e) C1NO2C6H3  
(a) C12C6H3 
(b) (NO2)2CGH3 
(c) (MeO)2C6H3  
(d) FC1C6H3  
(C) CIN02C6H3 
El-Latif and co-workersil reported the reaction of 3 /3-indoly1acry1oy1pyridin (40) 
with malononitrile in presence of piperidine to yield 2-amino-4-(3-indolyl)-6-(3-pyridyl)- 
pyran-3-carbonitrile (41). 
0 
i 	HN r 
(40) 
NH2 
0 	CN 
NC-CH2-CN 
Piperidine 	 HN r 1 
(41) 
Moghadam and Miri'2 reported the reaction of isatins (42 a-b), malononitrile or ethyl 
cyanoacetate and 1, 3-dicarbonyl compound in the ionic liquid to yield Spiro [4H-pyran-
oxindole] derivatives (43 a-d) in better amounts. 
0 
f 
R 
(42) 
R 	 X 
(a) H 	 CN 
(b) Bu COOEt 
O 	0 	[Bmim]BF4 
+ H3COEt 	1  
H2N 0  
I  CH3  
.x 
Ct70Et 
N 0  
R 
(43) 
R X 
(a) H CN 
(b) H COOEt 
(c) Bu CN 
(d) Bu COOEt 
Mane and co-workers13 reported the Baker's yeast catalyzed one-pot three-component 
cyclocondensation of aryl aldehydes (44 a-g), malononitrile and /3-dicarbonyls (45 a-c) in 
dimethylacetamide solvent to obtain polyfunctionalized 4H-pyrans (46 a-g). 
0 	R 
R-CHO + NC-CH2-CN + 
	 Baker yeast 	
R1 	
i 	
CN 
0 »z 
(44) 
	
(45) 
	
(46) 
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R 	11 	 R 	Rz 
(a) (MeO)2C6H3 	 (a) OEt 	 (a) (MeO)2C6H3 	OEt 
(b) C12C6H3 	 (b) Me (b) C12C6H3 	Me 
(c) 3-CIC6H4 (e) OMe 	 (c) 3-C1C6H4 	OMe 
(d) 4-OHC6H4 	 (d) 4-OHC6H4 	OEt 
(e) 4-FC6H.s (e) 4-FC6H4 Me 
(f) 3-Pyridyl 	 (f) 3-Pyridyl 	OMe 
() 4-CH3C6H4 (g) 4-CH3C6H4 	OEt 
Seeliger and co-workers14 have reported the formation of dihydropyrano [2, 3 - c] 
pyrimidinedione (49) in 80% yields by the reaction of 1, 3-dimethylbarbituric acid (47) with 
arylidene malononitrile (48) upon protonation. 
0 
f,N 
p~0 ~ CN 	 CN 
O Ph 
(47) 	 (48) 	 (49) 
Martin and co-workers15 reported the synthesis of pyrano [2, 3 - b] pyridine derivative 
(51) from malononitrile and 2-benylidene-1, 3-diketone (50). The compound 50 is easily 
accessible via Knoevenagel condensation of benzaldehyde and pentan-2, 4-dione. 
Ph 0 
Me 
+ NC-CH2-CN 
O Me 
Piperidine 
EtOH  
Me 
(50) 
	
(51) 
Feng and co-workers16 reported the multi-component reactions of nucleoside (52), 4- 
hydroxy-2-pyranone (53a) or 4-hydroxy-pyridin-2(1H)-one (53b) and malononitrile in 
presence of ionic liquid to provide the efficient synthesis of pyrano [4, 3 - b] pyran 
nucleoside derivative (54a) and pyrano [3, 2 - c] pyridine nucleoside derivative (54b) which 
were also found as potential antiviral and anti-leishmanial agents. 
38 
HO 	O 0 
HN 	CHO 
HO 	O N 	 [bmim]BF4 	HO 
+ I 	 + NC-CHI-CN 	 0 
80°C 	X 	CN 
OH 	OH 
NHS 
(52) 	(53) 	 (54) 
X X 
(a) O (a) O 
(b) NH 	 (b) NH 
Yao and co-workers17 reported a rapid and facile synthesis of cyclopenta [b] pyran 
derivatives namely, 2-amino-4-aryl-5-oxo-tetrahydrocyclopenta [b] pyran-3 -carbonitriles (57 
a, c) and ethyl-2-amino-4-aryl-5-oxo-tetrahydrocyclopenta [b] pyran-3-carboxylates (57 b, d) 
under solvent free conditions by triturating a mixture of the three components; aromatic 
aldehydes (55 a, b), malononitrile / ethyl cyanoacetate and cyclopentadione (56) at 80°C. 
O 	O 	Ar 
R 
Ar-CHO + NC-CH,-R +  
O 	 O 	
IIII' NH 
(55) 	(56) (57) 
Ar R 	 Ar 	R 
(a) CslAs 	 CN 	 (a) C~H5 	CN 
(b) Cl-C6H4 COOEt (b) C6H5 	COOEt 
(c) Cl-C6114 	CN 
(d) Cl-C6H4 COOEt 
Karimi-3aberi and Pooladian18 synthesized a series of substituted 2-amino-4H-pyran-
3-carbonitriles (59 a-s) through a one-pot condensation of malononitrile and a, a'-bis 
(arylidene) cyclopentangnes (58 a-s) in ethanol by using K2CO3 as a catalyst. Short 
experimental reaction times, excellent yields, no need to use cumbersome apparatus for 
purification of the products, inexpensiveness and commercially availability of the catalyst 
were the advantages of this method. 
39 
0 
\ 	/ 	\ 	 K2CO3 (1 0%) 
NC-CH2-CN — 	r 
EiOH / Reflux 
R1 
(58) 	 (59) 
R R' R RI 
(a) CHI 2-Cl (a) CH2 2-Cl 
(b) CH2 H (b) CH2 H 
(c) CH, 2-Cl, 4-Cl (c) CH2 2-Cl, 4-Cl 
(d) C2H4 2-Cl (d) C2H4 2-CI 
(e) C2H4 H (e) C2H4 H 
(1) C2H4 2-Cl, 4-Cl (f) C2H4 2-Cl, 4-Cl 
(9) C2H4 4-F (9) C2H4 4-F 
(h) C2H4 4-Br (h) C2H4 4-Br 
(i) C,H4 4-OMe (1) C,H4 4-OMe 
0) C,H;  4-Me (j) C2H. 4-Me 
(k) C2H4 2-Cl, 6-F (k) C2H4 2-Cl, 6-F 
(1) C3H6 H (1) C3H6 H 
(m) C3H6 2-Cl (m) C3H6 2-Cl 
(n) C3H6 2-Cl, 4-Cl (n) C3H6 2-Cl, 4-Cl 
(o) C3H6 4-F (o) C3H6 4-F 
(p) C3H6 4-Br (p) C3H6 4-Br 
(q) C3H6 4-OMe (q) C3H6 4-OMe 
(r) C3H6 4-Me (r) C3H6 4-OMe 
(s) C3H6 2-Cl, 6-F (s) C3H6 2-Cl, 6-F 
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Steroidal pyrans have always attracted considerable attention because of being an important 
class of biologically active molecules. Their profound physiological and clinical importance is 
now well validiated.19 They have the potential to act as drugs for the treatment of a number of 
diseases including microbial and viral infections, tumours, diuretic disorders, and anti-
leishmanial agents and antianaphylactic proximities.'6' 20"" The diversity in the biological 
action might be due to the presence of different functional groups located around the 
tetracyclic core which serve as substrates for different targets. The advantage of employing 
hydrophobic steroid units is their ability to interact with cell membranes and thus pave the 
way for biological activity of such hybrid molecules.23  
Attention has been devoted in the literature to the synthesis of several heterocycles 
that exhibit valuable pharmacological activities.24-26 Among these are 4H-pyran derivatives 
which represent an important class of organic compounds with wide number of applications. 
They are not only used in cosmetics, pigments and biodegradable agrochemicals27' 28 but also 
constitute a structural unit of many natural products.29 These compounds have been reported 
to possess various pharmacological activities such as antiallergic, 28 antitumor30 and 
antibacterial.' 
The biological importance of these steroidal 4H-pyrans 28, 30.31  and study of interesting 
behavior of ethyl cyanoacetate and malononitrile with simple a, j7-unsaturated ketones giving 
4H-pyrans encouraged us to make similar studies with steroidal a, /3-unsaturated ketones. The 
substrates selected for synthesizing the new steroidal 4H-pyrans include cholest-5-en-7-one32 
(60), 3fl-acetoxycholest-5-en-7-one32 (61) and 3fl-chlorocholest-5-en-7-one32 (62). The 
products obtained have been characterized on the basis of spectral (IR, 'H NMR, 13C NMR, 
MS) and elemental analyses. 
X 
(60) H 
(61) OAc 
(62) Cl 
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Reaction of cholest-5-en-7-one (60) with ethyl cyanoacetate. 
The cholest-5-en-7-one (60) in absolute ethanol was allowed to react with ethyl 
cyanoacetate in presence of piperidine. After completion of the reaction, the reaction mixture 
was taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 63, m.p. 142 °C. 
CN-CH:-CO-OEt, Piperidine p. 
EtOH C` O 
o NH, 
(60) 	 (63) 
Characterization of the compound, m.p. 142 °C as 2'-amino-3'-carboethoxycholest-6-eno 
[5, 7- d e] 4H-pyran (63): 
The elemental analysis of compound 63 corresponded to the molecular formula 
C32H51NO3. Its IR spectrum showed a band at 3290 cni 1 which could be assigned to NH2 
group while as the bands at 1669, 1625, 1619, 1216 and 1067 cm 1 were attributed to OCOC, 
C6=C-7, C2'=C3', C7-0 and OC-O group, respectively. These values supported the presence of 
4H-pyran moiety33 in the product molecule. The structure 63 was well supported by its 'H 
NMR spectrum which displayed broad singlet integrating for two protons at 9 2.48 
(exchangeable with D20) indicating the presence of NH2 while as the singlet integrating for 
one proton at 9 5.3 showed the presence of C6-olefmic proton. A quartet integrating for two 
protons at a 5.7 was assigned for methylene protons (CH3CH2) while as a triplet integrating 
for three protons at 6 1.03 was assigned for methyl protons (CH3CH2). The prominent peaks 
for angular and side-chain methyl protons were observed at 6 1.13, 0.99 and 0.86. Its '3C 
NMR spectrum displayed characteristic signals at S 168.9 (CO-OEt), 166.3 (C2A, 155.8 (C7), 
112.5 (C6), 108.4 (C3') and 23.6 (C3). Remaining carbon atoms were seen in accordance to the 
cholestane series. The structure of compound 63 was further supported by its mass spectrum 
in which the distinct molecular ion peak (W 497) was observed. 
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On the basis of foregoing discussion and the mechanism proposed (Scheme 2.1), this 
compound can be best characterized as 2'-amino-3'-carboethoxycholest-6-eno [5, 7- d e] 4H-
pyran (63). 
Reaction of 3fl-acetoxycholest-5-en-7-one  (61) with ethyl cyanoacetate. 
The 3fl-acetoxycholest-5-en-7-one (61) in absolute ethanol was allowed to react with 
ethyl cyanoacetate in presence of piperidine. After completion of the reaction, the reaction 
mixture was taken in diethyl ether, washed with water and dried over anhydrous sodium 
sulfate. Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 64, m.p. 176 °C. 
N-CH,-CO-OEt. Piperidine 
EtOH 
 
O  
uef0lf 	fiNH, 
(61) 	 (64) 
Characterization of the compound, m.p. 176 °C as 3/1-acetoxy-2'-amino-3'-carboethoxy 
cholest-6-eno 15,  7- del 4H-pyran (64): 
The compound 64 was correctly analyzed for the molecular formula C34H53NOS. Its 
IR spectrum showed a band at 3310 czn I which could be assigned to NH2 group. The strong 
absorption bands at 1740 and 1036 cm 1 indicated the presence of acetate group, while as the 
bands at 1673, 1620, 1618, 1246 and 1036 cni l were attributed to OCOC, C6=C7, C2'=C3', 
C7-O and OC-O group, respectively. These values supported the presence of 4H-pyran 
moiet?J in the product molecule. The structure 64 was well supported by its 'H NMR 
spectrum which displayed broad singlet integrating for two protons at S 2.46 (exchangeable 
with D-,O) indicating the presence of NH2 while as the singlet integrating for one proton at 9 
5.3 showed the presence of C6-olefinic proton. The quartet integrating for two protons at d 
5.7 was assigned for methylene protons (CH3CH2) while as the triplet integrating for three 
protons at d 1.02 was assigned for CH3CH2. A broad multiplet (W112 = 15 Hz, axial) for one 
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proton was observed at 6 4.7 which could be assigned to C3a-H. The three acetoxy group 
protons appeared at J 2.03 as a sharp singlet. Other prominent peaks for angular and side-
chain methyl protons were observed at 6 1.14, 1.02, 0.97 and 0.82. The 13C NMR spectrum of 
compound 64 displayed characteristic signals at 6 171.2 (OCOCH3), 167.9 (CO-OEt), 165.1 
(C2'), 157.2 (C7), 112.5 (C6), 104.7 (C3') and 72.2 (C3). Remaining carbon atoms were seen in 
accordance to the cholestane series. The structure of compound 64 was further supported by 
its mass spectrum in which the distinct molecular ion peak (M4' 555) was found. 
On the basis of above studies and its analogy with earlier compound 63, this 
compound can be best characterized as 3fi-acetoxy-2'-amino-3'-carboethoxycholest-6-eno [5, 
7 - d e] 4H-pyran (64) 
Reaction of 3Q-chlorocholest-5-en-7-one (62) with ethyl cyanoacetate. 
The 3fi-chlorocholest-5-en 7-one (62) in absolute ethanol was allowed to react with 
ethyl cyanoacetate in presence of piperidine. After completion of the reaction, the reaction 
mixture was taken in diethyl ether, washed with water and dried over anhydrous sodium 
sulfate. Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 65, m.p. 114 °C. 
N.-CH2-CO-OEt, Piperidine 
EtOH 	 Cl 
(62) 	 (65) 
Characterization of the compound, m.p. 114 °C as 3f-ebloro-2'-amino-3'-carboethoxy 
cholest 6-eno [5, 7- d e] 4H-pyran (65): 
The compound 65 was correctly analyzed for the molecular formula C32H50CIN03 
(Beilstein positive). Its 1R spectrum showed a band at 3296 cm' which could be assigned to 
NH2 group while as the bands at 1661, 1622, 1618, 1297, 1080 and 749 cmi t were attributed 
to OCOC, C6=C7, C2'=C3', C7-O, OC-O and C-Cl group, respectively, These values supported 
the presence of 4H-pyran moiety33 in the product molecule. The structure 65 was well 
supported by its 1H NMR spectrum which displayed a broad singlet integrating for two 
44' 
NC-CH-CO-OEt 
s 
x 
x 
x 	_ 
/C /
O 
Eto-oc 	C 
NH 
x 
H (63) 
OAc (64) 
C1 (65) 
protons at S 2.7 (exchangeable with D20) indicating the presence of NH2 while as the singlet 
integrating for one proton at d 5.6 showed the presence of C6-olefinic proton. The quartet 
integrating for two protons at 6 6.07 was assigned for CH3CH2 while as the triplet integrating 
for three protons at 6 1.01 was assigned for CH3CH2. A broad multiplet (W172 = 17 Hz, axial) 
for one proton was observed at 6 3.9 which could be assigned to C3a-H. The prominent peaks 
for angular and side-chain methyl protons were observed at d 1.13, 1.01, 0.96 and 0.82. The 
13C NMR spectrum of compound 65 displayed characteristic signals at 6 166.4 (CO-OEt), 
163.1 (C2'), 156.4 (C7), 111.6 (C6), 106.5 (C3') and 50.7 (C3). Remaining carbon atoms were 
seen in accordance to the cholestane series. The structure of compound 65 was further 
supported by its mass spectrum in which the distinct molecular ion peak (M+' 529/531) was 
found. 
The above data led to the structure of compound 65 as, 3f3-chloro-2'-amino-3'- 
carboethoxycholest-6-eno [5, 7 - d e] 4H-pyran. 
Formation of steroidal 411-pyrans (63-65) under the condition case and in the light of 
available literatureI I ' 18 may be shown according to the proposed mechanism (Scheme 2.1). 
H,N 
r 
Scheme 2.1 Mechanism for the formation of 2'-amino-3'-carboethoxycholest-6-eno [5, 7 - d 
e] 4H-pyran derivatives (63-65) 
Work published; 
Synthesis, molecular docking and biological evaluation of new steroidal 4H-pyrans, 
Shamsuzzaraan, Ayaz Mahmood Dar, et aI, Spectrochimica Acta Part A: Molecular and 
Biomolecular Spectroscopy 117 (2014) 493-501 
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Reaction of cholest-5-en-7-one (60) with malononitrile. 
The cholest-5-en-7-one (60) in absolute ethanol was allowed to react with 
malononitrile in presence of piperidine. After completion of the reaction, the reaction mixture 
was taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of the solvents gave an oil which was crystaIIized from methanol to afford 
compound 66, m.p. 149 °C. 
CN-CH,-CN, Piperidine 
EtOH NC" ' ~O 
'NH, 
(60) 	 (66) 
Characterization of the compound, m.p. 149 °C as 2'-amino-3'-cyanocholest-6-eno [5, 7 -  
d e] 4H-pyran (66): 
The elemental analysis of compound 66 corresponded to the molecular formula 
C30H46N20. Its IR spectrum showed a band at 3363 cm t which could be assigned to NI-I2 
group while as the bands at 2234, 1630, 1617, 1078 and 1037 cni t were attributed to C=N, 
C6=C7, C2'=C3', C7-O and C-N group, respectively. These values supported the presence of 
4H-pyran moiety33 in the product molecule. The structure 66 was well supported by its t H 
NMR spectrum which displayed broad singlet integrating for two protons at (S 2.67 
(exchangeable with D20) indicating the presence of NH2 while as the singlet integrating for 
one proton at 6 5.26 showed the presence of C6-olefinic proton. The prominent peaks for 
angular and side-chain methyl protons were observed at 6 1.17, 1.04, 1.02 and 0.86. The 13C 
NMR spectrum of compound 66 displayed characteristic signals at d 164 (C2A, 154.3 (C7), 
134.4 (C=N), 113.3 (C6), 66.7 (C3') and 23.2 (C3). Remaining carbon atoms were seen in 
accordance to the cholestane series. The structure of compound 66 was further supported by 
its mass spectrum in which the distinct molecular ion peak (M+ 450) was found. 
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On the basis of foregoing discussion and the mechanism proposed (Scheme 2.2), this 
compound can be best characterized as 2'-amino-3'-cyanocholest-6-eno [5, 7 - d e] 4H-pyran 
(66). 
Reaction of 311-acetoxycholest-5-en-7-one (61) with malononitrile. 
The 3fl-acetoxycholest-5-en-7-one (61) in absolute ethanol was allowed to react with 
malononitrile in presence of piperidine. After completion of the reaction, the reaction mixture 
was taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 67, m.p. 165 °C. 
-CR -CN, Piperidine 
EtOH 
(61) 	 (67) 
Characterization of the compound, m.p. 165 °C as 3J1-acetoxy-2'-amino-3`-cyanocholest-
6-eno 15, 7- d eJ 4H-pyran (67): 
The compound 67 was correctly analyzed for the molecular formula C32H48N203. Its 
IR spectrum showed a band at 3340 cm-1 which could be assigned to NH2 group. The IR 
spectrum of the compound 67 also exhibited strong absorption bands at 1713 and 1036 cm 1  
indicating the presence of acetate group and the bands at 2203, 1625, 1620, 1065 and 1019 
cm' were attributed to C N, C6=C7, C2'=C3', C7-O and C-N group, respectively. These 
values supported the presence of 4H-pyran moiety33 in the product molecule. The structure 67 
was well supported by its 'H NMR spectrum which displayed broad singlet integrating for 
two protons at 6 2.5 (exchangeable with D20) indicating the presence of NH2 while as the 
singlet integrating for one proton at o 5.69 showed the presence of C6-olefinic proton. A 
broad multiplet (W,,2 = 15 Hz, axial) for one proton was observed at b 4.7 which could be 
assigned to C3a-H. The acetoxy group protons appeared at S 2.05 as a sharp singlet. Other 
prominent peaks for angular and side-chain methyl protons were observed at 6 1.14, 1.04, 
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1.02 and 0.82. The 3CNMR spectrum of compound 67 displayed characteristic signals at d 
173.1 (OCOCH3), 168 (C2'), 157.2 (CA), 132.2 (C=N), 111.6 (Ce), 72.2 (C3) and 67.2 (C3'). 
Remaining carbon atoms were seen in accordance to the cholestane series. The structure of 
compound 67 was further supported by its mass spectrum in which the distinct molecular ion 
peak (M+- 508) was found. 
On the basis of above studies and its analogy with earlier compound 66, this 
compound can be best characterized as 3/3-acetoxy-2'-amino-3'-cyanocholest-6-eno [5, 7- d e] 
4H-pyran (67). 
Reaction of 3Q-chlorocholest-5-en-7-one (62) with malononitrile. 
The 3fl-chlorocholest-5-en-7-one (62) in absolute ethanol was allowed to react with 
malononitrile in presence of piperidine. After completion of the reaction, the reaction mixture 
was taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of the solvents gave an oil which was crystallized from methanol to afford 
compound 68, m.p. 139 °C. 
-CH_,-CN, Piperidine 
EtOH 
NHS 
(62) 	 (68) 
Characterization of the compound, m.p. 139 °C as 3/t-chloro-2'-amino-3'-cyanocholest-
6-eno [5, 7- d e] 4H-pyran (68): 
The compound 68 was correctly analyzed for the molecular formula C3oH45C1N20 
(Beilstein positive). Its IR spectrum showed a band at 3396 cm:l which could be assigned to 
NH2 group while as the bands at 2259, 1630, 1625, 1116, 1054 and 742 cm l were attributed 
to C=N, C6=C7, C2'=C3', C7-O, C-N and C-Cl group, respectively. These values supported 
the presence of 4H-pyran moiety33 in the product molecule. The structure of 68 was well 
supported by its 'H NMR spectrum which displayed broad singlet integrating for two protons 
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NC 
HEN 
NCH-CN 
e  B 
CH y-OH 
NC C 
x 
NC  
NH 
x 
H (66) 
OAc (67) 
Cl (68) 
at d 2.72 (exchangeable with D20) indicating the presence of NH2 while as the singlet 
integrating for one proton at S 5.3 showed the presence of C6-olefinic proton. A broad 
multiplet (WI,,2 = 17 Hz, axial) for one proton was observed at d 3.9 which could be assigned 
to C3a-H. Other prominent peaks for angular and side-chain methyl protons were observed at 
5 1.16, 1.04, 1.02 and 0.82. The 13C NMR spectrum of compound 68 displayed characteristic 
signals at S 166 (C2'), 155.2 (C7), 129.2 (C N), 114.6 (C6), 67.3 (C3') and 50.2 (C3). 
Remaining carbon atoms were seen in accordance to the cholestane series. The structure of 
compound 68 was further supported by its mass spectrum in which the distinct molecular ion 
peak (M+- 4841486) was found. 
The above data led to the structure of compound 68 as, 38-chloro-2'-amino-3'- 
cyanocholest-6-eno [5, 7- d e] 4H-pyran. 
Formation of steroidal 4H-pyrans (66-68) under the condition case and in the light of 
available literature)1,18 may be shown according to the proposed mechanism (Scheme 2.2). 
Scheme 2.2 Mechanism for the formation of 2'-arnino-3'-cyanocholest-6-eno [5, 7- d e] 4H-
pyran derivatives (66-68) 
Work published; 
Synthesis and biological studies of steroidal pyran based derivatives, Shamsuzzaman, Ayaz 
Mahmood Dar, et al., Journal of Photochemistry and Photobiology B: Biology 129 (2013) 
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All the melting points were determined in degrees Celsius on a Kofler apparatus and are 
uncorrected. The IR spectra were recorded on KBr pellets with Perkin Elmer RXI 
Spectrophotometer and values are given in cm'. 1 H and 13C NMR spectra were run in CDC13 
on a JEOL Eclipse (400 MHz) instrument with TMS as internal standard and values are given 
in ppm (b). Mass spectra were recorded on a JEOL SX 102/DA-6000 Mass Spectrometer. 
Thin layer chromatography (TLC) plates were coated with silica gel G and exposed to iodine 
vapors to check the homogeneity as well as the progress of reaction. Petroleum ether refers to 
a fraction of boiling point 60-80 °C. Sodium sulfate (anhydrous) was used as a drying agent. 
Cholest-5-ene: 
3fl-Chlorocholest-5-ene (10 g) was dissolved in warm amyl alcohol (230 mL) and 
sodium metal (20 g) was added in small portions to the solution with continuous stirring over 
the period of 8 h. The reaction mixture was warmed occasionally. When all the sodium metal 
was dissolved, the reaction mixture was poured into water, acidified with dilute hydrochloric 
acid and allowed to stand overnight. A white crystalline solid thus obtained was filtered under 
suction, washed thoroughly with water and air dried. Recrystallization of the crude material 
from acetone gave cholest-5-ene (8.3 g) in cubes, m.p. 92 °C (reported m.p. 89-91 0C).32 
Cholest--en-7-one (60): 
A solution of tent-butyl chromate [tent-butyl alcohol (60 mL), chromium trioxide (20 
g), acetic acid (84, mL) and acetic anhydride (10 mL)] were added at 0 °C to a solution of 
cholest-5-ene (8 g) in CC14 (150 mL), glacial acetic acid (30 mL) and acetic anhydride (10 
mL). The contents were refluxed for 3 h and then diluted with water. The organic layer was 
washed with sodium bicarbonate solution (5 %) and water and dried over anhydrous sodium 
sulfate. Evaporation of solvents under reduced pressure provided an oil which was 
crystallized from methanol to give cholest-5-en-7-one (3.1 g) as needles, m.p. 128 °C 
(reported m. p. 125-129 °C).32 
3 fl-Acetoxycy olest ~.5-ene: 
A mixture of cholesterol (50 g), pyridine (75 mL freshly distilled over KOH) and 
freshly distilled acetic anhydride (50 mL) was heated on a water bath for 2 h. The resulting 
brown colored reaction mixture was poured into crushed ice-water mixture with stirring. A 
light brown solid thus obtained was filtered under suction, washed with water until free from 
50 
pyridine and air dried. The crude product on crystallization from acetone gave pure 3fl-
acetoxycholest-5-ene (45 g), m.p. 115 °C (reported m.p. 115-116 °C).34 
3J3-Acetoxycholest-5-en-7-one (61): 
To a solution of 3fl-acetoxycholest-5-ene (8 g) in carbon tetrachloride (150 mL), acetic 
acid (30 mL) and acetic anhydride (10 mL) was added at 0 °C a solution of tent-butyl 
chromate [tert-butyl alcohol (60 mL), chromium trioxide (20 g), acetic acid (84 mL) and 
acetic anhydride (10 mL)]. The reaction mixture was heated under reflux for 4 h and then it 
was diluted with cold water. The organic layer was taken in diethyl ether, washed with water, 
sodium bicarbonate solution (5%) and again with water and dried over anhydrous sodium 
sulfate. Evaporation of solvents under reduced pressure provided an oil which was 
crystallized from methanol to give 3/3-acetoxycholest-5-en-7-one (61) as crystals (3.5 g), nip. 
156 °C (reported m. p. 156-158 °C).32 
3fl-Chlorocholest-5-ene: 
Freshly purified thionyl chloride (40 mL) was added gradually to cholesterol (50 g) at 
room temperature. A vigorous reaction ensured with evolution of gaseous products. When the 
reaction slackened, the mixture was gently heated at temperature 50-60 °C on water bath for 1 
h and then poured into crushed ice-water with stirring. The yellow solid thus obtained was 
filtered under suction and washed several times with ice-cold water and air dried. 
Recrystallization of crude product from acetone gave 3fl-chlorocholest-5-ene (42 g), m.p. 95-
96 °C (reported m.p. 96-97 0C).35 It gave positive Beilstein test and a yellow color with tetra-
nitromethane in chloroform. 
3/J-Chlorocholest-5-en-7-one (62): 
A solution of tert-butyl chromate [tert-butyl alcohol (60 mL), chromium trioxide (20 
g), acetic acid (84 mL,) and acetic anhydride (10 mL)] were added at 0 °C to a solution of 3/3-
chlorocholest-5-ene (8 g) in CC14 (150 mL), glacial acetic acid (30 mL) and acetic anhydride 
(10 mL). The contents were refluxed for 3 h and then diluted with water. The organic layer 
was washed with sodium bicarbonate solution (5 %) and water and dried over anhydrous 
Na25O4. Evaporation of solvents under reduced pressure furnished the product as an oil which 
was crystallized from methanol to give 3/3-chlorocholest-5-en-7-one (62) (3.3 g) as needles, 
m.p. 144 °C (reported m. p. 144-145 °C). 32 
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Reaction of cholest-5-en-7-one derivatives (60-62) with ethyl cyanoacetatelmalononitrile: 
To a solution of cholest-5-en-7-one derivatives (60-62) (1 mmol) in absolute ethanol 
(20 mL) was added ethyl cyanoacetate/ malononitrile in equimolar ratio followed by 
piperidine (1.5 mL). The reaction mixture was refluxed for 11 h. The progress of reaction was 
monitored by TLC. After completion of the reaction, excess solvent was reduced to three 
fourths of the original volume under reduced pressure. The reaction mixture was taken in 
diethyl ether, washed with water and dried over anhydrous sodium sulfate. Evaporation of 
solvents and crystallization of the oily residue from methanol afforded corresponding 
products (63-68). 
2'-Ainilio-3'-carboethoxycholest-6-eno [5, 7- d e] 4H-pyran (63): 
Yield 70%; m.p. 142 °C; Analysis found: C 77.27, H 10.26, N 2.81%. C32H51NO3 requires: C 
77.18, H 10.06, N 2.77%; IR (KBr): v ma.x 3290 (NH2), 1669 (OCOC), 1625 (C6=C7), 1619 
(C2'=C3'), 1216, 1067 (C-O); 'H NMR (CDC13): S 5.7 (2H, q, CHZ), 5.3 (1H, s, C6 H), 2.48 
(2H, s, NH2, exchangeable with D20), 1.13 (3H, s, C10-CH3), 1.2 (3H, s, C13-CH3), 1.03 (3H, 
t, CH3), 0.99 and 0.86 (other methyl protons); 13C NMR (CDC13): S 168.9 (CO-OEt), 166.3 
(C2'), 155.8 (C7), 112.5 (C6), 108.4 (C3'), 23.6 (C3); MS: m/z 497 [M}']. 
3/1-Acetoxy-2'-amino-3'-tarboethoaytIiolest-6-eno [5, 7- d e] 4H-pyran (64): 
Yield 70%; m.p. 176 °C; Analysis found: C 73.51, H 9.54, N 2.52%. C34H53N05 requires: C 
73.44, H 9.37, N 2.48%; IR (KBr): v max 3310 (NH2), 1740 (OCOCH3), 1673 (OCOC), 1620 
(C6=C7), 1618 (C2'=C31), 1246, 1036 (C-O); 'H NMR (CDC13): 6 5.7 (2H, q, CH2), 5.3 (1H, s, 
C6 H), 4.7 (1H, m, C3a-H, W% = I5 Hz), 2,46 (2H, s, NH?, exchangeable with D20), 2.03 
(3H, s, OCOCH3), 1.20 (3H, s, C,3-CH3), 1.14 (3H, s, C14-CH3), 1.02 (3H, t, CH3), 0.97 and 
0.82 (other methyl protons); 13C NMR (CDC13): 6 171.2 (OCOCH3), 167.9 (CO-OEt), 165.1 
(C2'), 157.2 (C7), 112.5 (C6), 104.7 (C3'), 72.2 (C3); MS: m/z 555 [M}']. 
311-Chloro-2'-amino-3'-carboethoxycliolest-6-eno [5, 7- d e] 4H-pyran (65): 
Yield 70%; m.p. 114 °C; Analysis found: C 72.58, H 9.48, N 2.64%. C32H54C1NO3 requires: 
C 72.45, H 9.34, N 2.62%; IR (KBr): v „pax 3296 (NH2), 1661 (OCOC), 1622 (C6=C7), 1618 
(C21=C3'), 1297, 1080 (C-O), 749 (C3-Cl); 'H NMR (CDC13): 6 6.07 (2H, q, CH2), 5.6 (1H, s, 
C6 H), 3.9 (IH, m, C3a-H, W'h = 17 Hz), 2.7 (2H, s, NH2, exchangeable with D,O), 1.2 (3H, 
s, C13-CH3), 1.13 (3H, s, C10-CH3), 1.01 (3H, t, CH3), 0.96 and 0.82 (other methyl protons); 
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'3C NMR (CDC13): (5166.4  (CO-OEt), 163.1 (C2`), 156.4 (C7), 111.6 (C6), 106.5 (C3'), 50.7 
(C3); MS: m/z 5291531 [M+']. 
2' Ammo-3'-cyanocholest-6-eno [5, 7- d e] 4H-pyran (66): 
Yield 75%; m.p. 149 °C; Analysis found: C 80.0, H 10.22, N 6.22%. C30H46N20 requires: C 
79.96, H 10.12, N 6.17%; IR (KBr): v max  3363 (NH2), 2234 (CN), 1630 (C6=C7), 1617 
(C2'=C3'), 1078 (C-O), 1037 (C-N); 'H NMR (CDCI3): (55.26 (I H, s, C6 H), 2.67 (2H, s, NH2, 
exchangeable with D20), 1.2 (3H, s, C13-CH3), 1.17 (3H, s, C,o-CH3), 1.04 and 1.02 (other 
methyl protons); '3C NMR (CDC13): S 164 (C2'), 154.3 (C7), 134.4 (C=N), 113.3 (C6), 66.7 
(C3'), 23.2 (C3); MS: m/z 450 [M+']. 
31)-A  cetoxy-2 'amino-3'-cyanocliolest-6-eno 15, 7- d e] 4H-pyran (67): 
Yield 75%; m.p. 165 °C; Analysis found: C, 75.59, H 9.44, N 5.51%. C32HASN2O3 requires: C 
75.43, H 9.26, N 5.44%; IR (KBr): v max 3340 (NH2), 2203 (CN), 1713 (OCOCH3), 1625 
(C6' C7), 1620 (C2'=C3'), 1065 (C-O), 1019 (C-N); 'H NMR (CDC13): (55.69 (111, s, C6 H), 4.7 
(1H, m, C3a-H, W% = 15 Hz), 2.5 (2H, s, NH2, exchangeable with D20), 2.05 (3H, s, 
OCOCH3), 1.2 (3H, s, C3-CH3), 1.14 (3H, s, C10-CH3), 1.04 and 1.02 (other methyl protons); 
'3C NMR (CDC13): 6 173.1 (OCOCH3), 168 (C2'}, 157.2 (C7), 132.2 (CEN), I11.6 (C6), 72.2 
(C3), 67.2 (C3'); MS: nz/z 508 [Mt]. 
3/1-Chloro-2'-amino-3'-cyanocl:olest-6-eno [5, 7- d e] 4H pyran (68): 
Yield 75%; m.p. 139 °C; Analysis found: 74.38, H 9.29, N 5.78%. C30H45C1N20 requires: C 
74.26, H 9.12, N 5.61%; IR (KBr): v max 3396 (NH2), 2259 (CN), 1630 (C6=C7), 1625 
(C2'=C3'), 1116 (C-O), 1054 (C-N), 742 (C-Cl); 'H NMR (CDC13): (5 5.3 (1H, s, C6 H), 3.9 
(1H, m, C3a-H, Wt/ = 17 Hz), 2.72 (211, s, NH2, exchangeable with D20), 1.23 (3H, s, C13-
CH3), 1.16 (3H, s, Coo-CH,r), 1.04 and 1.02 (other methyl protons); 13C NMR (CDC13): (5 166 
(C2'), 155.2 (C7), 129.2 (CEN), 114.6 (C6), 67.3 (C3'), 50.2 (C3); MS: m/z 484/486 [M+']. 
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The pyrazole system (1) consists of a doubly unsaturated five membered ring with two 
adjacent nitrogen atoms. Knorr, 2 first synthesized compounds containing this system in 
1883 by the reaction of ethyl acetoacetate with phenyl hydrazine, which yielded 1-phenyl-3-
methyl-5-pyrazolone (2). Knorr3 introduced the name pyrazole for these compounds to 
denote that the nucleus was derived from pyrrole by the replacement of a carbon by nitrogen. 
They synthesized many members of this class and systematically investigated their 
properties. 
~H3 
	
N\ 	 ' 
N NN 
H 	 Phi 
(1) 	 (2) 
Literature survey has revealed that till 1930s very little had been done for the synthesis of 
steroidal pyrazole derivatives. Probably the first steroidal pyrazole was reported in 1938 by 
Ruzicka et a1.4 and only a single derivative; cholest-4-eno [3, 2 - c] pyrazole-5-carboxylic 
acid (3) was mentioned. 
II7 
(3) 
After a considerable span of time, much attention has been paid by a number of 
organic chemists towards the synthesis of several steroidal pyrazoles. The effect on different 
biological activities produced by the fusion of a pyrazole ring to the steroid nucleus has 
prompted us to investigate such type of compounds. The compounds containing pyrazole ring 
system can be synthesized by different routes and here we have summarized only important 
examples, as below. 
Kira et al. reported that treatment of acetophenone phenylhydrazone (4 a-d) with two 
moles of DMF-POC13 in DMF at 70-80 °C for 6 h gave immonium perchlorate. Alkaline 
hydrolysis of immonium perchlorate afforded 1, 3-diarylpyrazole-4-carboxaldehyde (5 a-d). 
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R2 	 I H3C-N=HC 	Rz 	- 	OHC 	R2 
H3C-< POC11 	3 C104 	N 	OH 	' 1 
\ N` 	DMF r N ~ ~N 
R1 	
R~ 	 (I 
(4) 	 (5) 
R' 	R2 R' 	R2 
(a) C6Hs 	C6H5 	 (a) C6Hs 	C6H5 
(b) C6Hs CH3 (b) CGHs CH3 
(c) C6H5 	p-C6H4NO2 	 (c) C6H5 	p-CUH4NO2 
(d) p-C6H4NO2 C6H5 	 (d) p-C&H4NO2 	C6H5 
Kira et a1.6 synthesized 3-substituted pyrazole-4-carboxaldehyde (7 a-f) by the 
reaction of semicarbazones (6 a-f) with two moles of DMF-POC13 in DMF. 
P flHC 	R 
H3C ~ 
POC13 	' 
`r 	N 
N—NIL DMF 	 H 
(6) (7) 
R R 
(a) C6H5 (a) CbH5 
(b) o-CH3O-C6H4 (b) O-CH3O-C6H4 
(c) P-NO2-C6H4 (c) p-NO2-C6H4 
(d) m-NO2-Cf H4 (d) m-NO,-C6H4 
(e) 2-thienyl (e) 2-thienyl 
(1) CH3 (t) CH3 
Bavatenko and co-workerss2 reported substituted pyrazoles (9 a-d) by cyclizing aryl 
hydrazones (8 a-d) under Vilsmeier conditions. 
0 	Ar 	0 
OHC 
Ph 
	N~NH 	
DMF- POC13 	Ph 	\ 
CH3 	 N--N~ 
Ar 
(8) (9) 
Ar 
(a) C6H5 
(b) 4-F-C6H4 
(C) 4-CH3-C6H4 
(d) 4-CH30-C6H4 
Ar 
(a) C6Hs 
(b) 4-F-05H4 
(e) 4-CH3-C6 
(d) 4-CH3O-C6H4 
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POC13). 
OH N— N 
R~ 
H 
C1 
(14) 
R` 	R2 
(a) CH3 
(b) C2H5 
(c) (CH2)-CH3 
(d) (CH2)2-CH3 
(e) CH3 
(t) CH3 
Ph 
Ph 
Ph 
Ph 
CONH2 
No 
ti 
3, 5-Disubstituted pyrazoles (11 a-d) were obtained by the reaction of germ 
dichlorocyclopropylacetates (10 a, b) with 4 equivalents of hydrazine or phenyl hydrazine at 
room temperature while metacyclophane (13a) and its isomer (13b) were obtained from 1-
acetoxy-2, 2-dichlorobicyclo [10.1.0] tridecane (12) with hydrazine under same condition. 
0 
II O — C —CH3 	 Rl 
Rl 	RZ 	R3NHNH, 	 C\N Z 
R 	N 
CI 	CI R3 
(10) (11) 
R' RZ RI R2 R3 
(a) CH3 	H 	 (a) CH3 	H 	H 
(b) C6Hs 	CA (b) C(,H5 	C6Hs H 
(c) CH3 H 	C6H5 
(d) CHs 	Cr.H5 Calls 
C1 Ct 
0 
11 o-C—CH_j 
HZNNHZ 	' 	+ 
~N 
H _N N H 
(49%) 	 (-5%) 
(12) 	 (13a) 	(13b) 
Pawar and Borse9 reported 4-n-alkyl substituted pyrazoles (15 a-f) from phenyl 
hydrazones (14 a-d), semicarbazone (14e) and azine of 2-n-acyl-5-chlorophenol (14!) by 
monoformylation and cyclization by using one mole of the Vilsmeier-Haack reagent (DMF- 
OH 	R' 
DMF/ POCI3 
N'2 
C1 
(15) 
RI 	R2 
(a) CH3 	Ph 
(b) C2H5 Ph 
(c) (CH2)-CH3 	Ph 
(d) (CH2)2-CH3 	Ph 
(e) CH3 	 CONH2 
(t) CH3 	CI ~o 
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Sridhar1D reported pyrazole-4-carboxaldehyde (17 a-h) by the reaction of hydrazones 
of aliphatic and aromatic methylketones (16 a-h) with Vilsmeier reagent. They also studied 
the reactivity of hydrazones of fl-ketoesters towards Vilsmeier reagent, both by conventional 
and microwave methods. 
R' 
R2 
	
~C=N–HN 	NO2 	Dl F- POCl3 	
R) 
-  
CO-OCH2-R1 	 Reflux or MWI  
CO-OCH2-R' 
(16) 	 (17) 
R 	R1 	RZ 	R 	R' 	RZ 
(a) CH3 	H 	H 	 (a) CH3 	H 	H 
(b) CH3 CH3 	H (b) CH3 CH3 	H 
(c) CH3 	H NO2 	 (c) CH3 	H NO2 
(d) CH3 CH3 	NO2 (d) CH3 CH3 	NO2 
(e) C6H5 	CH3 	H 	 (e) C6H5 	CH3 	H 
(f CA CH3 	NO2 (f) C6H5 CH3 	NO2 
(g) p-CIC6H4 CH3 	H 	 (g) p-ClC6H4 	CH3 	H 
(h) p-CIC6H, CH3 	NO2 (h) p-CIC6H4 	CH3 	NO2 
Borrell et al. 1 1 synthesized pyrazole library by using Merrifield resin as a solid-phase 
support to a hydroxyacetophenone (18), Vilsmeier-Haack formylation on methyl group and 
cyclization with substituted hydrazine to afford 4-hydroxybenzoyl- I -substituted pyrazo les (20 
a-e). 
0 	 0 	 0 
 H,N POC13-DMF ct::jcHO  HR' 
 H 
	
I~ OH N•R] HO ~ 	 HO 
(18) 	 (19) 	 (20) 
(a) H
(b) C6H5 
(c) C2H5 
(d) C2H40H 
(e) C2H4CN 
Dhar and Bhat'2 reported the synthesis of 3, 5-diphenyl-IH-pyrazole (24) from 
chalcone (21) by the action of hydrazine hydrate on chalcone-epoxide (22) followed by 
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simultaneous dehydration in presence of catalytic amount of concentrated sulfuric acid in 
acetic acid. 
0 	 0 	 N-NH 
H2O, 	 H2NNH2,H20 	.~ 	\ 
(21) 	 (Z2) 	( N-NH 	 (23) 
(24) 
Kidwai and coworkers13 used microwave irradiation and synthesized 4-methyl-2-[3'- 
substituted-phenyl-4'-formylpyrozolyl] quinoline (26 a-d) by the reaction of hydrazones of 
methylquinoline (25 a-d) with DMF and POC13 under microwave irradiation of 3-4 min. 
H3C 
NHN=C \ , 
CH3 
(25) 
R 
(a) H 
(b) 4-Cl 
(c) 4-CH3 
(d) 4-Br 
H3C 
/ Ni N— N /R 
1 
CHO 
(26) 
lS 
(a) H 
(b) 4-Cl 
(c) 4-CH3 
(d) 4-Br 
3-Aryl-4-formyl-1-[3(2-chlorophenyl)-1, 8-naphthyridin-2-yl] pyrazoles (28 a-d) were 
obtained when hydrazones (27 a-d) were subjected to microwave irradiation14 in the presence 
of Vilsmeier-Haack reagent. 
C[ O 
IPOC13-DMF / SiO2 
N N NHN= C —Ar 	MW! 
H3C 
(27) 
Ar 
(a) C6H5 
(b) 4-CH3-C6H4 
(c) 4-CH3O-C6H4 
(d) 4-C1C6I{, 
C1 
CHO 
(28) 
Ar 
(a) CsHA 
(b) 4-CH3-C6H4 
(c) 4-CH30-C6H4 
(d)4-C1C6Ha 
4 
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Selvi and Perumul 15 synthesized 4-ethoxy-4H-benzopyrano [4, 3 - c] pyrazoles (30 
a-f) from o-hydroxyacetophenone-2, 4-dinitrophenylhydrazone (29 a-f) under Vilsmeier 
conditions. 
02N 	 02N 
N—NH \ / NO2 
\ 	 DMF / POC13 
CHO 
R 	OH 	 r.t., 4h 	R 	OH 
(29) 	 (30) 
	
R 	R' R 	R' 
(a) H	H (a) H 	H 
(b) H 	OCH3 	 (b) H 	OCH3 
(c) H CH3 (e) H 	CH3 
(d) H	Cl (d) H 	CI 
(e) H OH 	 (e) H 	OH 
(t) OCH3 H (f) OCH3 H 
Singh et al.' 6 reported the synthesis of pyrazolo [3, 2 - c] cholest-4-ene (32) and [1' 
HJ-S'-(rnethylthio) pyrazolo [3, 2 - c] cholest-4-ene (34) from 2-ethoxymethylene-4-cholest-4- 
en-3-one (31) and bis (methylthio) methylene cholest-4-en-3-one (33), respectively by the 
action of hydrazine hydrate in ethanol under reflux. 
C2H5OHC 	
N2H4•H20 N~ 
o 
ETON Reflux 	N  
(31) 
	
(32) 
We 
Me5 
Mes 	 N2H4,H2O 	N / 
EIOH, Refux 	N 
O 	 H 
(33) 
	
(34) 
Clinton et al." reported that the treatment of 17a-methylandrostan-17fl-ol-3-one (35) 
with ethylformate and sodium methoxide gave 2-hydroxymethylene derivative (36) which on 
condensation with hydrazine gave 17fl-hydroxy-17a-methylandrostano [3, 2 - c] pyrazole 
(37). Similar treatment of 2-hydroxymethylene-17a-androst-4-en-17/3-ol-3-one (38) furnished 
17fl-hydroxy-17a-methylandrost-4-eno [3, 2 - c] pyrazole (39). 
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CH3 
` OH 
HCOOC21 
O CH3ONa  
H 
(35) 
HOHC 
N_H4.Hz0 HN 
H 	N 	= 
(36) H 
(37) 
CH3 
OH 
HOHC 
0 
(38) 
N,H4.HZ0 HN 
N 
(39) 
Berbalk and coworkers' 8 reported that the epoxyandrostane (40 a-c) underwent 
formolysis to give phenyl acetylandrostane (41 a-c) which on further cyclocondensation with 
hydrazine afforded steroidal pyrazoles (42 a-c). 
R 
3 
I 	H 
Ph 
R 
HO 
C 
Ph — CH2 
R 
N 
C 
Ph—CHZ H 
(40) (41) (42) 
R 	R' R 	R' R 	R' 
(a) OAc 	H (a) OAc 	H (a) OAc 	H 
(b) OH H (b) OH 	H (b) OH 	H 
(c) R, R' 	^O (c) R, R' 	=0 (c) R, R' 	=0 
Bonn and Dodson19 carried out the hydrazine reduction of 16a, 17-epoxy-
pregnenolone (43) to obtain 3Q-hydroxyandrost-5-eno [16, 17- c]-5-methylpyrazole (44) 
along with the two isomeric allylic alcohols, 5, 17 [20]-(cis)-pregnadiene-3f, 16a-diol (45a) 
and 5, 17 [20]-(trans)-pregnadiene-3/i, 16a-diol (45b). 
	
H3C r 	H3C 
~`O 	 —N H 	 C113 
.,IOH ,-L,JOI3 
HO 	" 	HO 	HO 	HO 
(43) 	 (44) 	 (45a) 
	
(45b) 
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Laitonjan and co-workers'° synthesized substituted steroidal [3, 2 - c] pyrazoles (47 a, 
b) by the reaction of 2-ethoxymethylene-4-cholestan-3-one (46a) and 2-his (inethylthio) 
methylene cholest-4-en-3-one (46b) with hydrazine hydrate and refluxed for 3 h. 
C8H1~ 	 C5H17 
TI:E;:f:i R~ 	 R R 	 H2NNH2 	N 
/ 	 reflux 	H 
II1t: ±  
(46) (47) 
R 	R' R 
(a) H 	OC2H5 (a) H 
(b) SCH3 	SCH3 (b) SCH3 
Peseke et al.21 reported that the treatment of 3f-acetoxy-16-[bis (methylthio) 
methylene]-5-androst-5-en-17-one (48) with hydrazine hydrate and methyihydrazine afforded 
the 5-methylthio-pyrazolo [4', 3': 16, 17] androst-5-en-3/3-ols (49 a, b). 
0 	 N-Nr R 
SCH3 
SCH
3 
H2NNHR 	 SCH3 
HO 	 HO 
(48) 
	
(49) 
R 
(a) H 
(b) CH3 
Shamsuzzaman et al.22 reported that the treatment of Sa-cholestan-6-one 
tosylhydrazones (50 a-c) with Vilsmeier reagent gave 5'-formyl-5a-cholestan [6, 7 - c] 
pyrazole derivatives (51 a-c) in 60-65% yields. 
R H N-NH—Is 
(50) 
DMF-POCI3 
0°C 	R 
 
N—NH 
(51) 
R 
	
R 
(a) H (a) H 
(b) OAc 	 (b) OAc 
(c) Cl (c) Cl 
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Sidhaye et al.23 reported that nicotinoyl chloride (52) reacted with hydrazine and gave 
nicotinohydrazide (53). The compound (53) on reaction with acid derivatives yielded (3, 5- 
dimetbyl-lH-pyrazo1-1-yl)(pyridine-3-yl) methanone (54), 3-methyl-l-nicotinoyl IH-pyrazol-
5(4H)-one (55), 3-amino-l-nicotinoyl-1H-pyrazol-5(4H)-one (56) in good amounts. 
0 
COCI 
H 	
NH
-)NNH, 	 1 
N 	 N NH2 
(53) (52)  
/CH3COCH2COOC2H3  0 
N O 
(55) 
0 
CH3COCII2COCH3 C__ ` N H3C 
(54) 
i C-CHy-CO-OEt 
0 
N 0 
(56) 
Isloor and co-workers24 reported the reaction of substituted hydrazines (57 a-g) with 
ethyl acetoacetate in absolute alcohol which provided the corresponding substituted 
pyrazolones (58 a-g) in good yields. 
Ar' FIN—NH2H3C 	0CH3  
0 0 
C2H5OH 
0 
H3C 
(57) 
	
(58) 
Ar 	 Ar 
(a) Cis (a) C6H5 
(b} 2, 4-DNP 
	
(b) 2, 4-DNP 
(c) 4-Chlorophenyl 
	
(c) 4-Chlorophenyl 
(d) 4-OCH3-C6H4 	 (d) 4-OCH3-C6H4 
(e) Biphenyl 
	
(e) Biphenyl 
(t) 2, 4-Dichlorophenyl 
	
(f) 2, 4-Dichlorophenyl 
(g) 4-SCH3-C6H4 	 (g) 4-SCH3-C6H4 
Mariappan and co-workers'$ reported that the reaction of ethyl acetoacetate with 
hydrazine hydrate in absolute alcohol yielded pyrazolone (59). The pyrazolone (59) upon 
reaction with different substituted aromatic aldehydes in presence of alcoholic sodium 
hydroxide yielded corresponding substituted pyrazolones (60 a-h). 
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H3C 	O. ,CH3 	H3C 
0
~ 
	
H,NNH ~ C 	O 
C,H5OH 	N N 
x 
H 
(59) 
R 
CHO 	 HC 
_/ 
1 0 
R 
H3C/)r 
E 	O 
alc. NaOH 	N`N 
H 
(60) 
R 
(a) N(CH3)2 	(e) 3-Cl 
(b) Ph-CH=CH (t) 4-OMe 
(c) OCH3 (2.3) (g) 3-OMe 
(d) 3-NO2 	(h) OH 
Rao and Chunduru26 reported the one pot synthesis of 4-arylidene-3-methyl-1-[4-(2-
oxo-2H-chromen-3-yl) thiazol2-yl]-1H-pyrazol5(4H)-ones (63 a-d) by reacting 3-(2- 
bromoacetyl) coumarin derivatives (61 a-d), thiosemicarbazide, ethyl acetoacetate and 
substituted aryl aldehydes (62 a-d) in presence of sodium acetate in acetic acid. 
O 0 
 
S 
+ 	1! H 	+ 	o 	o 	
+ (:11] 
 HZN -C-N-NHZ  
R~ / / 	Br 	 H3C 	OEt R- 
O 	 AcONa 	 (62) 
(61) o 0 
N 	3 R!  'N R 
(63) 
(61) 	(62) 	(63) 
RI R2 Rt 	R2 
(a) H 	 (a) NH2 	 (a) H 	NH2 
(b) Br (b) NMe, (b) Br NMe2 
(c) NO2 	 (c) NO2 	 (c) NO2 	NO2 
(d) OCH3 (d) NHMe (d) OCH3 	NHMe 
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As a part of our continuing effort towards the synthesis of heterosteroids, which are expected 
to be biologically active, the fusion of heterocycles to steroids often lead to a change in 
physiological activities or appearance of new interesting biological behavior.27 Thus, several 
steroid appended heterocycles have been synthesized which act as potential inhibitors of 
cytochrome P450 aromatage28. 29 with their subsequent clinical applications in the treatment of 
estrogen dependent breast cancer. 
Pyrazole moiety being called as pharmacophore plays an essential role in biologically 
active compounds and therefore represents an interesting template for combinatorial as well 
as medicinal chemistry.30, 31 In addition pyrazoles have played a vital role in the development 
of theory in heterocyclic chemistry and are also used extensively as useful synthons in organic 
synthesis.32 These derivatives have wide spread potential biological activities such as 
antimicrobial, anticancer, antioxidant, analgesic, anti-inflammatory, antipyretic, antiviral, 
anticonvulsant, antihistaminic, antidepressant, insecticidal and anti-HIV.33-38  The recent 
success of pyrazole COX-2 inhibitor has further highlighted the importance of these 
heterocycles in medicinal chemistry. 
The therapeutic importance of these steroidal pyrazoles16 and study of interesting 
behavior of Vilsmeier reagent with simple hydrazones giving pyrazoles encouraged us to 
make similar studies with steroidal thiosemicarbazones. The substrates selected for 
synthesizing the new steroidal pyrazoles include 5a-cholestan-6-one thiosemicarbazone39 
(64), 3f -acetoxy-5a-cholestan-6-one thiosemicarbazone39 (65) and 3fl-chloro-5a-cholestan-6-
one thiosemicarbazone39 (66). The products obtained have been characterized on the basis of 
spectral (IR, 1H NMR, 13C NMR, MS) and elemental analyses. 
N-NH-  C -NH2 
11 
S 
X 
(64) H 
(65) OAc 
(66) Cl 
Reaction of 5a-cholestan-6-one tbiosemicarbazone (64) with POC13 and acetamide. 
The 5a-cholestan-6-one thiosemicarbazone (64) in CH3CN was allowed to react with 
POCI3 and acetamide. After completion of the reaction, the reaction mixture was taken in 
diethyl ether, washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvents gave an oil which was crystallized from methanol to afford compound 67, m.p 121 
°C. 
H3C•CO• NH2 / POC13 
H3C-CN 
N-NH- C-NH2 
S 
 
 
N-N--C-NH2 
S 
(64) 	 (67) 
Characterization of the compound, m.p. 121 °C as 5a-cholestano [6, 7 - c] 5'-methyl-l'-
carbothioic acid amido pyrazole (67): 
The elemental analysis of compound 67 corresponded to the molecular formula 
C30H49N3S. Its IR spectrum showed a band at 3393 cm 1 which could be assigned to NH group 
while as the bands at 1652, 1620, 1375 and 1275 cm I were attributed to C=N, C=C, C-N and 
C=S group, respectively. These values supported the presence of pyrazole moiety ° in the 
product molecule. The structure 67 was well supported by its 'H NMR spectrum which 
displayed broad singlet integrating for two protons at S 7.6 (exchangeable with DzO) 
indicating the presence of NH2 while as the singlet integrating for three protons at S 2.4 
showed the presence of C5'-CH3. Other prominent peaks for angular and side-chain methyl 
protons were observed at S 1.19, 0.96, 0.83 and 0.75. The 13C NMR spectrum of compound 
67 displayed characteristic signals at a 179.2 (C=S), 150.1 (C6), 118(C7), 137 (C5') and 25.2 
(C3). Remaining carbon atoms were seen in accordance to the cholestane series. The structure 
of compound 67 was further supported by its mass spectrum in which the distinct molecular 
ion peak (M+  483) was observed. 
On the basis of foregoing discussion and the mechanism proposed (Scheme 3.1), this 
compound can be best characterized as Sa-cholestano [6, 7 - c} 5'-methyl-l'-carbothioic acid 
.amido pyrazole (67). 
67 
Reaction of 3J1-acetoxy-Sa-cholestan-6-one thiosemicarbazone (65) with POCI3 and 
acetamide. 
The 3fi-acetoxy-5a-cholestan-6-one thiosemicarbazone (65) in CH3CN was allowed to 
react with POC13 and acetamide. After completion of the reaction, the reaction mixture was 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. Removal 
of the solvents gave an oil which was crystallized from methanol to afford compound 68, m.p 
147 °C. 
13C-CO-NH2 / POCI3 
H3C-CN 	AcC N—NH-C—N 12 
S 
 
N—N—C— NH2 
S 
(65) 	 (68) 
Characterization of the compound, m.p. 147 °C as 3/1-acetoxy-5a-cholestano 16, 7 - Cl 5'- 
methyl-1'-carbothioic acid amido pyrazole (68): 
The compound 68 was correctly analyzed for the molecular formula C32H51N302S. Its 
IR spectrum showed a band at 3390 cm 1 which could be assigned to NH group. The strong IR 
absorption bands at 1714 and 1210 cm 1 indicated the presence of acetate group, while as the 
bands at 1655, 1632, 1376 and 1269 cm I were attributed to C=N, C=C, C-N and C=S group, 
respectively. These values confirmed the presence of pyrazole moiety40 in the product 
molecule. The structure 68 was well supported by its 'H NMR spectrum which displayed a 
broad singlet integrating for two protons at d 8.2 (exchangeable with D20) indicating the 
presence ofNH2 while as the singlet integrating for three protons at d 2.3 showed the presence 
of C5'-CH3. A broad multiplet (W,, = 15 Hz, axial) was observed at 5 4.7 for one proton 
which could be assigned to C3a-H. The three acetate group protons appeared at S 2.03 as a 
sharp singlet. The prominent peaks for angular and side-chain methyl protons were observed 
at d 1.18, 0.97, 0.83 and 0.70. The i3C NMR spectrum of compound 68 displayed 
characteristic signals at S 181.2 (CS), 148.3 (C6), 119 (C7), 134 (C5') and 75.1 (C3). 
Remaining carbon atoms were seen in accordance to the cholestane series. The structure of 
compound 68 was further supported by its mass spectrum in which the distinct molecular ion 
peak (M~, 541) was found. 
r 
68 
On the basis of above studies and its analogy with earlier compound 67, this 
compound can be best characterized as 3Q-acetoxy-5a-cholestano [6, 7 - c] 5'-methyl-l'-
carbothioic-acid ano 'do pyrazole (68). 
Reaction of 3/1-chloro-5a-cholestan-6-one thiosemicarbazone (66) with POCI3 and 
acetamide. 
The 3fl-chloro-5a-cholestan-6-one thiosemicarbazone (66) in CH3CN was allowed to 
react with POC13 and acetamide. After completion of the reaction, the reaction mixture was 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. Removal 
of the solvents gave an oil which was crystallized from methanol to afford compound 69, m.p 
156 °C. 
13C-CO- NH2 / POC13  
H3C-CN 	Cl 
u ` 
S 
 
 
N-N-C-NH2 
S 
(66) 	 (69) 
Characterization of the compound, m.p. 156 °C as 3/J-chloro-5a-cholestano 16, 7 - c] 5'-
methyl-1'-carbothioic acid amido pyrazole (69): 
The elemental analysis of compound 69 corresponded to the molecular formula 
C30H48N3CIS (Beilstein positive). Its IR spectrum showed a band at 3410 cni ] which could be 
assigned to NH group while as the bands at 1650, 1625, 1378, 1275 and 756 crn 1 were 
attributed to C=N, C=C, C-N, C=S and C-Cl group, respectively. These values supported the 
presence of pyrazole moiety4° in the product molecule. The structure 69 was well supported 
by its 1H NMR spectrum which displayed broad singlet integrating for two protons at 8 7.8 
(exchangeable with D20) indicating the presence of NH2 while as the singlet integrating for 
three protons at d 2.4 showed the presence of C5'-CH3. A broad multiplet (Wrn =17 Hz, axial) 
for one proton was observed at 6 3.9 which could be assigned to C3a-H. Angular and side-
chain methyl protons were observed at S 1.19, 0.97, 0.75 and 0.80. The 13C NMR spectrum of 
compound 69 displayed characteristic signals at S 184.2 (C=S), 144.5 (C6), 119.2 (C7), 132 
69 
(CS') and 52.6 (C3). Remaining carbon atoms were seen as per the cholestane series. The 
structure of compound 69 was further supported by its mass spectrum in which the distinct 
molecular ion peak (M+ 515/517) was observed. 
The above data led to the structure of compound 69 as, 3fl-chloro-5a-cholestano [6, 7 - 
c] 5'-methyl- 1 '-carbothioic acid amido pyrazole. 
Formation of steroidal pyrazoles (67-69) under the condition case and in the light of 
available literature 1522 may be shown according to the proposed mechanism (Scheme 3.1). 
	
o~ 	o 0 
O~P`C[ It3C~C=+ 
H3C-C 	Cl.p-c[ 	_ 0 &I1,r1 CI 	/ 
NH_ CI H3C-C Cl —T H C-C— [ 	 ~ Cl 	
oPOCIZ 
NI-I2 3 ( I G Imminium cation 
. NH, 
C8H17 
CsHl7 
x 	1 H -— O ^~ X 	 C=NH2 
AN-NH--- C-NH2 	 CI 
H'NH-C- NH S 	 , 
5 
CsH 17 
HH3C 
X 	
H2 
CI 
HNC-NH- C-NH1 
S 
CH 17 
H 
HCI, -H He X 	 C ' NH 	 1 
Z X 
N- NH-C-NH2 
I I 
S 
snl7 
H3C 	1 
- NHa 
tC NH3 	H+ 
N--NH-C-NH, 
II 
S 
CBH17 
X 	 CH5 
N—N—C— NH, 
S 
x 
(67) H 
(68) OAc 
(69) CI 
Scheme 3.1 Mechanism for the formation of cholestano [6, 7 - c] 5'-methyl-l'-carbothioic 
acid amido pyrazole derivatives (67-69) 
Work communicated; 
DNA binding studies and in vitro cytotoxicity of newly synthesized steroidal pyrazoles, 
Shamsuzzaman, Ayaz Mahmood Dar, et al., (communicated) 
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Pyrazolones have gained importance as drug substances in pharmaceutical industry in view of 
their biological importance. For instance, the pyrazolones, viz. phenazone, propyphenazone, 
ampyrone and metamizole are useful antipyretic and analgesic drugs,41 whilst edaravone 
(MCI-186) has been used for treating brain' and myocardial ischemia.43 In addition, 
pyrazolones possess antimicrobial, antimycobacterial, anti-inflammatory, antitumor, gastric 
secretion stimulatory, antidepressant and antifilarial activities.44-50  They also serve as 
precursors for the synthesis of dyes, pigments, pesticides and chelating agents.51 Besides 
finding applications in the extraction and separation of various metal ions,52 they are also 
employed in chromatography, petrochemical industry, as laser materials and 'H NMR shift 
reagents.53, 54 
The substrates selected for synthesizing the new steroidal pyrazolones (73-75) include 
5a-cholestan-6-one55 (70), 3Q-acetoxy-5a-cholestan-6-one56 (71) and 3/J-chloro-5a-cholestan- 
6-one57 (72). The products obtained have been characterized on the basis of spectral (1R, 'H 
NMR, '3C NMR, MS) and elemental analyses. 
►;1 
X 
(70) H 
(71) OAc 
(72) Cl 
Reaction of 5a-cholestan-6-one (70) with cyanoacetohydrazide. 
The 5a-cholestan-6-one (70) in acetic acid (15 mL was allowed to react with 
cyanoacetohydrazide in equimolar ratio. After completion of the reaction, the reaction mixture 
was taken in diethyl ether, washed with water, 5% NaHCO3, again with water and dried over 
anhydrous sodium sulfate. Removal of the solvents provided crude product which was 
recrystallized from methanol to afford compound 73, m.p 119 °C. 
71 
NC-CH,-CO-NH-NH, 
AcOH N H,N- ~NH 
1l`l"~~I
0 
(70) 	 (73) 
Characterization of the compound, m.p. 119 °C as cholest-6[5'-amino-1', 2'-dihydro 
pyrazol-3-one-1'-yl] 5-ene (73): 
The elemental analysis of compound 73 corresponded to the molecular formula 
C301-L49N3O. Its IR spectrum showed bands at 3470 and 3296 cni' which could be assigned to 
NH and NH.) group while as the bands at 1680, 1620/1624, 1441 and 1461 cm I were 
attributed to CONH, C=C, C-N and N-N group, respectively. These values supported the 
presence ofpyrazolone moiety4° in the product molecule. The structure 73 was well supported 
by its 'H NMR spectrum in which a singlet at 6 8.8 (exchangeable with D20) was assigned for 
one proton (NH) while as the broad singlet at d 2.1 (exchangeable with D20) depicted the 
presence of two protons (NH2). Another singlet appeared at S 5.6 showed the presence of an 
olefinic proton (C4'-H) in the compound. The prominent peaks for angular and side-chain 
methyl protons were observed at 6 1.12, 0.92, 0.85 and 0.71. The 13C NMR spectrum of the 
compound 73 displayed characteristic signals at 6 171 (C31), 151 (C$'), 132 (C6), 117 (C5), 127 
(C4') and 22.3 (C3). Remaining carbon atoms were seen in accordance to the cholestane series. 
The structure of compound 73 was further supported by its mass spectrum in which the 
distinct molecular ion peak (M}- 467) was found. 
On the basis of foregoing discussion and the mechanism proposed (Scheme 3.2), this 
compound can be best characterized as cholest -6[5'-amino-l', 2'-dihydropyrazol-3-one-1'-yl] 
5-ene (73). 
Reaction of 3/3-acetoxy-5a-cholestan-6-one (71) with cyanoacetohydrazide. 
The 3fl-acetoxy-5a-choIestan-6-one (71) in acetic acid (15 mL) was allowed to react 
with cyanoacetohydrazide in equimolar ratio. After completion of the reaction, the reaction 
mixture was taken in diethyl ether, washed with water, 5% NaHCO3, again with water and 
dried over anhydrous sodium sulfate. Removal of the solvents gave crude product which was-
recrystallized from methanol to afford compound 74, m.p 145 °C. 
NC-CH2-CO-NH-NH2 
AcOH N 
~O 
(71) 	 (74) 
Characterization of the compound, m.p. 145 °C as 3/J-acetoxycholest.-6[5'-amino-1', 2'-
dihydropyrazol-3-one-1'-yl] 5-ene (74): 
The compound 74 was correctly analyzed for the molecular formula C32H51N303. Its 
IR spectrum showed bands at 3345 and 3280 cm 1 which could be assigned to NH and NHS 
group. The strong absorption bands at 1735 and 1210 cm 1 indicated the presence of acetate 
group, while as the bands at 1680, 1615/1625, 1455 and 1480 cm I were attributed to CONH, 
C=C, C-N and N-N group, respectively. These values suggested the presence of pyrazolone 
moiety ° in the product molecule. The structure 74 was well supported by its 'H NMR 
spectrum which showed a singlet at 5 9.0 (exchangeable with 020) depicted the presence of 
NH while as the broad singlet at 5 2.2 (exchangeable with D20) showed the presence of two 
protons (NH2). A broad multiplet (W112 = 15 Hz, axial) for one proton was observed at 54.7 
which could be assigned to C3a-H. The three acetoxy group protons appeared at 5 2.01 as a 
sharp singlet. Another singlet appeared at 6 5.2 revealing the presence of an olefinic proton 
(C4' 	in the compound. Other prominent peaks for angular and side-chain methyl protons 
were observed at 8 1.12, 0.92, 0.85 and 0.71. The 13C NMR spectrum of compound 74 
displayed characteristic signals at 8 171 (CO), 176 (C31), 159 (C5'), 135 (C6), 119 (C5), 123 
(C4') and 70.2 (C3). Remaining carbon atoms were seen as per the cholestane series. The 
structure of compound 74 was further supported by its mass spectrum in which the distinct 
molecular ion peak (M'-' 525) was observed. 
On the basis of above studies and its analogy with earlier compound 73, this 
compound can be best characterized as 3/3-acetoxycholest-6[5'-amino-1', 2'-dihydropyrazol-3-
one-1'-yII 5-ene (74). 
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Reaction of 3/1-chloro-5a-cholestan-6-one (72) with cyanoacetohydrazide. 
The 3J3-chloro-5a-cholestan-6-one (72) in acetic acid (15 mL) was allowed to react 
with cyanoacetohydrazide in equimolar ratio. After completion of the reaction, the reaction 
mixture was taken in diethyl ether, washed with water, 5% NaHCO3, again with water and 
dried over anhydrous sodium sulfate. Removal of the solvents provided crude product which 
was recrystallized from methanol to afford compound 75, m.p 131 °C. 
NC-CH2-CO-NH-NH2 
AcOH N H2N~ `NH C 
(72) 
	
(75) 
Characterization of the compound, m.p. 131 °C as 3/1-chlorocholest-6[5'-amino-1', 2'- 
dihydropyrazol-3-one-1'-yl] 5-ene (75): 
The elemental analysis of compound 75 corresponded to the molecular formula 
C3oH4sCIN30 (Beilstein positive). Its IR spectrum showed bands at 3375 and 3291 cm' which 
)uld be assigned to NH and NH-, group while as the bands at 1685, 1618/1622, 1448, 1467 
741 cm-1 were attributed to CONH, C=C, C-N, N-N and C-Cl group, respectively. These 
supported the presence of pyrazolone moiety4Q in the product molecule. The structure 
n well supported by its 'H NMR spectrum which showed one proton singlet at 5 8.5 
geable with D20) suggesting the presence of NH while a two-proton broad singlet at d 
:hangeable with D20) depicted the presence of NH,). A broad multiplet (Wiz = 17 Hz, 
it one proton was observed at d 3.9 which could be assigned to C3a-H. Another singlet 
d at d 5.4 indicating the presence of an olefinic proton (Ca'-H) in the compound. The 
;nt peaks for angular and side-chain methyl protons were observed at 6 1.12, 0.92, 
1 0.71. The 13C NMR spectrum of compound 75 displayed characteristic signals at 6 
'), 154.7 (C5'), 136 (C6), 117 (C5), 120 (C4') and 52.6 (C3). Remaining carbon atoms 
en in accordance to the cholestane series. The structure of compound 75 was further 
-d by its mass spectrum in which the distinct molecular ion peak (W- 499/501) was 
74 
17 
N 
H2N \NH 
The above data led to the structure of compound 75 as, 3fl-chlorocholest-6[5'-amino-
1', 2'-dihydropyrazo l-3-one-1'-yl] 5-ene. 
Formation of steroidal pyrazolones (73-75) under the condition case and in the light of 
available literature58 may be shown according to the proposed mechanism (Scheme 3.2). The 
mechanism for the formation of these pyrazolones involve the simple condensation thus 
formation of 5a-cholestan-6-one cyanoacetohydrazone takes place first which then undergoes 
the nucleophilic attack of nitrogen on the terminal carbon (C=N) of cyanoacetohydrazone to 
get converted to C=NH which later changes into C-NH2 leads to the cyclization of 
heterocycle. 
17 CSH 7 
h-CO-NH-NHS 
X 	A !~ 	H 
H Iv— NH-C-C? CN 
It 
0 
17 
HNC NH 
HO 
X 
He 
x 
C8H17 
x 
N H NH 
o 
(73) H
(74) OAc 
(75) CI 
Scheme 3.2 Mechanism for the formation of cholest-6[5'-amino-l', 2'-dihydropyrazol-3-one-
1'-yl] 5-ene derivatives (73-75) 
Work published; 
Structural, optical and antimicrobial studies of 3/]-acetoxycholest-5-ene, 3fl-acetoxy-6-
nitrocholest-5-ene and newly synthesized steroidal pyrazolones, Shamsuzzaman, Ayaz 
Mahmood Dar, et al., Journal of Taibah University for Science, http://dx.doi.org/10.1016/j.j 
tusci.2013.08.003 (in press) 
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All the melting points were determined in degrees Celsius on a Kofler apparatus and are 
uncorrected. The IR spectra were recorded on KBr pellets with Perkin Elmer RXI 
Spectrophotometer and values are given in cm'. 'H and 13C NMR spectra were run in CDC13  
on a JEOL Eclipse (400 MHz) instrument with TMS as internal standard and values are given 
in ppm (d). Mass spectra were recorded on a JEOL SX 102/DA-6000 Mass Spectrometer. 
Thin layer chromatography (TLC) plates were coated with silica gel G and exposed to iodine 
vapors to check the homogeneity as well as the progress of reaction. Petroleum ether refers to 
a fraction of boiling point 60-80 °C. Sodium sulfate (anhydrous) was used as a drying agent. 
The synthesis of 3fl-chlorocholest-5-ene, cholest-5-ene, 6-nitrocholest-5-ene, 5a-
cholestan-6-one and 5a-cholestan-6-one thiosemicarbazone is shown in chapter 1, page 23 
and 24. The synthesis of 3/3-acetoxycholest-5-ene, 3Q-acetoxy-6-nitrocholest-5-ene, 3/3-
acetoxy-5a-cholestan-6-one and 3/3-acetoxy-5a-cholestan-6-one thiosemicarbazone is shown 
in chapter 1, page 24, 25 while as the synthesis of 3/3-chloro-6-nitrocholest-5-ene, 3fl-chloro-
5a-cholestan-6-one and 3i-chloro-5a-cholestan-6-one thiosemicarbazone is shown in 
chapter 1, page 25 and 26. 
Reaction of 5a-cholestan-6-one thiosemicarbazone derivatives (64-66) with POC13 and 
acetamide: 
To a solution of 5a-cholestan-6-one thiosemicarbazone derivatives (64-66) (1 mmol) 
in CH3CN (10 mL), was added acetamide (1 mmol) under ice-cold condition. POC13 (I 
mmol) was then added at such a rate that the temperature of the reaction mixture did not 
exceed 10 °C with constant stirring. After the complete addition, the reaction mixture was 
allowed to attain room temperature; however, the stirring was continued for an additional 
period of 3 h. The progress of reaction was followed by TLC. After completion of the 
reaction, the reaction mixture was poured onto crushed ice, left overnight in a refrigerator and 
was extracted with diethyl ether. The ethereal layer was further washed with water and dried 
over anhydrous sodium sulfate. Removal of solvents gave an oil which was crystallized from 
methanol to give corresponding steroidal pyrazoles (67-69). 
5a-Cholestano [6, 7- cJ 5'-niethy!-.l'-carbothioic acid amino pyrazole (67): 
Yield 70%; m.p. 121 °C; Analysis found: C 74.53, H 10.14, N, 8.69%. C3oH19N3S requires: C 
74.40, H 10.07, N 8.60%; IR (KBr): v max 3393 (NH), 1652 (C=N) 1620 (C=C), 1375 (C-N), 
76 
(i'7 	!• 
1275 (C=S); 'H NMR (CDCI3): S 7.6 (s, 2H,•NH2, exchangeable with D20), 2.4 (s, 3H, C5'-
CH3), 1.19 (s, 3H, C,o-CH3), 0.75 (s, 3H, C13-CH3), 0.96 and 0.83 (other methyl protons); '3C 
NMR (CDCI3): S 179.2 (C=S), 150.1 (C6), 137 (C51), I18 (C7), 41.8 (C5), 42.76 (C9), 39.45 
(Cjo), 36.53 (C13), 25.2 (C3); MS: in/z 483 [M+•]. 
311-Acetoxy-5a-clholestano [6, 7- eJ 5! methyl-I'-carbothioic acid a nido pyrazole (68): 
Yield 70%; m.p. 147 °C; Analysis found: C 70.97, H 9.42, N 7.76%. C32H51N302S requires: 
C 70.89, H 9.19, N 7.55%; IR (KBr): v 	3390 (NH), 1714 (CH3COO), 1655 (C= N), 1632 
(C=C), 1376 (C-N), 1269 (C=S), 1210 (C-0); 'H NMR (CDCI3): 9 8.2 (s, 2H, NH2, 
exchangeable with D20), 4.7 (m, 1H, C3a-H, W % = 15 Hz), 2.3 (s, 3H, C5'-CH3), 2.03 (s, 3H, 
OCOCH3), 1.18 (s, 3H, C,o-CH3), 0.70 (s, 3H, C13-CH3), 0.97 and 0.83 (other methyl 
protons); '3C NMR (CDC13): r5 181.2 (C=S), 171.0 (CH3COO), 148.3 (C6), 134 (C51), 119.3 
(C7), 75.1 (C3), 40.5 (C5), 39.52 (Cio), 36.70 (C13); MS: m/z 541 [M+•]. 
3/J-Chloro-5a-cholestano [6, 7- cJ 5'-methyl-I! carbothioic acid amido pyrazole (69): 
Yield 65%; m.p. 156 °C; Analysis found: C 69.63, H 9.28, N 8.12%. C3cH4gN3C1S requires: C 
69.49, H 9.11, N 8.02%; IR (KBr): v m.. 3410 (NH), 1650 (C=N), 1625 (C=C), 1378 (C-N), 
1275 (C=S), 756 (C-Cl); 'H NMR (CDC13): S 7.8 (s, 2H, NH, exchangeable with D2O), 3.9 
(m, 1H, C3a-H, WY2 = 17 Hz), 2.4 (s, 3H, C5'-CH3), 1.19 (s, 3H, C,o-CH3), 0.75 (s, 3H, C,3-
CH3), 0.97 and 0.80 (other methyl protons); 13C NMR (CDCI3): J 184.2 (C=S), 144.5 (C6), 
132 (C51), 119.2 (C7), 52.6 (C3), 42.2 (C5), 42.92 (C5), 39.32 (C,o), 36.31 (C13); MS: m/z 
515/517 [M+']. 
Reaction of 5a-cholestan-6-oue derivatives (70-72) with cyanoacetohydrazide: 
To a solution of 5a-cholestan-6-one derivatives (70-72) (1 mmol) in acetic acid (15 
mL) was added cyanoacetohydrazide in equimolar ratio in same solvent. The reaction mixture 
was refluxed for 5 h. The progress of reaction was monitored by TLC. After completion of 
the reaction, the excess solvent was reduced to three fourths of the original volume under 
reduced pressure. The reaction mixture was washed with water (30 mL), neutralized with 
saturated aqueous NaHCO3 and then taken in diethyl ether. The ethereal layer was further 
washed with water and dried over anhydrous sodium sulfate. Removal of solvent gave the 
crude product which was recrystallized from methanol to furnish corresponding steroidal 
pyrazolones (73-75). 
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Cholest-6 (5'-amino-1, 2'-dilzydropyrazol-3-one-1' yl]5-ene (73): 
Yield 70%; m.p. 119 °C; Analysis found: C 77.08, H 10.49, N 8.99. C30H49N30 requires: C 
77.01, H 10.41, N 8.63; IR (KBr): v max  3470, 3296 (NH, NH2), 1680 (CONH), 1624, 1620 
(C=C), 1461 (N-N), 1441 (C-N); 'H NMR (CDC13): o 8.8 (s, 1H, NH, exchangeable with 
D20), 5.6 (s, 1H, C4'-H), 2.1 (s, 211, NH2, exchangeable with D20), 1.12 (s, 3H, C,0-CH3), 
0.71 (s, 3H, C13-CH3), 0.92 and 0.85 (other methyl protons); '3C NMR (CDC13): d 171 (C3'), 
151 (C5'), 132 (C6), 117 (C5), 127 (C4'), 22.3 (C3), 118 (C7), 42.76 (C9), 39.45 (CIO), 36.53 
(C13); MS: m/z 467 [M+']. 
3f1 Acetoayclwolest-6[5'-amino-1, 2'-dihydropyrazol-3-one-1' y1J5-ere (74): 
Yield 80%; m.p. 145 °C; Analysis found: C 73.14, H 9.71, N 8.0%. C32H51N303 requires: C 
73.04, H 9.65, N 7.95%; IR (KBr): v max  3345, 3280 (NH, NH2), 1735 (OCOCH3), 1680 
(CONH), 1625, 1615 (C=C), 1210 (C-0), 1455 (C-N), 1480 (N-N);'H NMR (CDC13): 6 9.0 
(s, 1H, NH, exchangeable with DSO), 5.2 (s, 1H, C41-II),  4.7 (m, 1H, C3a-H, WI/ = 15 Hz), 
2.2 (s, 2H, NH2, exchangeable with D7O), 2.01 (s, 3H2OCOCH3), 1.12 (s, 3H,C,o-CH3), 0.71 
(s, 3H, C13-CH3), 0.92 and 0.85 (other methyl protons); 13C NMR (CDC13): c5 171.1 (CO), 176 
(C3'), 159 (Cs'),  135 (C6), 119 (C5), 123 (C4'), 70.2 (C3), 118 (C7), 42.76 (C9), 39.45 (C10), 
36.53 (C13); MS: m/z 525 [MJ. 
3/1-Clrloroclsolest-6[5'-aniiiio-.1; 2'-dilzydropyrazol-3-one-.1' ylJS-erne (75): 
Analysis found: C 72.14, H 9.61, N 8.41%. C30H48CIN30 requires: C 72.32, H 9.58, N 
8.32%; IR (KBr): v max 3375, 3291 (NH, NH2), 1685 (CONH), 1622, 1618 (CC), 1448 (C-
N), 1467 (N-N), 741 (C-Cl); 'H NMR (CDC13): 6 8.5 (s, 1H, NH, exchangeable with )2O), 
5.4 (s, 1H, C4'-H), 3.9 (1H, m, C3a-H, W%z = 17 Hz), 2.3 (s, 2H, NH2, exchangeable with 
D20), 1.12 (s, 3H, C10-CH3), 0.71 (s, 3H, C13-CH3), 0.92 and 0.85 (other methyl protons); '3C 
NMR (CDCI3): 6 177 (C3'), 154.7 (C5'), 136 (C6), 117 (C5), 120 (C4'), 52.6 (C3), 118(C7), 
42.76 (C9), 39.45 (C10), 36.53 (C,3); MS: m/z 499/501 [M+']. 
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Benzothiazine is a heterocyclic compound consisting of a benzene ring attached to the 6-
membered heterocycle thiazine. The molecular formula is CSH7NS. The name is applied to 
both the 2H isomer (1) and 4H isomer (2) which differ by the location of the double bonds. 
Benzothiazines were first reported in the 1960s. Subsequently, their preparation and intensive 
biological studies have been reported. In recent years benzothiazines have been of enormous 
interest to synthetic chemists. The enantioselcetive synthesis of such benzothiazines has been 
developed and formulated and transformations of these compounds were designed to target 
chiral, non-racemic building blocks as well as natural products. 
cc' 
(1) 
~ s 
N 
(2) 
Locv and Kormendy' in 1965 reported the first procedure for the synthesis of 
sulfostyril (2, 1-benzothiazine 2, 2-dioxide) (4) during which 2-nitrophenethyl bromide (3) 
was converted in two steps to sulfonyl chloride. Alkaline hydrolysis gave the sodium 
sulfonate which was catalytically reduced to the amine. The amine upon trituration with PC15 
yielded desired product sulfostyril (4). 
\ 
	
Ya 
 
SO2CI 
NO 
 	
HNBr
H2O-HOAc
NH, 
R 	 - 
- 
NO, 
 
C12 	/ 
(3) 
\ 	SO3Na 	503Na Na011 	 ~C~ 
H
-, 
No, 	 NH, 	AcCI 	 SO1 
H 
(4) 
Prota and co-workers2 reported the hydrolysis of (1 -o-aminophenylthio-2, 2-diethoxy) 
ethane (5) resulted in the formation of (2-o-aminophenylthio)acetaldehyde (6) which after 
condensation formed ring in the form of 2H-1, 4-benzothiazine (7). 
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NH2 	 NH2 	 N 
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S CH(OEth 	aS"-"CHO 	 5 
(5) 	 (6) (7) 
Corona et al.3 reported that N-substituted aminothiophenols (8 a-c) reacted with 
haloester and gave 3-oxo-3, 4-dihydro-2H-benzothiazine-2-carboxylic acid ethyl ester 
derivatives (9 a-c) which upon reaction with different amines provided 2H-1, 4-benzo-
thiazine-3, 4-dihydro-3-oxo-2-carboxamides (10 a-h) in good yields. 
aSH 	 as  COOEt 	 ~ S 0 CO-NRZ R3  Na _ NHR'  XCH(COOEt)2 	 N 	0 R3-NH-OH Rz N 
R~ Ri 
(8) 	 (9) 	 (10) 
Rt Rt Rt 	R2 	R3 
(a) H 	 (a) H 	 (a) H 	H 	C6H4C1 
(b) CH3 (b) CH3 (b) CH3 	CH3 	CH3 
(c) C2H5 	 (c) C2H5 	 (c) C2H5 	C,H5 	C6H4OCH3 
(d) H H 	C6I4OCH3 
(e) H 	C2H5 	C6H302CH2 
(f) H CH3 	C6H5 
(g) C2H5 	H 	C4H4CI 
(h) C2H5 	H 	C6H40CH3 
Farag and co-workers4 reported that the aryl hydrazonoyl dichlorides (11 a-c) on 
reaction with 2-aminothiophenol in refluxing ethanol in the presence of triethylamine 
afforded 2, 3-bis(arylhydrazono)-2, 3-dihydro-4H-1, 4-benzothiazines (12 a-c) in good yields 
which on treatment with Iead tetracetate in acetic acid at room temperature provided 
respective oxidation products (13 a-c). 
Ar-HN 	SH 5 	. NHAr 	 S 	N _NHAr 
N* .Cl 	I~ N 
	aN
Cl 	N ' NH2 I 	 Pb(OAc)q 
NH-Arl EtN 0 	 N-    	NHAr~ 	NAr 
H 
(11) (12) (13) 
Ar Ar' Ar Ar' Ar Art 
(a) Ca115 CaH5 (a) CrH5 C,.H5 (a) C6H5 C(,H5 
(b) CIC6H4 C1C6I-14 (b) C1C6H4 CIC61'14 (b) CJC6H4 C1C6H4 
(c) C12C6H3 C12C6H3 (c) C12C6H3 C12C6H3 (c) C12C6H3 C12C6H3 
83 
Napolitano and co-workers5 reported that the oxidation of cysteinylcatechols (14 a-d) 
gave cysteinyldopaquinones (15 a-d) which after ring closure of the cysteine side chain under 
reflux conditions yielded 2H-benzothiazine derivatives (16 a-d). 
OH 
\ QH 
NH2 
[01
-  
R 	S-''ç 
COOH 
(14) 
R 
0 
II O 
NHz 
R S~ COON 
(15) 
R 
0 
N H 
COOH 
R ` S 
(16) 
R 
(a) CH2-CH(NH2)-COOH 
(b) CH3 
(c) OCH3 
(d) OC2H5 
(a) CH2-CH(NH2)-COOH 
(b) CH3 
(c) OCH3 
(d) OCZH5 
(a) CH2-CH(NH2)-COOH 
(b) CH3 
(c) OCH3 
(d) OC2H5 
Guarda et al_6 reported that the treatment of 2-chloro-5-nitro aniline (17) with sodium 
sulfide and sulfur gave 2-amino-4-nitrobenzenethiol sodium salt (18), which was cyclized to 
2H-1, 4-benzothiazin-3-one (19), with chloroacetic acid. N-alkylation with octyI bromide and 
KOH in methanol afforded 4-octyl-6-nitro-2H-1, 4-benzothiazfn-3-one (20). Reduction of the 
nitro group of 20 by SnC1 in acidic medium gave 6-amino-4-octyl-2H-1, 4-benzothiazin-3-
one (21). The N-acetylation of 21 resulted in acetylated product, acetylamino-4-octyl-2H-1, 
4-benzothiazin-3-one (22). 
LIIIJ1I
\ Cl 	 \ SNa 	 S 
Na2S2H2O I
/ 
C1CWCOpH 	 C8H17Br 
O OZN 	NH2 S 02N 	NH2 OH/HH 02N cC N 0 OH 
H 
(17) 	 (18) 	 (19) 
S S \ s 
\ 	SnCh.H2O 	 Ac2O 
` 	 ~ 02N N 0 0 H7N 	N O 	H 'N 	N 0 
H3COC ' 
C8H17 	 C8H17 	 C8H17 
(20) 	 (21) 	 (22) 
Esmaili and co-workers7 reported that a magnetically stirred solution of 2- 
aminothiophenol in 40% ethyl acetate/hexane (5 mL) was allowed to react with the solution 
of dimethyl acetylenedicarboxylate (23 a, b) in 40% ethyl acetate/hexane (2 mL) that resulted 
in the formation of 3, 4-dihydro-3-oxo-2H-b.enzo-1, 4-thiazine derivatives (24 a, b). 
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R02C\
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/ NH2 
C=C\  
CO2R I 	SH 
(23) 
R 	R' 
(a) iso-Pr 	iso-Pr 
(b) tert-Bu 	tert-Bu  
N O 
II 	I 	+ 	R' OH 
` 
(24) 
	
R 	R' 
(a) iso-Pr 	 iso-Pr 
(b) tert-Bu tert-Bu 
Joanna Matysiak8 reported that reaction between substituted anilines (25 a-d) and 
sulforyl bis (2, 4-dihydroxythiobenzoyl (STB) resulted in the formation of 2, 4-dihydroxy-N-
(substituted phenyl) thiobenzamide derivatives (26 a-d) which in turn underwent 
intramolecular cyclization and gave 2-(2, 4-dihydroxy substituted phenyl)-4H-3, 1-benzo 
thiazines (27 a-d). 
HO 
s f R 	OH 
 } 
NH3  0 
R1 	 OH S 
HO 
/ R 	 / 
S 
R' 	EEr OH — H2O 
~ 	 r OH 
OH 
(25) (26) (27) 
R R' R R' R' 
(a) OH OH (a) OH OH (a) OH 
(b) NH2 OCH3 (b) NH2 OCH3 (b) OCH3 
(c) NHCH3 NH2 (c) NHCH3 NH2 (c) NH2 
(d) N(CH3)2 NHCH3 (d) N(CH3)2 NHCH3 (d) NHCH3 
Madrid et al.9 reported the synthesis of diphenylamine derivatives (29 a-d) by the 
coupling of substituted aniline (28 a-d) with bromobenzene using BuchwaId palladium 
coupling reaction. The compounds 29 (a-d) were then cyclized through reaction with sulfur 
and catalytic iodide under microwave irradiation and yielded 1OH-phenothiazines (30 a-d). 
Buchwald  
+ 	coupling 	
JL 	I 	S, I2' H2O 	:I : s Jl:I / 
R NH2 	Br 	 R H R  H 
(28) (29) 	 (30) 
R 	 R 	 R 
(a) COOEt 	 (a) COOEt 	 (a) COOEt 
(b) CN (b) CN (b) CN 
(c) CF3 	 (c) CF3 	 (c) CF3 
(d) CH3 (d) CH3 (d) CH3 
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Bakavoli and co-workers]° reported the reaction of 5-bromo-2, 4-dichloro-6-methyl 
pyrimidine (31) with 2-aminothiophenol which gave 2-(5-bromo-2-chloro-6-methyl 
pyrimidin-4-ylthio) benzenamine (32). The compound 32 reacted with secondary amines and 
yielded 2-(5-bromo-6-methyl-2-substituted-aminopyrimidin-4-ylthio) benzene amines (33 a-
h) which on further reaction with sodamide in acetonitrile furnished pyrimido [4, 5 - b] [1, 4] 
benzothiazines (34 a-h) in good yield. 
CI yN. C1 ` I NH1 HEN ~ 1 
N / SH CI 	1 Br 	T 	N~ S NH, R NH 	R'N 	 N S 
CHCS3 	N 	EIOH 	
NaNHZ~ 
CH3 	 Br 	 N 	Br 	CH'CN 
CH3 CH3 
(31) 	 (32) 	 (33) 
R' 
R'N
II ~ NT 
CH3 H 
(34) 
R' 
(a) Pyrrolidine 
(b) Piperidine 
(c) Methylpiperidine 
(d)Methyl-6H-pyrimidine 
(e) Ethyl-6H-pyrimidine 
(t) Morpholine 
(g) Piperidin-4-ol 
(h) 1-Phenyl-piperazine  
(a) Pyrrolidine 
(b) Piperidine 
(c) Methylpiperidine 
(d) Methyl-6H-pyrimidine 
(e) Ethyl-6H-pyrimidine 
(t) Morpholine 
(g) Piperidin-4-o1 
(h) 1-Phenyl-piperazine 
Tandon and co-workers" reported the reaction of 2-chloro-3-aryl sulfanyl-[1, 4] 
naphthoquioones (35 a-c) with aniline that provided 2-phenylamino-3-aryl sulfanyl-[1, 4] 
naphthoquinones. (36 a-c) which in turn reacted with p-formaldehyde in the presence of 
tetrafluoroborate to yield quaternary intermediate that underwent intramolecular cyclization 
and gave dihydrobenzo [f] naphtha [2, 3 - b][1, 4] thiazepine-6, 11-drone (37 a-c). 
0 
SAr 	 5 A 	0 	R 
LiJL,11
J Aniline  i I BFS 
Cl 	 NH HCHO CHzO 	
L01 
(35) 	 (36) 	 Quaternary salt 
Ar Ar 
(a) Cis 	 (a) C6H5 
(b) 3-OMeC6H4 	(b) 3-OMeC6H4 
(c) Naphthyl (c) Naphthyl 
o 	R 
L~1 1 
N 
0 ~ 1 
1 
(37) 
R 
(a) H 
(b) 3-OMe 
(c) C4H12 
k 
m 
Pratap and co-workers'' reported the synthesis of 1, 4-benzothiazine derivatives (38 
a-j) by the condensation of 2-aminobenzenethiols and 1, 3-dicarbonyl compounds using 
biocatalyst, baker's yeast under ultrasonic conditions. 
\ sx 
 
0  OCS /+R'JRBaker yeast
NHZ 	 '—CH3OH,)))
R 	N 	Rs 
R H 
(38) 
R R1 R2  R R' R2  
(a) H (a) CH3  CH3  (a) H CH3  CH3  
(b) CH3  (b) CH3  OC2H5  (b) H CH3  .002H5  
(c) Cl (c) CH3  Ph (c) H CH3  Ph 
(d) CH3  CH3  (d) CH3  CHI CH3  
(e) CH3  OCZHS (e) CH3  CH3  OC2H5  
(f) CH3  Ph (f) CH3 CH3  Ph 
(g) CH3 CH3  (g) Cl CH3 CH3  
(h) CH3  OC2H5 (h) C1 CH3 OC-,H5  
(1) CH3  Ph (i) Cl CH3 Ph 
(j) Ph Ph (j) H Ph Ph 
Alam et al.13 reported the synthesis of amino and phenyl amino derivatives of 5a-
cholest-6-eno [6, 7 - d] thiazole (40 a-f) by reacting the lachrymatory 5-bromosteroidal 
ketones (39 a-c) with thiourea or phenylthiourea in methanol under reflux conditions. 
X Br 
H2N-CS-NHR 
MeOH, Reflux 
NHR 
(39) 
	
(40) 
X 	 R 
(a) OAc H 
(b) C2H5COO H 
(c) H ;' H 
(d) OAc Ph 
(e) C2H5COO Ph 
(1) H Ph 
11 
(a) OAc 
(b) CZHSCOO 
(c) H 
Mushfiq et al.L4 modified the procedure reported by Alam et al.t3 and reported the one 
pot synthesis of 2'-amino-Sa-cholest-6-eno [6, 7 - d] thiazole derivatives (42 a-c) by the 
reaction of steroidal ketones (41 a-c) with iodine and phenylthiourea under microwave 
conditions. 
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HZN-CS-NHPh 
12, Isopmpanol 	x 
MW 
ti 
NHPh 
(42) 
x 
(a) H 
(b) OAc 
(c) OPr 
x 
(a) H 
(b) OAc 
(c) OPr 
Kumar and co-workers15 reported the reaction of 2, 4-substituted aniline derivatives 
(43 a-d) with ammonium thiocyanate that yielded 2, 4-substituted phenylthiourea derivatives 
(44 a-d) which in turn reacted with bromine and gave substituted benzothiazoI-2-ylamine 
bromate derivatives (45 a-d) which later upon reacted with liquid ammonia yielded 
benzothiazole derivatives (46 a-d). 
RZ 	R2 
Q
HNSCN   
 NH, 	 Ri  NN CS NH2 
Ra 
\ 	s 	Liq. NH3 
NH,. HBr 
(43) 
R' R2 
(a) CH3 H 
(b) CF3 H 
(c) OCH3 H 
(d) H 	Br 
(44) 
R' RZ 
(a) CH3 H 
(b) CF3 H 
(c) OCH3 H 
(d) H 	Br 
(45) 
R' R' 
(a) CH3 CH3 
(b) CF3 H 
(c) OCH3 H 
(d) H 	Br 
(46) 
R' R2 
(a) CH3 H 
(b) CF3 H 
(c) OCH3 H 
(d) H 	Br 
Zav'yalov and co-workers16 reported that 5, 5-dimethyl-cyclohexane-1, 3-dione (47) 
underwent reaction with bromine to provide 2-bromo-5, 5-dimethyl-cyclohexane-1, 3-dione 
(48) which in turn reacted with thiourea to yield 2-amino-5, 5-dimethyl-5, 6-dihydro-4H-
benzo-1, 3-thiazol-7-one (49). 
0 	 0 
Br- 	 Br 
0 DMF, Urea 	 0  
N
~—NH2 
 
H2N CS NH_  
DMF 	 S 
0 
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(49) 
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(50) H 
(51.) OAc 
(52) Cl 
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Nitrogen containing steroids have the ability to regulate a variety of biological processes and 
thus are potential drug candidates for the treatment of a large number of diseases including 
breast cancer, prostate cancer, leukaemia, autoimmune diseases and osteoporosis. 17-21 So is 
the case with the nitrogen containing derivative, benzothiazines in which the presence of a 
fold along the nitrogen-sulfur axis is one of the features responsible to impart their biological 
activity22, hence they show broad spectrum of biological activities such as antagonists, 
anticancer, vasorelaxant, antidiabetic, antihypertensive and antimicrobial.23"28 
Thiazole derivatives have also attracted continuing interest over the years because of 
their varied biological activities. They have been reported as antiallergic, antihypertensive, 
anti-inflammatory, antischizophrenic, antibacterial, anti-HIV, hypnotic, selective COX-2 
inhibitors, fibrinogen receptor antagonists with antithrombotic activity and inhibitors of 
bacterial DNA gyrase B.29-38 The substituted thiazoles have a number of other characteristic 
pharmacological features such as relative stability and ease of starting materials built in 
biocidal unit, enhanced lipid solubility with hydrophilicity and easy metabolism of 
compounds.39 
The biological importance of these steroidal benzothiazines25 30  and steroidal 
thiazoles'9-37 encouraged us to undertake the synthesis of new steroidal benzothiazines and 
aminothiazoles. The substrates selected for synthesizing these steroidal derivatives include 
5a-cholestan-6-one4° (50), 3l-acetoxy-5a-cholestan-6-one41 (51) and 3fl-chloro-5a-cholestan-
6-one42 (52). The products obtained have been characterized on the basis of spectral (IR,'H 
NMR, 13C NMR, MS) and elemental analyses. 
Reaction of 5a-cholestan-6-one (50) with iodine and 2-aminothiophenol. 
The 5a-cholestan-6-one (50) (1 mmol) in absolute ethanol (10 mL) was allowed to 
react with 2-aminothiophenol (1 mmol) and iodine (2 mmol). After completion of the 
reaction,- the reaction mixture was taken in diethyl other, diluted with Na2S207 solution, 
subsequently washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvents gave an oil which was crystallized from methanol to give compound 53, m.p 152 T. 
Iodine 12-aminothiophenol 
I tOH, reI1ux, 19h 
g N 
(50) 	 (53) 
Characterization of the compound, m.p. 152 °C as Sa-cholestano 15, 6 - b] benzothiazine 
(53) 
The compound 53 was correctly analyzed for the molecular formula C33H4sNS. Its IR 
spectrum showed a band at 1628 cm' assigned to C=N group while as the bands at 3062 and 
1600 cni t confirmed the presence of an aromatic moiety. The bands at 711 and 1385 cm 
were attributed to C-S and C-N groups, respectively. These values supported the presence of 
benzothiazine moiety 3 in the product molecule. The structure 53 was well supported by its 
'H NMR spectrum which displayed a multiplet at d 6.43-6.24 integrating for four protons,. 
indicating the presence of an aromatic ring. A two-proton doublet appeared at S 2.05 (J= 8.0 
Hz) for C4-H2 and another doublet at 6 2.04 (J = 4.4 Hz) for C7-H2. The prominent peaks for 
angular and side-chain methyl protons were observed at S 1.17, 0.97, 0.80 and 0.75. The 13C 
NMR spectrum of compound 53 displayed characteristic signals at S 163 showing the 
presence of C=N while as the signals at 149, 125, 124, 122.8, 122 and 120 confirmed the 
presence of an aromatic ring. Remaining carbon atoms were seen in accordance to the 
cholestane series. The structure of compound 53 was further supported by its mass spectrum 
in which the distinct molecular ion peak (M`' 491) was found. 
On the basis of foregoing discussion and the mechanism proposed (Scheme 4.1), this 
compound can be best characterized as 5a-cholestano [5, 6 - b] benzothiazine 53. 
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Reaction of 3/J-acetoxy-5a-cholestan-6-one (51) with iodine and 2-aminothiophenol. 
The 3f-acetoxy-5a-cholestan-6-one (51) (1 mmol) in absolute ethanol (10 mL) was 
allowed to react with 2-aminothiophenol (1 mmol) and iodine (2 mmol). After completion of 
the reaction, the reaction mixture was taken in diethyl ether, diluted with Na2S2O7 solution, 
subsequently washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvents gave an oil which was crystallized from methanol to give compound 54, m.p 163 °C. 
k- 
ne / 2-aminothiophenol 
tOti, reflax, 19 h 
S N H O 
(51) 	 (54) 
Characterization of the compound, m.p. 163 °C as 3fl-acetoxy-5a-cholestano 15, 6 - b} 
benzothiazine (54) 
The elemental analysis of the compound corresponded to the molecular formula 
C35H51NO2S. Its IR spectrum showed a band at 1650 cm 1 which could be assigned to C=N 
group while as the bands at 3060 and 1603 em l` confirmed the presence of an aromatic 
moiety. The IR spectrum of the compound 54 exhibited strong absorption bands at 1714 and 
1206 cnz ' indicating the presence of an acetoxy group while as the bands at 750 and 1388 
cm 'I were attributed to C-S and C-N groups, respectively. These values suggested the 
presence of benzothiazine moiety 3 in the product molecule. The structure 54 was well 
supported by its I H NMR spectrum which displayed a multiplet at 6 6.33-6.28 integrating for 
four protons, indicating the presence of an aromatic ring. A broad multiplet (W,,2 = 15 Hz, 
axial) for one proton was observed at d 4.7 which could be assigned to C3a-H. The three 
acetoxy group protons appeared at 6 2.03 as a sharp singlet. A doublet for two protons 
appeared at 9 1.8 (J= 8.0 Hz) for C4-H2 and another doublet integrating for two protons at S 
1.9 (J = 5.2 Hz) for C7 H2. Other prominent peaks for angular and side-chain methyl protons 
were observed at S 1.18, 0.97, 0.83 and 0.70. The 13C NMR spectrum of compound 54 
displayed characteristic signals at 6 174 and 163 showing the presence of C=O and C=N, 
respectively while as the signals at 148, 129, 128, 126, 124 and 122 confirmed the presence 
of an aromatic carbons. The signal at 73 was assigned to the C3 of the steroidal molecule 
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with acetoxy group attached to it.Remaining carbon atoms were seen in accordance to the 
cholestane series. The structure of compound 54 was further supported by its mass spectrum 
in which- the distinct molecular ion peak (M+  549) was observed. 
On the basis of above studies and its analogy with earlier compound 53, this 
compound can be best characterized as 3/i-acetoxy-5a-cholestano [5, 6 - b] benzothiazine 54. 
Reaction of 3/3-chloro-5a-cholestan-6-one (52) with iodine and 2-aminothiophenol. 
The 3fl-chloro-5a-cholestan-6-one (52) (1 mmol) in absolute ethanol (10 mL) was 
allowed to react with 2-aminothiophenoI (1 mmol) and iodine (2 mmol). After completion of 
the reaction, the reaction mixture was taken in diethyl ether, diluted with Na2S2O7 solution, 
subsequently washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvents gave an oil which was crystallized from methanol to give compound 55, m.p 146 °C. 
CI 
Udine / 2-aininothiophenol 
Et0H, reflux, 19 h 
 
n 
  
o 
(52) 	 (55) 
Characterization of the compound, m.p. 146 °C as 3f1 chloro-5a-cholestano 15, 6 - b] 
benzothiazine (55) 
The compound 55 was correctly analyzed for the molecular formula C33H48C1NS 
(Beilstein positive). Its IR spectrum showed a band at 1626 cm' which could be assigned to 
C=N group while as the bands at 3058 and 1598 cm' confirmed the presence of an aromatic 
moiety and the bands at 710, 1380 and 740 cm' were attributed to C-S, C-N and C-Cl 
groups, respectively. These values supported the presence of benzothiazine moiety43 in the 
product molecule. The structure 55 was well supported by its 'H NMR spectrum which 
displayed a multiplet at S 6.43-6.24 for four protons, indicating the presence of an aromatic 
ring. A broad multiplet (W,,2 = 17 Hz, axial) for one proton was observed at S 3.5 which 
could be assigned to C3a-H. A doublet for two protons appeared at S 2.07 (J= 8.0 Hz) for C4-
H2 and another doublet at S 1.87 (J = 4.8 Hz) for two C7-methyl protons. The prominent 
peaks for angular and side-chain methyl protons were observed at 8 1.18, 0.97, 0.80 and 0.75. 
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The '3C NMR spectrum of compound 55 displayed a characteristic signal at 6 164 showing 
the presence of C=N while as the signals at 146, 127, l26, 125, 123 and 122 confirmed the 
presence of an aromatic moiety. The signal at 5 59 was assigned to the C3 of the steroidal 
molecule with chlorine attached to it. Remaining carbon atoms were seen in accordance to 
the cholestane series. The structure of compound 55 was further supported by its mass 
spectrum in which the distinct molecular ion peak (W 5251527) was found. 
Formation of steroidal benzothiazincs (53-55) under the condition case may be shown 
according to the proposed mechanism (Scheme 4.1), The mechanism for the formation of 
these benzothiazines involves formation of 5a-iodocholest-6-one in situ as an intermediate, 
which on further reaction with 2-aminothiophenol undergoes SN4 reaction at C5 and 
condensation at C6 resulting in cyclization that leads to the formation of corresponding 
product. The remarkable feature of the reaction is the formation of 5a-iodoketone in sibs as 
an intermediate which might be obtained separately by the reaction of ketones with iodine. 
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Scheme 4.1. Mechanism for the formation of steroidal benzothiazine derivatives (53-55) 
Work published; 
Anticancer and antimicrobial evaluation of newly synthesized steroidal 5, 6 fused 
benzothiazines. Shamsuzzaman, Ayaz Mahmood Dar, et al., Arabian Journal of Chemistry, 
http://dx.doi.org/10.1016/j.arabje.2013.06.027 (in press) 
Reaction of 5a-cholestan-6-one (50) with iodine and thiosemicarbazide. 
The 5a-cholestan-6-one (50) (1 mmol) in absolute ethanol (15 mL) was allowed to 
react with thiosemicarbazide (1 mmol) and iodine (2 mmol). After completion of the reaction, 
the reaction mixture was taken in diethyl ether, diluted with Na2S2O7 solution, subsequently 
washed with water and dried over anhydrous sodium sulfate. Removal of the solvent gave an 
oil which was crystallized from methanol to afford compound 56, m.p 129 °C. 
Iodine/ Thiosemicarbazide 
Ethanol, reflux 
~. 0 
NH—NH2 
(50) 	 (56) 
Characterization of the compound, m.p. 129 °C as 2'-hydrazireocholest-6-eno 14, 5 - 17 
thiazole (56) 
The compound 56 was correctly analyzed for the molecular formula C2gH47N3S. Its IR 
spectrum showed bands at 3376 and 3328 cm' which could be assigned to NH and NH,) 
groups, respectively while as the bands at 1617, 1557, 1328 and 634 cm' were attributed to 
C=C, C=N, C-N and C-S groups, respectively. These values suggested the presence of 
aminothiazole moiety43 in the product molecule. The structure 56 was well supported by its 
'H NMR spectrum which displayed a broad singlet integrating for two protons at d 6.2 
(exchangeable with D20) depicted the presence of NH2 while as the singlet integrating for 
one proton at 6 3.8 (exchangeable with D20) showed the presence of NH. A double doublet 
appeared at S 2.74 (J = 16.9 and 5.5 Hz) depicting the presence of Csa-H. The prominent 
peaks for angular and side-chain methyl protons were observed at 5 1.18, 0.97, 0.83 and 0.70. 
The 13C NMR spectrum of compound 56 displayed characteristic signal at b 163 showing the 
presence of C=N while as the signals at b 130 and 120 assigned to C6 and C7, respectively. 
Remaining carbon atoms were seen in accordance to the cholestane series. The structure of 
compound 56 was further supported by its mass spectrum in which the distinct molecular ion 
peak (M+- 457) was found. 
On the basis of foregoing discussion and the mechanism proposed (Scheme 4.2 a, b), 
this compound can be best characterized as, 2'-hydrazinocholest-6-eno [4, 5 - d] thiazole 56. 
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Reaction of 3j3-acetoxy-5a-cholestan-6-one (51) with iodine and thiosemicarbazide. 
The 3fl-acetoxy-5a-cholestan-6-one (51) (1 mmol) in absolute ethanol (15 mL) was 
allowed to react with thiosemicarbazide (1 mmol) and iodine (2 mmol). After completion of 
reaction, the reaction mixture was taken in diethyl ether, diluted with Na2S2O7 solution, 
subsequently washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvent gave an oil which was crystallized from methanol to give compound 57, m.p 136 °C. 
!Dine/ Thiosemicarbazic 
Ethanol, reflux 
N~ 
M—NH2 
(51) 	 (57) 
Characterization of the compound, m.p. 136 °C as 3J1-acetoxy-2'-hydrazinocholest-6-eno 
14, 5 - dl thiazole (57) 
The elemental analysis of compound 57 corresponded to the molecular formula 
C30H49N302S. Its IR spectrum showed bands at 3395 and 3310 cm I which could be assigned 
to NH and NH? groups, respectively. The IR spectrum of the compound exhibited strong 
absorption bands at 1730 and 12I0 cni ' indicating the presence of acetate group while as the 
bands at 1625, 1555, 1320 and 645 cm i were attributed to C=C, C=N, C-N and C-S groups, 
respectively. These IR values supported the presence of aminothiazole moiety 3 in the 
product molecule. The structure 57 was well supported by its 'H NMR spectrum which 
displayed broad singlet integrating for two protons at S 6.8 (exchangeable with D2O) 
indicating the presence of NH2 while as a singlet integrating for one proton at S 4.4 
(exchangeable with D20) showed the presence of NH. A broad multiplet (Wj z = 15 Hz, axial) 
for one proton was observed at 5 4.7 which could be assigned to C3a-H. The three acetoxy 
group protons appeared at o 2.03 as a sharp singlet. A double doublet for one proton appeared 
at 6 2.7 (J = 15 and 5 Hz) for C5a-H. Other prominent peaks for angular and side-chain 
methyl protons were observed at 6 1.18, 0.97, 0.83 and 0.70. The 13C NMR spectrum of 
compound 57 displayed characteristic signals at 6 171.2, 163 showing the presence of C=O 
and C N while as the signals at 6 132, 120 and 70.2 were assigned to C6, C7 and C3, 
respectively. Remaining carbon atoms were seen in accordance to the cholestane series. The 
k1 
structure of compound 57 was further supported by its mass spectrum in which the distinct 
molecular ion peak (M+' 515) was found. 
On the basis of above studies and its analogy with earlier compound 56, this 
compound can be best characterized as 3fl-acetoxy-2'-hydrazinocholest-6-eno [4, 5 - d] 
thiazole (57). 
Reaction of 3/I-chloro-5a-cholestan-6-one (52) with iodine and thiosemicarbazide. 
The 3f-chloro-5a-cholestan-6-one (52) (1 mmol) in absolute ethanol (15 mL) was 
allowed to react with thiosemicarbazide (1 mmol) and iodine (2 mmol). After completion of 
reaction, the reaction mixture was taken in diethyl ether, diluted with Na2S2O7 solution, 
subsequently washed with water and dried over anhydrous sodium sulfate. Removal of the 
solvent gave an oil which was crystallized from methanol to give compound 58, m.p 143 °C. 
Cl 
odin& Thiosemicarbazide 
Ethanol, reflux CI 
 
oil 
 
NH— NH2 
(52) 	 (58) 
Characterization of the compound, m.p. 143 °C as 3/1-chloro-2'-hydrazinocholest-6-eno 
14, 5 - dJ thiazole (58) 
The compound 58 was correctly analyzed for the molecular formula C28H46CIN3S 
(Beilstein positive). Its IR spectrum showed bands at 3370 and 3320 cm ~ which could be 
assigned to NH and NH2 groups, respectively. The IR spectrum of the compound 58 exhibited 
absorption bands at 1622, 1560, 1323, 745 and 635 cm 1 which were attributed to C=C, C=N, 
C-N, C-Cl and C-S groups, respectively. These IR values depicted the presence of 
aminothiazole moiety43 in the product molecule. The structure 58 was well supported by its 
'H NMR spectrum which displayed broad singlet integrating for two protons at 5 6.63 
(exchangeable with D20) indicating the presence of NH2 while as a singlet integrating for one 
proton at S 4.45 (exchangeable with D20) showed the presence of NH. A broad multiplet 
(Wj,2 = 15 Hz, axial) for one proton was observed at 6 3.9 which could be assigned to C3a-H. 
A double doublet for one proton appeared at (52.8 (J = 17.05 and 5.3 Hz) depicting the 
presence of C5a-H. The prominent peaks for angular and side-chain methyl protons were 
observed at 5 1.18, 0.97, 0.83 and 0.70. The 13C NMR spectrum of compound 58 displayed 
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N 
Ham® ~S 
NH — NH, 
characteristic signal at 6 162 showing the presence of C=N while as the signals at 5 134, 120 
and 57.7 were assigned to C6, C7 and C3, respectively_ Remaining carbon atoms were seen in 
accordance to the cholestane series. The structure of compound 58 was further supported by 
its mass spectrum in which the distinct molecular ion peak (M+' 4891491) was found. 
The mechanism for the formation of steroidal aminothiazole derivatives (56-58) can 
be explained by considering that during the reaction the a-iodoketone la formed in situ 
undergoes allylic displacement of iodine via enolization and the subsequent attack of sulfur of 
thiosemicarbazide followed by cyclization leads to the formation of products 56-58 (Scheme 
4.2a). An enol tautomeric form lb might be the driving force to accelerate the reaction 
towards product formation. 
12 
x 	 X 
o 	Io 
la 
x 
HN C_NH. NHi 
x 
7  HO ,~ 
S 
1b 	II 
H1N —C — NH— NH2 
x 
H 
`ll 
HNJ C — NH`NH, 
j 
H 
x 	H 	x 
HO 5 	HBO  N~ , 	 H N~ ,S 
C C 
NH — NH, 	 NH—NH2 
X 
(56) H 
(57) OAc 
(58) Cl 
x 	S H 
N:C 
NH —NH2 
Scheme 4.2a. Mechanism for the formation of steroidal aminothiazole derivatives (56-58) via 
the allylic displacement of iodine. 
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The formation of products 56-58 may also be explained by an alternate route 
considering that during the reaction 1, 3-shift of iodine from C5 to C7 leads to the formation of 
intermediate 1c in situ followed by SN2 attack • of sulfur of the reagent and subsequent 
cyclization provides the desired products 56-58 (Scheme 4.2b). 
r , HO ,, 
I• 
1,3-shift of iodine 
- 0 	~~ SN'snackof'reagent X 	a 
H -I S 	 H 
1c 	~~ 	 I 
12 
~C-13H - IVHZ 
X 	 X 
:5} 	X 	H 
	
}j O) g 	 H 
~C H p s 	- H N C,S 
NH-NH, 
NH-NH, 
NH-NH, 
1120 
X 
(56)H 	 H N=C 	 N~C,S 
57 OAc { ) 	 NH-NH, 	 NH-NH2 
(58) Cl 
Scheme 4.2b. Mechanism for the formation of steroidal aminothiazole derivatives (56-58) 
via 1, 3-shift of iodine. 
Work accepted; 
Synthesis, characterization and in vitro anticancer activity of newly synthesized steroidal 6, 7-
fused thiazoles, Shamsuzzaman, Ayaz Mahmood Dar, et aI., Journal of Chemistry 
(accepted) 
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All the melting points were determined in degrees Celsius on a Kofler apparatus and are 
uncorrected. The IR spectra were recorded on KBr pellets with Perkin Elmer RXI 
Spectrophotometer and values are given in cm'. 'H and '3C NMR spectra were run in CDC13 
on a JEOL Eclipse (400 MHz) instrument with TMS as internal standard and values are given 
in ppm ((5'). Mass spectra were recorded on a JEOL SX 102/DA-6000 Mass Spectrometer. 
Thin layer chromatography (TLC) plates were coated with silica gel G and exposed to iodine 
vapors to check the homogeneity as well as the progress of reaction. Petroleum ether refers to 
a fraction of boiling point 60-80 °C. Sodium sulfate (anhydrous) was used as a drying agent. 
The synthesis of 3fl-chlorocholest-5-ene, cholest-5-ene, 6-nitrocholest-5-ene and 5a-
cholestan-6-one is shown in chapter 1, page 23, 24. The synthesis of 3fl-acetoxycholest-5-
ene, 3f-acetoxy-6-nitrocholest-5-ene and 3/J-acetoxy-5a-cholestan-6-one is shown in chapter 
1, page 24, 25. The synthesis of 3/3-chloro-6-nitrocholest-5-ene and 3Q-chloro-5a-cholestan-
6-one is shown in chapter 1, page 25, 26. 
Reaction of 5a-cholestan-6-one derivatives (50-52) with iodine and 2-aminothiophenol: 
To a solution of 5a-cholestan-6-one derivatives (50-52) (1 mmol) in absolute ethanol 
(10 mL) was added 2-aminothiophenol( thiosemicarbazide (1 mmol) and iodine (2 mmol) in 
the same solvent (25 mL) and the reaction mixture was refluxed for 13-21 h. The progress of 
the reaction was monitored by TLC. After completion of reaction the excess solvent was 
reduced to three fourths of the original volume under reduced pressure. Then it was cooled to 
room temperature, diluted with Na2S2O7 solution and subsequently with water. The mixture 
was extracted with diethyl ether, washed with water and finally dried over anhydrous sodium 
sulfate. Evaporation of solvents and crystallization of the oily residue from methanol afforded 
corresponding products (53-58). 
5a-Cholestano [5, 6- bJ benzothiazine (53): 
Yield 83%; m.p. 152 °C; Analysis found: C 80.59, H 10.04, N 2.85%. C33H4sNS requires: C 
80.12, H 9.86, N 2.63%; IR (KBr): v ,,,a., 3062, 1600 (aromatic), 1628 (C=N), 1385 (C-N), 
711 (C-S); 'H NMR (CDC13): (56.43-6.24 (in, 4H, aromatic), 2.05 (d, 2H, C4-H2, J = 8.0 Hz), 
2.04 (d, 2H, C7-H2, J= 4.4 Hz), 1.17 (s, 2H, C,o-CH3), 0.75 (s, 3H, C13-CH3), 0.97 and 0.80 
(other methyl protons); 13C NMR (CDCl3): S 163 (C=N), 149, 125, 124, 122.8, 122, 120 
(aromatic carbons), 48 (C3), 46 (C14), 42.2 (C4), 39 (C,o), 35 (C5), 26 (C!9), 24 (C1,), 22 (C[8), 
20 (C15 ); MS: inlz 491 
6- 
as 
3J3Acetoxy-5a-cholestano [5, 6- bJ benzothiazine (54): 
Yield 80%; m.p. 163 °C; Analysis found: C 76.45, H 9.35, N 2.55%. C35H51NO2S  requires: C 
76.17, H 9.08, N 2.32%; IR (KBr): v max  3060, 1603 (aromatic), 1714 (OCOCH3), 1650 
(C=N), 1388 (C-N), 1206 (C-O), 750 (C-S); 'H NMR (CDCI3): 6 6.33-6.28 (m, 4H, 
aromatic), 4.7 (m, 1H, C3a-H, W'/2 = 15 Hz ), 2.03 (s, 3H, OCOCH3), 1.9 (d, 2H, C7-H2, J 
5.2 Hz), 1.8 (d, 2H, C4-H2, J= 8.0 Hz), 1.18 (s, 3H, C , o-CH3), 0.70 (s, 3H, C , 3-CH3), 0.97 
and 0.83 (other methyl protons); i3C NMR (CDC13): 6 174 (OCOCH3), 163 (C=N), 148, 129, 
128, 126, 124, 122 (aromatic carbons), 73 (C3), 46 (C14), 44 (C,3), 42 (C4), 39 (C,o), 35 (C5), 
26 (C19), 24 (C,,), 22 (Cis); MS: nt/z 549 [M+,]. 
3/i-Chloro-5a-cholestano [5, 6- bJ benzothiazine (55): 
Yield 85%; m.p. 146 °C; Analysis found: C 75.32, H 9.19, N 2.66%. C33H48CINS requires: C 
75.07, H 9.03, N 2.61%; IR (KBr): v max  3058, 1598 (aromatic), 1626 (C=N), 1380 (C-N), 
740 (C-Cl), 710 (C-S); 1 H NMR (CDC13 ): cS 6.43-6.24 (m, 4H, aromatic), 3.5 (m, 1H, C3a-H, 
W !/ = 17 Hz), 2.07 (d, 2H, C7-H2, J = 8.0 Hz), 1.87 (d, 2H, C4-H2, J = 4.8 Hz), 1.18 (s, 2H, 
C,o-CH3), 0.75 (s, 3H, C13-CH3), 0.97 and 0.80 (other methyl protons); 13C NMR (CDC13 ): S 
164 (C--N), 146, 127, 126, 125, 123, 122 (aromatic carbons), 59 (C3), 47 (C14), 46 (C,3), 42.6 
(C4), 39 (C;o), 3S (C5), 26 (Ci9), 24 (Ci 1), 22 (Cis), 20 (C15), 17 (C16); MS: m/z 525/527 [M]. 
2' Hydrazinocholest-6-eno ]4, 5- d] thiazole (56): 
Yield 73%; m.p. 129 °C; Analysis found: C 73.52, H 10.28, N 9.19%. C28H47N3S requires: C 
73.47, H 10.19, N 9.13%; IR (KBr): v max  3376, 3328 (NH, NH2), 1617 (C=C), 1557 (C=N), 
1328 (C-N), 634 (C-S); 'H NMR (CDC13): S 6.2 (br s, 2H, NHZ, exchangeable with D20), 3.8 
(s, 111, NH, exchangeable with D20), 2.74 (dd, 111, C5a-H, J =16.9 Hz, 5.5 Hz), 1.18 (s, 3H, 
Co-CH3), 0.70 (s, 3H, C13-CH3), 0.97 and 0.83 (other methyl protons); 13C NMR (CDC13): 6 
163 (C=N), 130 (CO), 120 (CA), 50 (C3), 46 (C14), 42.2 (C4), 39 (CIo), 35 (C5), 26 (C19), 24 
(C11), 22 (C18), 20 (C,5), 17 (C16); MS: m/z 457 [M*']. 
3/1-A cetoxy-2 '-I:ydrazinocholest- i-eno [4, 5- d] thiazole (57): 
Yield 82%; m.p. 136 °C; Analysis found: C 69.90, H 9.51, N 8.15 %. C30H49N302S requires: 
C 69.84, H 9.39, N 8.11%; IR (KBr): v 	3395, 3310 (NH, NH2), 1730 (OCOCH3), 1625 
(C=C), 1555 (C=N), 1320 (C-N), 1210 (C-O), 645 (C-S); 'H NMR (CDC13): d 6.8 (br s, 2H, 
NH2, exchangeable with D20), 4.7 (m, 1H, C3a-H, W%a =15 Hz), 4.4 (s, 1H, NH, 
exchangeable with D20), 2.7 (dd, IH, C5a-H, J=15 Hz, 5 Hz), 2.03 (s, 3H, OAc), 1.18 (s, 
100 
3H, C,0-CH3), 0.70 (s, 3H, C, 3-CH3), 0.97 and 0.83 (other methyl protons); 13C NMR 
(CDCl3): 9171.2 (OCOCH3), 163 (C=N), 132 (C6), 120 (C 7 ), 70.2 (C3), 46 (C,4), 44 (C,3), 42 
(C4), 39 (C,o), 35 (C5), 26 (C19), 24 (C11), 22 (C18), 20 (C,5), 17 (C16); MS: m/z 515 [M+']. 
3/I-Chloro-2'-hydrazinocholest-6-eno [4, 5 - dJ tlziazole (58): 
Yield 76%; m.p. 143 °C; Analysis found: C 68.43, H 9.36, N 8.54%. C28H46C1N3S requires: C 
68.37, H 9.29, N 8.49%; IR (KBr): V max 3370, 3320 (NH, NH,,), 1622 (C=C), 1560 (C=N), 
1323 (C-N), 745 (C-Cl), 635 (C-S); 'H NMR (CDC13): c 6.63 (br s, 2H, NHz, exchangeable 
with D20), 4.45 (s, 1H, NH, exchangeable with D20), 3.9 (m, 1H, C3a-H, W7/2 = 17 Hz), 2.8 
(dd, 1H, C5a-H, J=17.05 Hz, 5.3 Hz), 1.18 (s, 3H, C10-CH3), 0.70 (s, 3H, C13-CH3), 0.97 and 
0.83 (other methyl protons); 13C NMR (CDC13): d 162 (C=N), 134 (C6), 120 (C,), 57.7 (C3), 
46 (C,4), 45 (C,3), 42.6 (C4), 39 (Cio), 35 (C5), 26 (C,9), 24 (C,,), 22 (Cis), 20 (Cis), 17 (C,6); 
MS: m/z 489/491 [M+']. 
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Steroids have been the important focus of research throughout the scientific history. But the 
recent past has seen an exhaustive focus of research being diverted towards these biologically 
important molecules. This is pertinently true of the rational semi-synthetic modifications of 
steroidal molecules. Probably, it is because of the various advantages associated with steroid 
based chemotherapeutics. These compounds turn out to be non-toxic, less vulnerable to 
multi-drug resistance (MDR) and highly bioavailable because of being capable of penetrating 
the cell wall.'  
Steroid based antimicrobial agents continue to play a prominent role in those 
organisms which do not rely upon external supply of drugs to fight against pathogens' 
because the entire morbidity and mortality mostly in developing countries is due to these 
microbial infections' among which Escherichia coli is responsible for the most common and 
serious infectious diseases like invasive dysentery and diarrhoea. The different microbes 
such as Staphylococcus aureus, Streptococcus pyogenes and Salmonella typhinwrium have 
important effect on the human's mucosal health. The infection with these microorganisms 
may have a significant impact on huge demolition of host tissue and severe diseases.5. 6 
Nitrogen containing steroids have the ability to regulate a variety of biological 
processes and thus are potential drug candidates for the treatment of a large number of 
diseases including breast cancer, prostate cancer, leukaemia, autoimmune diseases and 
osteoporosis.?" So is the case with the nitrogen containing derivatives, pyrimidines, pyrans, 
pyrazoles, pyrazolones, benzothiazines and thiazoles which exhibit a broad spectrum of 
biological -activities such as anticancer, antiviral, antibacterial, antifungal, antioxidant, 
anxiolytic and antidepressant. Furthermore, they possess anti-inflammatory and analgesic 
activities which are well documented in the literature. 12-20 
Antioxidants have gained much importance because of their potential as prophylactic 
and therapeutic agents in many diseases. Free radicals are constantly formed as a result of 
normal organ functions or excessive oxidative stress.21 High levels of free radicals can cause 
damage to biomolecules such as lipids, proteins, enzymes and DNA in cells and tissues, 
resulting in mutations that can lead to malignancy. Damage to DNA by oxidative stress has 
been widely accepted as a major cause of cancer.22 DNA mutation is a critical step in 
carcinogenesis and elevated levels of oxidative DNA lesions have been observed in various 
tumours. The discovery of the role of free radicals in cancer, diabetes, cardiovascular 
diseases, autoimmune diseases, neurodegenerative disorders, aging and other diseases has led 
to new medical insight.23. 24  Minimizing oxidative damage may be an important approach to 
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the primary prevention or treatment of these diseases, since antioxidants may stop the free-
radical formation, or interrupt an oxidizing chain reaction. This had attracted a great deal of 
research interest in therapeutic antioxidant-based drug formulations. The development of 
heterocycles which are capable of scavenging free radicals, have been a great success. 
El-zahar and co-workers25 reported the synthesis of substituted pyrimidine derivatives 
(1 a-d). These compounds were tested for cytotoxicity against human liver carcinoma cell line 
(HepG2) during which all compounds were highly active as compared to 5-fluorouracil (5-Fu) 
with IC50 < 10 µg/mL. During the docking study the actual docking target sites was found and 
the negative bonding energy against amino acid residues of protein was calculated. 
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Dabholkar and Gavande26 reported the synthesis of substituted 1, 4-benzoxazine 
derivatives (2 a-c). The compounds were investigated for antibacterial activity against Gram 
positive as well as Gram negative bacteria with Ampicillin as standard drug during which the 
new compounds were found active with potential zone of inhibition. 
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Naganagowda and co-workers27 also reported the synthesis of substituted thiophene 
derivatives (3 a-c). The compounds were screened for antimicrobial, analgesic and anti-
helmintic activity during which the compounds were found to be biologically active. 
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Parashar and co-workers28 reported the synthesis and antimicrobial activity of 
pyrazole derivatives (4 a-d) during which all the compounds were found to be biologically 
active against bacteria as well as fungi especially against B. subtitis, S. aureus and C. albicans. 
O 
N~ N' NH2 
0 
0 
0 
0 
0 	COCH3 
N 	
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O 
O 
Ph- N 	0 
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2NN  r 	/ N 
(4a) 	 (4b) 	 (4c) 	 (4d) 
El-Latif and co-workers29 reported the synthesis of 2-amino-4-(3-indolyl)-6-(3-pyridyl)- 
pyran-3-carbonitrile (5). 
The compound and its derivatives were screened for antimicrobial, analgesic and 
antieonvulsant activity during which these were found to be biologically active in comparison 
with the biological standards. 
Feng and co-workers3° reported the synthesis of pyrano [3, 2 - c] pyridine nucleoside 
derivative (6a). and pyrano [4, 3 - b] pyran nucleoside derivative (6b) as potential antiviral 
and anti-leishmanial agents. Both the compounds were found biologically active by being 
effective at less concentration. 
NH, 
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Devnath and IsIam31 reported the synthesis and anticancer studies of substituted 
quinolone derivatives (7 a-c). The ICS° obtained were 0.021, 0.0 I9 and 0.023 gg/mL. 1 
HN~ / 	~`N~R R 
N 	 / 	Q (a) Ph 
	
N (b) CgH MCW2 
C3A5 	 () CS-NH2 (7) 
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Mariappan and co-workers32 reported the synthesis of substituted pyrazolones (8 a-g). 
The compounds were screened for analgesic and anti-inflammatory activity on albino mice, 
during which all the synthesized compounds were found to be biologically active. 
R 
HC- )\~ 
H3C 
N 	0 N (8) 
H 
R 
(a) N(CH3)2 (e) CH=CH-Ph 
(b) 0(CH3)2 (I) OMe (c) Cl 	(g) OH 
(d) NO2 
Chunduru and Rao33 reported the one pot synthesis of 4-arylidene-3-methyl-l-[4-(2- 
oxo-2H-chromen-3-yl) thiazol-2-yl]-1H-pyrazol-5(4H)-one derivatives (9 a-d). The pyrazoles 
were screened for anticancer activity during which they showed IC50 < 15 pg/mL while as in 
antimicrobial activity these compounds depicted effective zone of inhibition. 
o0 
	CH3 
ti 	/ 	N 	
NMe~ 	a R 
R s 0 (b) Br 
(c) NO2 
(9) 	 (d) OCH3 
Kumar and co-workers34 reported the synthesis of benzothiazole derivatives (10 a-d). 
The compounds were tested for antioxidant (LPO and GSH) and radical scavenging activities 
(DPPH and ABTS assays) during which compounds showed potential antioxidant behavior. 
R 	S\ 	R 
N C' NH2 (a) CH3 (c) OCH3 
(b) CF3 (d) Br 
(10) 
Tandon and co-workers35 reported the synthesis of dihydrobenzo [f] naphtha [2, 3 - b] 
[1, 4] thiazepindiones (11 a-d) as antimicrobial agents. These compounds showed activity 
against Sporothrix schenckii (MIC50=1.56 µglnlL), significant profile against Candida 
albicans (MIC50=1.56 µg/mL), Cryptococcus neoforrnans (MIC50= 0.78 µg/mL) and 
t 
Trichophyton rnentagraphytes (MIC50=1.56 pg/mL) and same antifungal activity when 
- compared with Amphotericin-B against C. neoformans (MIC50 0.78 µg/mL). 
R 
(a)H 
(b) OMe 
N  
0 	Ph 	
(c) NO2 
(11) 	(d) C41112 
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Tandon and co-workers36 also reported the synthesis of 6H-benzo[b] phenothiazine-6, 
11(12H)-dione derivatives (12 a-c) as potential antiproliferative and antifungal agents. 
Compounds 12b and 12c were found to possess most potent antiproliferative and cell killing 
ability against human cervical cancer (HeLa) cells. These compounds exhibited MIC5o=5.0 
µg/mL against the strains of C. albicans, T. mentagrap/iytes, S. schenckii and C neoformans. 
0 
Ccx R  01-R  (a) H N 	 (b) OMe 
0 	H (c) C4H12 
(12) 
Sadanandam et al.37 reported the synthesis of 2-aryl-N, N', 4-trimethyl-1OH-pheno 
thiazine-1, 3-dicarboxamides (13 a-c) as enzyme inhibitors for inflammatory diseases. The 
results showed that these compounds exhibited promising target specific enzyme inhibition 
against phosphodiesterase, prostaglandin dehydrogenase and superoxide dismutase activity 
depending on steric factors of the molecules. 
CH3 0 
\NHCtt3 	R 
(a)C6H5 
 (b) C6H2C12 
0 NHCH3 	(C) C7H502 
(13) 
Bakavoli and co-workers35 reported the synthesis of pyrimido [4, 5 - b] [1, 4J 
benzothiazines (14 a-e) as potent 15-lipoxygenase inhibitors. Compounds showed the best 
IC5o of 15-LO inhibition (IC50 = 18 and 34 p.M). All compounds were docked into 15-LO. As 
a result, the sulfur atom was oriented toward the iron atom of the active site of 15-LO. 
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Materials and equipments: 
Tested microbes used in the study were Escherichia coil, Staphylococcus aureus, 
Pseudomonas aeruginosa, Streptococcus pyogenes, Klebsiella pneumoniae, Candida 
albicans, Aspergillus f rmigatus, Trichophyton mentagrophytes and Penicilliwn marjneffei. 
The microbial strains were provided by American Type Culture Collection (ATCC). The 
images were taken from Axio Imager 2 fluorescent microscope. The standard drugs used in 
the study were Ciprofloxacin, Chloramphenicol, Griseofulvin and Nystatin which were being 
purchased from Merk (India). 
In vitro antibacterial activity: 
The in vitro antibacterial activity of new steroidal derivatives was done by the disk diffusion 
method and zones were measured by Halo Zone Test.39 40 The MIC of synthesized 
compounds against bacterial and fungal strains was checked by micro dilution test and results 
were observed visually and spectrophotometrically. The new compounds were screened for 
antibacterial activity against the cultures of Escherichia coli (ATCC-25922), Staphylococcus 
aureus (MRSA +Ve) (ATCC-25923), Pseudomonas aeruginosa (ATCC-27853), 
Streptococcus pyogenes (ATCC 19615) and Klebsiella pneumoniae (Clinical isolate) 
Standard inoculums (1-2 x 107 c.f u./mL 0.5 McFarland standards) was introduced on to the 
surface of sterile agar plates, and a sterile glass spreader was used for even distribution of the 
inoculums. The discs. measuring 6 mm in diameter were, prepared from Whatman no. 1 filter 
paper and sterilized by dry heat at 140 °C for I h. The sterile discs previously soaked in a 
known concentration of the test compounds were placed in nutrient agar medium. Solvent 
and growth controls were kept. Ciprofloxacin and Chloramphenicol were used as positive 
controls while the disk poured in DMSO was used as negative control. The plates were 
inverted and incubated for 24 h at 37 °C. The susceptibility was assessed on the basis of 
diameter of zone of inhibition against Gram-positive and Gram-negative strains of bacteria. 
Inhibition zones were measured and compared with the controls. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The nutrient broth which contained logarithmic serially two fold diluted amount of 
test compound and controls were inoculated with approximately 5 x I05 c.fu.ImL of actively 
dividing bacteria cells. The cultures were incubated for 24 h at 37 °C and the growth was 
monitored visually and spectrophotometrically. The lowest concentration (highest dilution) 
lag 
required to arrest the growth of bacteria was regarded as minimum inhibitory concentration 
(MIC). To obtain the minimum bacterial concentration (MBC), 0.1 mL volume was taken 
from each tube and spread on agar plates. The number of c.£u. was counted after 18-24 h of 
incubation at 35 °C. MBC was defined as the lowest drug concentration at which 99.9% of 
the inoculums were killed. 
In vitro antifungal assay: 
The antifungal assay was studied against the cultures of Candida albicans (ATCC-10231), 
Aspergilhis frtmigatus (ATCC-1022), Trichophylon mentagrophytes (ATCC-9533) and 
Penicilliwn marneffei (recultured) in DMSO by agar diffusion method.41' 42  Sabourands agar 
media was prepared by dissolving peptone (1 g), D-glucose (4 g) and agar (2 g) in distilled 
water (100 mL) and adjusting pH to 5.7. Normal saline was used to make a suspension of 
spore of fungal strain for lawning. A loopful of particular fungal strain was transferred to 3 
mL saline to get a suspension of corresponding species. Agar media (20 mL) was poured into 
each Petri dish. Excess of suspension was decanted and the plates were dried by placing in an 
incubator at 37 °C for 1 h using an agar punch, wells were made and each well was labelled. 
A control was also prepared in triplicate and maintained at 37 °C for 3-4 days. The fungal 
activity of compounds was compared with Griseofulvin and Nystatin as standard drugs. 
Inhibition zones were measured and compared with the controls. The nutrient broth which 
contained logarithmic serially two fold diluted amount of test compound and controls was 
inoculated with approximately 1.6 - 6 x 104 c.fu./mL. 
The cultures were incubated for 48 h at 35 °C and the growth was monitored. The 
lowest concentration (highest dilution) required to arrest the growth of fungus was regarded 
as minimum inhibitory concentration (MIC). The nutrient broth, which contained logarithmic 
serially two fold diluted amount of test compound and controls were inoculated with 
approximately 5 x 105 c.fu./mL of actively dividing fungal cells. The cultures were incubated 
for 24 h at 37 °C and the growth was monitored visually and spectrophotometrically. To 
obtain the minimum fungicidal concentration (MFC), 0.1 mL volume was taken from each 
tube and spread on agar plates. The number of c.fu. was counted after 48 h of incubation at 
35 °C. MFC was defined as the lowest drug concentration at which 99.9% of the inoculums 
were killed. 
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I4', 6'-Dioxo-2'-thioxo-1B-pyrimidin-1-yl]6-imino-5a-cholestane derivatives (94-96) 
In vitro antibacterial activity: 
The antibacterial screening data of steroidal pyrimidines (refer to chapter 1 for synthesis) 
revealed that all the tested compounds (94-96) showed moderate to good antibacterial activity 
against S pyogenes, S. aureus and E-coli species. In general, all the compounds (94-96) were 
more effective against Gram positive bacteria as compared to Gram negative bacteria. The 
potential zone of inhibition was shown by compound 94 i.e. 17.3 mm against S. pyogenes 
with respect to the standard drug, Ciprofloxacin i.e. 23.0 mm against the same strain. 
Compound 94 also showed potential behavior against K pneumoniae by depicting zone of 
inhibition i.e. 16.1 mm with respect to the Ciprofloxacin i.e. 19.0 mm. The maximum zone of 
inhibition shown by compound 95 was 16.6 mm against S. aureus (MRSA +ve) with respect 
to the standard drug, Ciprofloxacin i.e. 22.0 nun against the same strain. The potential zone 
of inhibition shown by compound 96 was 16.5 mm against S. pyogenes with respect to the 
standard drug, Ciprofloxacin i.e. 23.0 mm against the same strain. The bacterial zones of 
inhibition of steroidal pyrimidines (94-96) against all strains are given in Table 1. 
Diameter of zone of inhibition (mm) 
Compounds Gram positive bacteria Gram negative bacteria 
S. pyogenes MRSA * P. aeruginosa 	K pneumoniae E. coli 
94 17.3±0.2 16.6±0.4 19.4±0.6 	16.1±0.4 16.7±0.4 
95 16.2*0.3 16.6±0.2 18.3±0.4 	15.2±0.3 16.610.4 
96 16.5±0.4 14.9±0.5 17.8±0.2 	13.7±0.2 14.7±0.2 
Ciprofloxacin 23.0±0.2 22.0±0.2 32.0±0.3 	19.0±0.2 27.0±0.2 
DMSO - - - - - 
Table 1. Showing the zone of inhibition of compound 94-96 with given bacterial strains 
The MICs of almost all the compounds were found to be two fold or four fold higher 
than MIC's of the standard drug, except compound 94 whose MIC was found to be same as 
that of standard drug i.e. 12.5 with respect to the S. pyogenes. The M1C's and MBC's are 
given in Table 2. From the Table 2 it is also clear that the lowest concentration at which 
compound 94 inhibited the visible growth of bacteria is 12.5 and 25 p.glmL while as 
compound 95 and 96 inhibited the growth of bacteria at lowest concentration of 25 and 50 
gg/mL against the given bacterial strains. 
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Compounds Grant positive bacteria Gram negative bacteria 
S. pyogenes MRSA* P. aeruginosa K. pneumoniae 	E coli 
MC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
94 	12.5 25 25 	50 25 50 25 	50 	25 50 
95 	25 50 25 	50 25 50 25 	100 	50 100 
96 	25 100 25 	100 50 100 50 	100 	50 100 
Ciproflxn. 12.5 12.5 6.25 	12.5 12.5 25 6.25 	25 	6.25 12.5 
Table 2. Showing the MIC's and MBC's of compound 94-96 with given bacterial strains 
In vitro antifungal activity: 
The steroidal pyrimidines (94-96) (refer to chapter 1 for synthesis) showed potential 
antifungal activity and in particular compound 94 was found active almost equivalent to the 
Griseofulvin against C. albicans', A. fiimigatus2, T mentagrophytes3 and P. marneffei by 
showing maximum zones of inhibition. The MFC of few compounds was found to be the 
same as MFC of standard drug but in most of the compounds it was two or three or four folds 
higher than the corresponding MFC results of Griseofulvin. Compound 94 exhibited potential 
antifungal activity among the three steroid derivatives as its activity is nearly equivalent to 
Griseofulvin against C. albicans strain with zone of inhibition 27.8 f 0.3 mm and MIC of 
12.5 pg/mL. Compound 95 also exhibited potential antifungal activity against C. albicans by 
showing diameter of zone of inhibition 25.7 mm with respect to the Griseofulvin 30.0 mm. 
The fungal zones of inhibition of the tested compounds are given in Table 3. From the Table 
4 it is clear that the MIC's and MFC's of all the compounds were found to be two to four 
folds higher than that of the Griseofulvin. 
Compounds 
Diameter of zone of inhibition (mm) 
CA' 	AF2 	TM3 	PM4 
94 27.8±0.3 22.7±0.4 19.6±0.2 17.5±0.2 
95 25.7±0.4 21.4±0.3 18.2±0.5 15.1±0.4 
96 23.5±0.3 19.8±0.4 17.2±0.6 12.9±0.4 
Griseofulvin 30.0±0.2 27.0±0.2 24.0±0.3 20.0±0.5 
DMSO - - - - 
Table 3. Showing the zone of inhibition of compound 94-96 with different fungal strains 
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Comp. CA' 
MIC 	MFC MIC 
AF2 
NEC MIC 
TM3  
MFC 
PM4 
MIC 	MFC 
94 12.5 25 .12.5 25 12.5 25 12.5 	50 
95 12.5 50 12.5 50 25 50 25 	50 
96 25 50 25 50 25 100 25 	100 
Griseofulvin 6.25 25 12.5 12.5 6.25 25 12.5 	25 
Table 4. Showing the MIC's and MFC's of compound 94-96 with different fungal strains 
2'-Amino-3'-carboethoxycholest-6-eno [5, 7 - d e] 4H-pyran derivatives (63-65) 
In vitro antimicrobial activity: 
The steroidal pyrans (63-65) (refer to chapter 2 for synthesis) were screened for antibacterial 
activity against E-coli (ATCC-25922), S. aureus (MRSA +Ve) (ATCC-25923), P. 
aeruginosa (ATCC-27853), S. pyogenes (ATCC 19615) and K pneumoniae (CIinical 
isolate). Activity of these compounds was studied by the disk diffusion method and zones 
were measured by Halo Zone Test.39• 40 The antibacterial screening data (Table 5 and Table 
6) revealed that the compound 63-65 showed good antibacterial activity against S. pyogenes, 
S. aureus and E. coli species. Compound 63 afforded good zone of inhibition i.e. 21.2 mm 
against S. pyogenes with respect to the standard drug, Ciprofloxacin i.e. 24.0 nm.. Except MIC 
of compound 63 against S. pyogenes, all the compounds showed MIC and MBC two to four 
fold higher than that of Ciprofloxacin. 
Diameter of zone of inhibition (mm) 
Comp. Gram positive bacteria Gram negative bacteria 
S. pyogenes MRSA * P. aeruginosa K pneumoniae E-coli 
63 21.2±0.4 18.7±0.4 26.1±0.3 17.2±0.3 22.1+0.2 
64 19.4+0.2 17.3±0.3 23.1±0.2 15.1±0.4 20.1±0.4 
65 19.2±0.4 17.2±0.6 22.1±0.3  15.1±0.3 19.1±0.3 
Ciprofloxacin 24.0+0.3 25.0±0.4 32.0±0.3 18.0±0.2 26.0±0.4 
DMSO - - - - - 
Table 5. Showing the zone of inhibition of compound 63-65 with different bacterial strains 
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Compounds Gram positive bacteria 
S. pyogenes MRSA 
MIC MBC MIC 	MBC 
63 12.5 25 25 	50 
64 25 50 100 	100 
65 25 50 50 	100 
Ciprofloxacin 12.5 50 12.5 	50 
Gram negative bacteria 
P. aeruginosa K pneinnoniae 	E. coli 
MIC MBC MIC MBC MIC MBC 
25 50 25 	50 	25 50 
50 100 50 	100 	50 100 
50 100 50 	100 	50 100 
12.5 25 25 	50 	12.5 50 
Table 6. Showing the MIC's and MFC's of compound 63-65 with given bacterial strains 
In vitro antifungal activity: 
Antifungal activity of steroidal pyrans (63-65) (refer to chapter 2 for synthesis) was done 
against the cultures of C. albicans' (ATCC-10231), A. fiemigatus2 (ATCC-1022), T. 
mentagropfrytes3 (ATCC -9533) and P. marneffei (recultured) in DMSO by agar diffusion 
method.41 42  The antifungal screening data (Table 7 and Table 8) revealed that all the 
compounds showed good antifungal activity against C. albicans, A. fiumigatus and P. 
marneffei fungal strains and depicted potential zones of inhibition with respect to positive 
control. All the compounds showed MIC and MFC two to four fold higher than MIC and 
MFC of the standards. Compound 63 showed maximum zones of inhibition i.e. 21.2 17.7, 
16.3, 14.9 mm against C. albicans, A. fwnigatus, T mentagrophytes and P. marneffei, 
respectively with respect to Greseofulvin among all the steroidal pyrans. 
Diameter of zone of inhibition (mm) 
Compounds 	CA' 	AF2 	TM3 	PM4 
63 	 20.6±0.2 	17.7±0.3 	16.3±0.2 	14.9±0.4 
64 	 18.8±0.4 	15.6±0.2 	14.3±0.6 	12.9±0.2 
65 
7 
18.7±0.5 15.4±0.3 13.5±0.6 
Greseofulvin 30.0±0.2 27.0±0.2 24.0±0.3 
DMSO 
12.7±0.6 
20.0±0.5 
Table 7. Showing the zone of inhibition of compound 63-65 with given bacterial strains 
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Comp. CA' 
MIC MFC 
AF2 
MIC MFC 
TM3  
MIC MFC 
PN 
MIC WC 
63 12.5 25 25 50 12.5 25 25 50 
64 25 50 25 50 25 50 25 100 
65 25 100 50 100 100 100 50 100 
Standard 6.25 12.5 12.5 25 6.25 25 12.5 25 
Table 8. Showing the MIC's and MFC's of compound 63-65 with given fungal strains 
Cholest-615'-amino-l', 2'-dihydro pyrazol-3-fine-1'-ylj 5-ene derivatives (73-75) 
In vitro antibacterial activity: 
The steroidal pyrazolones (73-75) (refer to chapter 3 for synthesis) were screened against the 
cultures of S. pyogenes (ATCC-29213), S. aureus (ATCC-25923), P. aeruginosa (ATCC-
27853) and E-coli (ATCC-25922) by disc diffusion method and zones were measured by 
Halo Zone Test.39, ao  The antimicrobial screening data (Table 9 and Table 10) suggests that 
steroidal pyrazolones (73-75) exhibited varying degree of inhibitory effects on the growth of 
bacterial and fungal strains. In antibacterial activity, compound 73 and 74 showed larger zone 
of inhibition (18.2 and 19.5 mm) in comparison with Chloramphenicol (21.5 mm) against S. 
pyogenes while as they showed zone of inhibition 17.3 and 16.1 mm against S aureus and P. 
aeruginosa, respectively in comparison with Chloramphenicol 20.6 and 22.2 against the 
given strains. The confocal microscopic diagrams of zones of inhibition are shown in Fig. 1. 
Compounds S. aureus 
Zone of Inhibition 
S. pyogenes 
(mm) 
P. aeruginosa E-coli 
73 17.3±0.6 18.210.2 15.4±0.4 13.9±0.6 
74 17.3 ± 0.3 19.5 ± 0.1 16.1 ± 0.3 14.9 ± 0.2 
75 15.8±0.4 13.7±0.5 14.6±0.5 15.4±0.5 
Chloramphenicol 20.6 ± 0.5 21.5 ± 0.4 22.2 ± 0.8 19.0 ± 0.2 
DMSO - - - - 
Table 9. The zones of inhibition of shown by the compound 73-75 in antibacterial activity 
Work published as; 
Structural, optical and antimicrobial studies of 3/3-acetoxycholest-5-ene, 3/J-acetoxy-6-nitrocholest-5-ene and 
newly synthesized steroidal pyrazolones. Shamsuzzaman, Ayaz Mahmood Dar, et al., J. Taibah University for 
Science, (Elsevier) hitpJldx.doi.org/10.10161j.jtusei.2013.08.003 (in press) 
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In vitro antifungal activity: 
For antifungal screening, C. albicans (ATCC-10231), A. , Cmigates (ATCC-1022), T 
mentagrophytes (ATCC-9533) and P. marneffei (ATCC-18224) were recultured in DMSO by 
agar diffusion method.41, 42  The pyrazolones 73-75 (refer to chapter 3 for synthesis) also 
exhibited varying degree of inhibitory effects ou the growth of fungal strains. The compounds 
showed moderate to potential antifungal activity and in particular compound 74 showed large 
zone of inhibition (26.2 mm) in comparison to Nystatin (29.0 mm) against C. albicans. 
Compound 73 also showed large zone of inhibition (23.2 mm) in comparison to Nystatin 
(29.0 mm) against T. mentagrophytes. 
Compounds C. albicans 
Zone of Inhibition (mm) 
T mentagrophytes P. niarnefei A. furnigafus 
73 24.2±0.2 23.2±0.6 16.2±0.3 15.1 ±0.2 
74 26.2 ± 0.5 22.1 ± 0.5 14.2 ± 0.2 13.3 ± 0.4 
75 23.6±0.6 21.6±0.4 13.9±0.5 16.2±0.2 
Nystatin 29.0 ± 0.5 29.0 ± 0.5 19.5 ± 0.5 19.5 ± 0.5 
DMSO - - - 
Table 10. The zones of inhibition of compound 73-75 in antifungal activity 
(a) 
	
(b) 
	
(c) 
(d) 	 (e) 
Fig. 1. Diagram showing zones created by the steroidal pyrazolone (74) against the strains: 
P. Aeruginosa (a), S. aureus (b),A. fumigatus (c), S. pyogenes (d) C. albicans (e). 
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5a-Cholestano [5, 6 - b] benzothiazine derivatives (53-55) 
In vitro antimicrobial activity: 
Antimicrobial activity of steroidal benzothiazines (53-55) (refer to chapter 4 for synthesis) 
was studied by the disk and agar diffusion method.3942 The screening data obtained after 
treating different microbial strains with test doses of the starting ketones (50-52) and steroidal 
benzothiazines (53-55) are given in Table 11-14. It is clear that the compound 53-55 showed 
moderate to good increase in antimicrobial activity than the starting compounds (50-52). In 
antibacterial activity, compound 54 and 53 showed potential inhibition zones against E-coli 
strain. Even the compound 54 was found to be more potent than Chloramphenicol, in case of 
E-coli strain. As shown in Table 11, compound 54 showed potential zones of inhibition i.e. 
18.6, 19.6 and 21.5 nun against S. aureus, S. pyogenes and P. aeruginosa, respectively in 
comparison with the Chloramphenicol. The compound 53 also showed zone of inhibition i.e. 
19.4 mm against the E-coli strain which is almost equal to that of Chloramphenicol i.e. 20.0 
mm against the same strain. The MIC's of starting ketones (50-52) and benzothiazines (53-
55) with different bacterial strains are given in Table 12 and it is clear from the data that 
MIC's of steroidal ketones (50-52) are two to four fold higher than those of benothiazine 
derivatives (53-55) suggesting that compound 53-55 are active at lower concentration than 
those of compounds 50-52. From the Table 12 it is clear that the lowest concentration at 
which compound 54 inhibited the visible growth of bacteria is 32 and 64 .g(mL while as 
compound 55 and 53 inhibited the growth of bacteria at 32, 64 and 128 pg/mL. 
Zone of Inhibition (mrim) 
Compounds S. aureus S. pyogenes P. aertuginosa E-coli 
50 12.510.4 11.6.±0.5 10.5±0.5 10.2*0.5 
51 14.3±0.4 12.2±0.4 12.6±0.2 14.2±0.4 
52 12.2±0.2 10.3 ± 0.2 10.4±0.4 11.210.2 
53 18.6±0.1 15.1±0.6 18.8±0.4 19,4±0.6 
54 18.6±0.2 19.6±0.4 21.5±0.5 23.2±0.2 
55 19.5±0.4 15.3±0.8 18.210.4 15.6±0.6 
Chloramphenicol 21.6 ± 0.5 22.5 ± 0.4 25.2 ± 0.8 20.0 ± 0.2 
DMSO - - - - 
Table 11. Showing the zone of inhibition of starting steroidal ketones 50-52 and steroidal 
benzothiazines 53-55 with given bacterial strains 
r 	 117 
MIC (g/mL) 
Strains 50 51 52 	53 54 55 Chloramphenicol 
S. aiireus 256 64 128 	32 32 32 32 
S. pyogenes 256 64 128 	64 32 64 32 
P. aeruginosa 128 128 128 	128 64 64 32 
E-coli 128 64 256 	32 32 128 32 
Table 12. Showing the MIC's of starting steroidal ketones (50-52) and steroidal 
benzothiazines (53-55) with given bacterial strains 
It is clear also from the antifungal screening data that the steroidal benzothiazines (53-
55) showed moderate to good increase in antifungal activity than the starting steroidal 
ketones (50-52). In antifungal activity, compound 54 and 55 showed potential inhibition 
zones against P. man:effei strain. But the inhibition zone of compound 55 is larger than 
compound 54 against P. marneffei in comparison with standard drug, Nystatin. As shown in 
Table 13, compound 54 showed potential zones of inhibition i.e, 24.5, 21.4, 16.6 and I5.1 
mm against C. albicans, T mentagrophytes, P. marheffei and A. f unigatos, respectively in 
comparison with the Nystatin. The compound 55 and 53 also showed influential zone of 
inhibition i.e. 17.4 and 24.2 mm against the P. rnarneffei and T. mentagrophytes strains which 
are very close to that of Nystatin i.e. 19.5 and 29.0 mm, respectively. The MIC's of starting 
steroidal ketones (50-52) and benzothiazines (53-55) with different fungal strains are given in 
Table 14 and it is clear from the data that MIC's of steroidal ketones are two to four fold 
higher than those of benothiazine derivatives (53-55) revealing that compound 53-55 are 
active against different fungal strains at lower concentration than those of compound 50-52. 
From the Table 14 it is also clear that the lowest concentration at which compound 54 and 55 
inhibited the visible growth of fungi is 32 gg/mL and 64 gg/mL while as compound 53 
inhibited the growth of fungi at lover concentration, i.e. 32 µg/mL against the different fungal 
strains. 
Work published; 
Anticancer and antimicrobial evaluation of newly synthesized steroidal 5, 6 fused benxothiazines. 
Shamsuzzaman, Ayaz Mahmood Dar, et al., Arabian Journal of Chemistry, http.// dx.doi.org/10. 
10161j.arabjc.2013.06.027 (in press) 
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Compounds C. albicans 
Zone of Inhibition (niml 
T. men tagrophytes 	P. marneffei A. fwnigatus 
50 14.2±0.5 11.2±0.4 12.1±0.2 10.1±0.3 
51 13.1 ±0.5 14.1 ±0.5 11.3±0.5 11.5±0.2 
52 12.2±0.2 09.2±0.2 10.1±0.5 09.210.4 
53 23.5±0.2 24.2±0.5 15.8±0.2 16.0±0.5 
54 24.5±0.3 21.4± 0.6 16.6±0.3 15.1 ±0.4 
55 19.1±0.4 18.2±0.4 17.4±0.5 14.4±0.2 
Nystatin 29.0±0.5 29.0±0.5 19.5±0.5 19.5±0.5 
DMSO - - - - 
Table 13. Showing the zone of inhibition of starting steroidal ketones (50-52) and steroidal 
benzothiazines (53-55) with different fungal strains 
MIC (ig/mL) 
Strains 50 51 52 	53 54 55 Nystatin 
C. albicans 128 256 256 	32 32 64 32 
T. inentagrophytes 256 128 256 	32 64 64 32 
P. marneffei 128 256 128 	32 32 32 32 
A. ftrmigatus 256 128 " 256 	32 32 32 32 
Table 14. Showing the MIC's of starting steroidal ketones (50-52) and steroidal 
benzothiazines (53-55) with different fungal strains 
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Materials and equipments: 
The human cancer cell lines used for the cytotoxicity experiment were SW480, A549, 
HepG2, HL-60, MCF7, HeLa, A545, HT-29 and DU145 which were obtained from National 
Cancer Institute (NCI), biological testing branch, Federick Research and Development 
Centre, USA. The treated and control cancer cells were viewed with a FluoView FV1000 
(Olympus, Tokyo, Japan) confocal laser scanning microscope (CLSM) equipped with argon 
and HeNe lasers. 2-Thiobarbituric acid (TBA) and trichloroacetic acid (TCA) were purchased 
from Merck (India). Single cell electrophoresis (comet assay) was studied with fluorescent 
microscope (Olympus BX-51, Japan). Supercoiled plasmid pBR322 DNA was purchased 
from GeNei (India) and was used for the agarose gel experiment without further purification. 
Anticancer activity: 
Cell lines and culture conditions: Human cancer cell lines used for the study were A545 
(lung carcinoma cells)/ATCC (CRL-2579), MCF7 (breast cancer cells)/ATCC (HTB-22), 
HeLa (cervical cancer cells)/ATCC (CCL-2), HL-60 (Leukaemia cells)/ATCC (CCL-240), 
SW480 (colon adenocarcinoma cells)/ATCC (CCL-228), HepG2 (hepatic carcinoma 
cells)/ATCC (CRL-8065), HT-29 (colon cancer cells)IATCC (HTB-38), DU145 (pancreatic 
cancer cells)/ ATCC (HTB-81) and A549 (lung carcinoma cells)/ATCC (CCL-185) were 
obtained from National Cancer Institute (NCI), biological testing branch, Federick Research 
and Development Centre, USA. SW480, A549, A545, HL-60, HT29, DU145 and HepG2 
cells were grown in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), IOU 
penicillin and 100 pg/mL streptomycin at 37 °C with 5% CO2 in a humidified atmosphere. 
HeLa and MCF7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
supplanted with FCS and antibiotics as described above for RPMI 1640. The non-cancer cells 
i.e. 184B5 and MCF10A breast cells were maintained in mammary epithelial basal medium 
supplemented with an MEGM mammary epithelial singlequot kit (Cambrex). NL-20 (normal 
lung cells), HPC (normal pulp cells), HPLF (periodontal ligament fibroblasts) were grown at 
37 °C with 5% CO2, 95% air under the humidified conditions. Fresh n'iedium was given every 
second day and on the day before the experiments were done. Cells were passaged at 
preconfluent densities, using a solution containing 0.05% trypsin and 0.5 mM EDTA. 
Cell viability assay (MTT): The in vitro cytotoxicity was measured using the MTT assay. 
The assay was carried out according to known protocol.43' 44 Exponentially growing cells 
were harvested and plated in 96-well plates at a concentration of 1 x 104 cells/well. After 24 h 
120 
incubation at 37 °C under a humidified 5% CO2 to allow cell attachment, the cells in the 
wells were respectively treated with target compounds at various concentrations for 48 h. The 
concentration of DMSO was always kept below 1.25%, which was found to be non-toxic to 
the cells. A solution of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT), was prepared at 5 mg/mL in phosphate buffered saline (PBS; 1.5 mM KH2PO4, 6.5 
mM Na2HPO4, 137 mM NaCl, 2.7 mM KCI; pH 7.4) and 20 gL of this solution was added to 
each well. After incubation for 4 h at 37 °C in a humidified incubator with 5% CO2, the 
medium/MTT mixtures were removed and the formazan crystals formed by the mitochondrial 
dehydrogenase activity of vital cells were dissolved in 100 gl, of DMSO per well. The 
absorbance of the wells was read with a microplate reader (Bio-Rad Instruments) at 570 nm. 
Effects of the drug cell viability were calculated using cell treated with DMSO as control. 
Data analysis: Cell survival was calculated using the formula: Survival (%) = [(absorbance 
of treated cells — absorbance of culture medium)/(absorbance of untreated cells — absorbance 
of culture medium)] x 100.41' 46  The experiments were done in triplicate and the inhibitory 
concentration (IC) values were calculated from a dose response curve. IC50 is the 
concentration in `pM' required for 50% inhibition of cell growth as compared to that of 
control. IC50 values were determined from the linear portion of the curve by calculating the 
concentration of agent that reduced absorbance in treated cells, compared to control cells by 
50%. Evaluation is based on mean values from three independent experiments, each 
comprising at least six micro-cultures per concentration level. 
Comet assay (Single cell gel electrophoresis): 
To assess the genotoxic effect of the new steroidal derivatives, comet assay 4'• 4S was 
performed in MCF7 cells. The MCF7 (lx 106) cells were treated with 10, 25 and 50 p.g/mL of 
steroidal derivatives for 24 h. The cells were then washed and 200 pl, of cell suspension in 
Iow melting agarose (LMA) was layered on to the labelled slides precoated with agarose (1.5 
°10). The slides were placed on ice for 10 min. and submerged in lysis buffer (2.5 % NaC1, 100 
mM EDTA, 10 mM Tris, 10 % DMSO and 1% Troton X-100) at 4 °C at pH 10 for more than 
1 h. The slides were then equilibrated in alkaline buffer (30 mM NaOH, I mM EDTA) at 4 
°C at pH 13, electrophoresed at 0.86 V/cm at 4 °C, neutralized, washed and dried. At the time 
of capturing the images, the slides were stained with ethidium bromide (EtBr, 150 gL IX) 
and cover slips were placed over them. For visualization of DNA-damage, EtBr-stained slides 
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were observed under 209 objectives of a fluorescent microscope (Olympus BX-51, Japan). 
The images of 50-100 randomly selected cells were captured per slide using a CCD camera. 
Treatment of supercooled plasmid pBR322 DNA with heterosteroids: 
To investigate the mechanism of cytotoxicity by studying the effect of heterosteroids on 
supercoiled plasmid pBR322 DNA, an experiment was done in which the reaction mixture 
containing 10 mM Tris HCl (pH 7.5), 0.5 jig of pBR322 plasmid DNA, 100 µM copper and 
the varying concentrations of heterosteroid and Cisplatin (20 µM) were taken. Incubation at 
room temperature was performed for specified time periods. After incubation, 10 µL of a 
solution containing 40 mM EDTA, 0.05% bromophenol blue (tracking dye) and 50% glycerol 
was added and the solution was subjected to electrophoresis in submarine 1% agarose gel. 
The gel was stained with ethidium bromide (0.5 mg/mL), viewed and photographed on a 
transilluminator. 
Detection of hydroxyl radicals ('OH): 
The detection of hydroxyl radicals was investigated by the method studied by Quinlan and 
Gutteridge.A9 The reaction mixture (0.5 mL) containing Tris HCI (10 mM, pH 7.5), Calf 
thymus DNA (200 µg), increasing concentrations of heterosteroid and Cisplatin (12.5 µM, 25 
µM, 50 µM, 75 pM, 100 jM, 200 jM, 400 µM, 600 jM), Cu (II) (100 µM) and volume was 
made up to 1 mL by buffer solutions and incubated for 60 min. at 37 °C. Reaction was 
stopped using 0.5 mL of TCA (28%) and 0.5 mL of 1% TBA was added, boiled for 15 min 
and cooled to room temperature. The intensity was read at 532 nrn. 
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[4', 6'-Dioxo-2'-thioxo-lH-pyrimidin-1-y1]6-imino-5a-cholestane derivatives (94-96) 
In vitro cytotoxicity: 
The in vitro cytotoxicity of steroidal pyrimidines (94-96) (refer to chapter 1 for synthesis) 
was measured using the MTT assay during which the conversion of the soluble yellowish 
MTT to the insoluble purple formazan by active mitochondrial lactate dehydrogenase of 
living cells has been used to develop an assay system for measurement of cell proliferation.A3' 
44 The data reported in Table 15 suggested that compound 94-96 showed different levels of 
cytotoxicity during which the compound 95 showed effective IC50 = 10.391imol L"' (HT-29), 
10.91 gmol L-1 (MCF7), 13.26 }tmoI L"1 (A549). Compound 96 also showed minimum IC5o 
value in the range of 13.04 hmol L-1 (HT-29) and 11.41 µmol L-' (MCF7) while as compound 
94 showed minimum IC50 = 11.72 µmot L"1 (A545) and 13.39 gmol L"1 (HepG2). 
From the Table 15 it is clear that compound 94 and 95 are showing potential 
cytotoxicity against A545, A549, HeLa, HepG2 cell lines by showing IC5o close to that of 
Cisplatin, thus can be considered as potential cytotoxic agents. Compound 94-96 also showed 
better cytotoxicity against HL-60 and HepG2 cell lines by showing IC5o less than that of 
standard anticancer drug, 5-fluorouracil (5-FU). 
IC so (IIM) 
Lung Breast Cervical Leukaemia Colon Hepatic Colon Lung 
Comp. A545 MCF7 HeLa HL-60 SW480 HepG2 HT-29 A549 
94 11.72 >50 17.12 25.86 37.52 13.39 >50 27.89 
95 17.31 10.91 12.37 11.17 >50 19.31 10.39 13.26 
96 >50 11.41 27.25 32.34 >50 >50 13.04 >50 
Cisplatin 8.9 9.3 9.43 7.83 3.52 9.63 7.24 12.1 
5-FU 15.4 14.7 16.32 >50 15.71 >50 9.79 12.8 
Table 15. The IC50 of compound 94-96, Cisplatin and 5-FU against given cancer cells 
To confirm the toxicity on normal cells, the compounds 94-96 were tested with some 
non-cancer cell lines; 184B5 (breast), MCF 1 OA (breast), NL-20 (lung), HPC (pulp) and 
HPLF (Periodontal) during which none of the synthesized compounds were found toxic, all 
the compounds showed GI50 > 60. This also suggests that the steroidal pyrimidine derivatives 
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can be used specifically for the treatment of cancer cells without showing toxicity to the non-
cancer cells. The GI50 values shown by compounds 94-96 are given in Table 16. 
GI50 (pM) 
Breast Breast Lung Pulp Periodontal 
Compounds 184B5 MCFIOA NL-20 HPC HPLF 
94 74.17 63.62 >100 67.78 67.13 
95 78.32 >100 67.25 63.27 >100 
96 >100 58.35 61.15 82.12 86.25 
Cisplatin 26.17 51.25 63.35 61.17 73.95 
5-FU >100 83.54 73.62 >100 96.51 
-GI50 is the molar concentration causing 50% growth inhibition of non cancerous cells. 
-Values are the mean of triplicates of at Ieast two independent experiments. 
Table 16. The GI50 of compound 94-96, Cisplatin and 5-FU against non-cancer cells 
Comet assay: 
In comet assay, the images of cells treated with Cisplatin and compound 94-96 showed the 
formation of comets. No comet pattern was observed in the control cells. There was dose-
dependent increase in tail length when treated with compound 94-96. Compound 95 
presented maximum apoptotic DNA damage among the three steroidal pyrimidines studied, 
which was in accordance with its maximum cytotoxicity as seen in MIT assay. None of the 
steroidal pyrimidines exhibited apoptotic DNA damage to the extent of Cisplatin. The 
quantified increase in DNA damage suggested that all three pyrimidines derivatives induced 
dose-dependent fragmentation of chromosomal DNA leading to apoptosis. The images of 
comet assay for control, cells treated with Cisplatin (0.1 µM, 54 gg/mL), compound 94 (50 
µg/mL), compound 95 (50 gg/mL), and compound 96 (50 ppg/mL) are shown in Fig. 2. Slides 
were analysed for parameter like tail length (TL), using image analyzer CASP software 
version 1.2.2. The results of the assay for tail length are shown in Fig. 3. 
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Compound 94 (50 µg/ mL) Compound 95 (50 µg1 mL) 	Compound 96 (50 µg1 mL) 
Cisplatin (0.1 µ1M 	Control (Untreated) 
Fig. 2. Detection of DNA damage in MCF7 cells. Treated cells (24 h) were layered over 
agarose gel, lysed, electrophoresed in alkaline buffer and stained with propidium iodide. 
Control cells were treated with DMSO alone. The DNA fragmentation resulting in a comet-
like appearance in cells treated with Cisplatin and compound 94-96. 
400 	 1=Control 
350 3=Cicplatun 
300 	 3=Blue (10 ilgrmL). red (251lgmiL). 
250 
Greet (50 poniQ 95 
~1=Blue (101tg+ nQ, red (231LJmL). 
200 	 Grecfz (50 pgAnL) 96 
150 5=B1ue (101kwnl), red (251ilrL), 
100 	 Grsui (50 µgrmI.) 94 
{0 
0 
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Fig. 3. Comparison of the compound 94-96 and Cisplatin on the tail length in comet assay. 
Treatment of supercoiled plasmid pBR322 DNA with compound 95: 
Cytotoxicity mechanism was also confirmed by studying the treatment of supercoiled 
plasmid pBR322 DNA with different concentrations of compound 95 and 100 µM copper. 
Our nucleolytic experiment suggested that cell death may be due to cleavage or 
fragmentation of DNA of these cancer cells and that the active species responsible for this are 
ROS ('OH) which resulted from the in vitro reaction of different concentrations of compound 
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95 with copper in presence of thiobarbituric acid. It has been observed from gel 
electrophoresis that by adding copper (100 AM) the radical concentration increased which in 
presence of different concentrations of compound 95 showed the plasmid pBR322 DNA 
nicking from its supercoiled form (Form 1) to open circular form (Form II). As shown in lane 
6, 7 and 8 (Fig. 4), the nicking is quite obvious by the disappearance of form I and 
appearance of form II and with the increase in concentration of compound 95 (lane 8), form 
II became maximum, depicting the more pronounced cleavage at high concentration. 
Fig. 4. Fragmentation pattern of supercoiled plasmid pBR322, Lane I contains DNA only, 
lane 2 contains DNA and copper, lane 3, 4 and 5 contain DNA and compound 95 (100, 200 
and 300 µM respectively), lane 6, 7 and 8 contain DNA and compound 95 (100, 200, 300 µM 
respectively) plus 100 gM copper and lane 9 contains DNA, Cisplatin (20 tM) plus 100 µM 
copper added to it. 
Detection of hydroxyl radicals ('OH): 
In the DNA cleavage reactions mediated by various antioxidants in the presence of Cu (II), it 
has been established that Cu (II) is reduced to Cu (I) by the antioxidants and that Cu (I) is an 
essential intermediate in the DNA cleavage reactions.50, 51  It is also generally understood that 
DNA cleavage by various antioxidants and Cu (II) is the result of the generation of hydroxyl 
radicals. As mentioned in literature,52 Cu (II) is reduced to Cu (I) and the re-oxidation of Cu 
(I) to Cu (II) by molecular oxygen gives rise to superoxide anion which in turn leads to the 
formation of H202. Presumably Cu (I) is oxidized to Cu (II) by H202 in a Fenton type 
reaction giving rise to hydroxyl radicals. 
To determine the hydroxyl radical production and the role of copper ions in DNA 
cleavage, an experiment was performed where progressively increasing concentrations of 
compound 95 and CispIatin (12.5-600 µM) were tested on thiobarbituric acid induced DNA 
breakage (Fig. 5) and from these results we may conclude that the DNA cleavage by 
tbiobarbituric acid involves endogenous copper ions (Cu (I) acts an intermediate) that leads to 
DNA cleavage. 
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Fig. 5. Determination of hydroxyl radical production by compund 95 (A) and Cisplatin (B) 
The compound 95-Cu (II) (Fig. 5A) and Cisplatin-Cu (II) (Fig. 5B) are shown to 
generate the hydroxyl radicals ( OH) which react with Calf thymus DNA, resulting in strand 
breaks. The assay is based on the fact that degredation of DNA by hydroxyl radical results in 
the release of TBA reactive material, which forms a colored adduct readable at 532 nm.53  
Increasing concentrations of compound 95 or Cisplatin in presence of Cu (II) showed a 
corresponding increase in the generation of hydroxyl radicals. The results in Fig. 5 confirmed 
the relatively higher rate of formation of hydroxyl radicals and correlated with the rate of 
DNA degredation by the compound 95 as well as Cisplatin. 
Work published: 
Steroidal pyrimidines: Synthesis, characterization, molecular docking studies with DNA and in vitro 
cytotoxicity, Shamsuzzaman, Ayaz Mahmood Dar, et al., Journal ofMolecular Structure 1045 (2013) 62-71 
[6'-Amino-2'-thioxo-4'-oxodihydro-1H-pyrimidin-1-yl]6-imino-5a-cholestane derivatives 
(97-99) 
In vitro cytotoxicity: 
The cytotoxicity of steroidal pyrimidines (97-99) (refer to chapter 1 for synthesis) was also 
studied by MTT assay.43' 44  The data reported in Table 17 suggest that compound 97-99 
showed different levels of cytotoxicity and the starting compounds 91-93 were found almost 
inactive against given cancer cells as they depicted much higher ICSO. During the screening 
the potential behavior was depicted by the compound 97-99 against given cancer cells. The 
compound 98 showed IC50 = 9.63 gmol L"I (HT-29), 9.73 gmol L'' (MCF7), 11.45 limo! L"1  
(A549). Compound 99 also depicted minimum IC50 value in the range of 12.79 gmol L"I 
(HT-29) and 10.60 µcool L"' (MCF7) while compound 97 showed minimum 1050=9. 11 pmol 
L-' (A545) and 11.26 ltmol L-' (HepG2) cell line. 
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From the Table 17 it is clear that the IC50 for compound 98 against A549 and HeLa cells 
was found to be 11.45 and 11.72 µM L-1 which is close to the IC5o of Cisplatin 12.0 and 9.43 
}tM L"1, respectively against the same cells.54 IC5o for compound 98 against HeLa cell line 
was found to be 11.72 which were also close to the IC5o of Cisplatin 9.43 against the same 
cell line.55 Similarly IC5o for compound 97 against HepG2 was found to be 11.26 which is 
also near to the IC5o of Cisplatin 9.8 against the same cell line.S4 It can be concluded that 
compound 98 and 99 showed potential in vitro cytotoxicity against A549, HeLa, HepG2 and 
A545 cell lines by depicting IC50 close to that of Cisplatin, thus can be considered as potential 
cytotoxic agents. Compound 97-99 also showed marked cytotoxicity against HL-60 and 
HepG2 cell lines by showing IC50 less than standard drug, 5-fluorouracil. 
Comp. Lung 
A545 
Breast 
MCF7 
cervical 
HeLa 
ICso (µM L-1) 
leukaemia Colon 
HL-60 	SW480 
Hepatic 
HepG2 
Colon 
HT-29 
Lung 
A549 
91 1823 34.58 33.68 >50 29.52 26.72 38.23 29.66 
92 29.46 22.17 37.77 45.29 19.26 34.12 26.73 33.18 
93 26.28 17.62 39.25 43.21 >50 30.51 35.97 41.32 
97 9.11 27.39 15.13 >50 26.11 11.26 17.12 16.31 
98 13.45 9.73 11.72 20.17 12.81 11.78 9.63 11.45 
99 16.53 10.60 17.37 28.34 >50 24.37 12.79 20.64 
Cisplatin 8.9 9.3 9.43 7.83 3.52 9.80 7.24 12.0 
5-FU 15.4 15.3 16.32 >50 15.71 >50 9.79 12.8 
5-FU = 5-Fluorouracil 
Table 17. The IC50 of starting compound 91-93 and product 97-99 against cancer cells 
To confirm the toxicity on normal cells, the compound 97-99 were tested with some 
known non-cancer cells; 184B5 (breast), MCF1OA (breast), NL-20 (lung), HFC (pulp) and 
HPLF (Periodontal) during which none of the synthesized compounds were found toxic, all 
the compounds showed GI50 > 60. This also suggests that the steroid pyrimidine derivatives 
can be used specifically for the treatment of cancer cells without being toxic to the normal 
cells. The GI50 values shown by compound 97-99 and Cisplatin are given in Table 18. 
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G15o (µM) 
Breast Breast Lung Pulp Periodontal 
Compounds 184B5 MCFIOA NL-20 HPC HPLF 
97 >100 63.62 97.13 64.26 71.13 
98 66.13 92.19 85.13 >100 83.25 
99 71.25 >100 66.15 73.21 >100 
Cisplatin 26.17 51.25 63.35 61.17 73.95 
5-FU >100 83.54 73.62 >100 96.51 
-Ui5O is me molar concentration causing )u /o growtn mnioitton or non-cancerous cells. 
Table 18. The GI50 of compound 97-99, Cisplatin and 5-flororuracil against non-cancer cells 
Comet assay: 
To understand the apoptotic degradation of DNA, the compound 97-99 were screened against 
MCF7 in comet assay. There was dose-dependent increase in the tail length when cells were 
97 (50 gg/mL) 	98 (50 gglmL) 	99 (50 gglmL) 	Control (Untreated) 
Fig. 6. Detection of DNA damage in MCF7 cells_ Treated cells (24 h) were layered over 
agarose gel, lysed, electrophoresed in alkaline buffer and stained with propidium iodide. 
1= Control (untreated) 
2= Blue (10 ug/mL), red (251zg/mL), 
Green (50 µg/mL) 95 
3= Blue (10 µglmL), red (25 µg/rL), 
Green (50 Etg/mL) 99 
4= Blue (10 µg/mL), red (25 ig/mL), 
Green (50 j,glmL) 97 
Fig. 7. Comparing the effect of steroidal pyrimidines on the tail length in comet assay 
treated with compound 97-99. Compound 98 presented maximum apoptotic DNA damage 
among the three steroidal pyrimidines studied, which is in accordance with its maximum 
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cytotoxicity as seen in MTT assay. The quantified increase in DNA damage suggested that 
the pyrimidine derivative 98 induced dose-dependent fragmentation of chromosomal DNA 
leading to apoptosis. The images of comet assay for control, cells treated with compound 97-
99 (50 µg/mL) are depicted in Fig. 6. SIides were analysed for parameter like tail length (TL), 
using image analyzer CASP software version 1.2.2. The results of the assay for tail length are 
shown in Fig. 7. 
Work published; 
DNA binding, docking studies, artificial nuclease activity and in vitro cytotoxicity of newly synthesized steroidal 
IH-pyrimidines, Sbamsuzzaman, Ayaz Mahmood Dar, et al., Comptes Rendlis Chimie, http://dx. doi.org/10.10 
161j.crci.2o13.07.001 (in press) 
2'-Amino-3'-carboetboxycholest-6-eno [5, 7- d e] 411-pyran derivatives (63-65) 
In vitro cytotoxicity: 
Literature reveals that synthetic steroids with a, /3-unsaturated ketone core gave the potency 
against human cancer cell lines.56-59 Thus with this intuition, an attempt of synthesizing the 
steroidal 4H-pyran derivatives (63-65) (refer to chapter 2 for synthesis) from steroidal a, /3-
unsaturated ketones (60-62) was made. Subsequently the compounds were evaluated for 
anticancer activity towards human cancer cells and in particular, the screening was done with 
the cell derived from human cancer types: SW480, A549, HepG2, HeLa, MCF7 and HL-60. 
The screening data given in Table 19 shows that compound 63-65 exhibited different 
levels of cytotoxicity. The preliminary screening showed that some of the compounds were 
found to have effective IC5o i.e. < 20 pmol L-' namely, compound 63 13.73 pmol L"1 (HeLa), 
19.29 µmot U' (A549), 11.18 µmol L"' (MCF7), compound 64 15.30 pmol L-' (HepG2), 17.12 
gmol L'' (MCF7) while compound 65'showed only effective IC50 =13.16 against MCF7. From 
the table it is clear that the IC50 for compound 63 against HeLa was found to be 13.73 µmol L'' 
which is close to the IC50 of Doxorubicin 11.53 µmol L`' against the same cell line. Similarly 
IC50 for compound 64 against MCF7 was found to be 11.18 ttmol L-' which is more effective 
than IC50 of Doxorubicin 12.41 ttmol L-' against the same cell line. 
To confirm the toxicity of compounds on non-cancer cells, the compounds 63-65 were 
tested with two non-cancer cell lines; NL-20 (lung) and HPC (pulp) during which none of the 
synthesized compounds were found toxic, all the compounds showed IC50 > 60 Itmol U'. This 
also suggests that the steroidal pyran derivatives can be used specifically for the treatment of 
cancer cells without showing toxicity to the non-cancer cells. 
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Compound 63 	Compound 64 	Compound 65 
Cisplatin (0.1 .tM) 	Control (Untreated) 
ICsfl (pmo1L"') 
Cancer cells Non-cancer cells 
Compound SW480 A549 HepG2 HeLa MCF7 HL-60 NL20 HPC 
63 23.83 19.29 32.43 13.73 11.18 10.37 >100 75.22 
64 29.50 22.10 15.30 28.21 17.12 13.17 62.11 87.21 
65 31.84 >50 >50 35.91 13.16 28.17 72.18 91.32 
Doxorubicin 10.34 8.28 7.36 11.53 12.41 9.64 69.14 81.71 
Cisplatin 3.52 12.1 9.63 9.43 9.3 7.83 57.13 64.88 
Table 19. Showing IC5o of compound 63-65 against cancer and non cancer cells 
Comet assay: 
In comet assay, the images of cells treated with Cisplatin and compound 63-65 - showed the 
formation of comets but no comet pattern was observed in the control cells. The images of 
comet assay for control, cells treated with Cisplatin (0.1 µM, 54 ug/mL), compound 63-65 (50 
µg/mL) are shown in Fig. 8 and it is clear that there is dose-dependent increase in tail length 
when treated with compounds 63-65. Compound 63 presented highest apoptotic DNA damage 
Fig. 8. DNA damage in MCF7 cells by compound 63-65. Treated cells (24 h) were layered 
over agarose gel, lysed and stained with propidium iodide. 
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among the three steroidal pyrans studied. None of the steroidal pyran exhibited apoptotic DNA 
damage to the extent of Cisplatin. The quantified increase in DNA damage suggested that all 
three pyran derivatives induced dose-dependent fragmentation of chromosomal DNA leading to 
apoptosis. Slides were analysed for parameter like tail length (TL), using image analyzer CASP 
software version 1.2.2. The results of the comet assay for tail length are shown in Fig. 9 which 
also suggests that compound 63 showed maximum chromosomal fragmentation at 50 p,g/mL 
leading to apoptosis. 
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Fig. 9. Comparing the effect of steroidal pyrans on the tail length in comet assay 
Treatment of supercoiled plasmid pBR322 DNA with compound 63: 
The treatment of supercoiled plasmid pBR322 DNA with different concentrations of compound 
63 and 100 pM copper was studied by gel electrophoresis in order to confirm the cytotoxicity 
mechanism. It was observed from gel electrophoresis that after adding copper (100 i.tM) the 
concentration of radicals increase which in presence of different concentrations of compound 
Form II 
Form I 
Fig. 10. Agarose gel fragmentation pattern of supercoiled plasmid pBR322, Lane 1 contains 
DNA only, lane 2 contains DNA + copper, lane 3, 4 and 5 contain DNA and compound 63 
(100, 200 and 300 gM respectively), lane 6, 7 and 8 contain DNA and compound 63 (100, 
200, 300 g.M respectively) + 100 pM copper and lane 9 contains DNA, Cisplatin (20 jM) + 
100 µM copper added to it. 
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63 showed the nicking of plasmid pBR322 DNA from its supercoiled form (Form I) to open 
circular form (Form II). As shown in lane 6, 7 and 8 of the Fig. 10, the nicking is quite clear by 
the appearance of form 11 and with the increase in concentration of compound 63 (lane 8), form 
II became maximum, revealing the more pronounced cleavage at high concentration. 
Detection of hydroxyl radicals ('OH): 
To study the role of copper ions in DNA cleavage and to determine the hydroxyl radical 
production, an experiment was performed where progressively increasing concentrations of 
compound 63 and Cisplatin (12.5-600 }tM) were tested on thiobarbituric acid induced DNA 
breakage. The graphical representation of radical generation in the experiment is shown in Fig. 
11 and from these results we may conclude that the DNA cleavage by thiobarbituric acid 
involves endogenous copper ions (Cu (I) acts an intermediate) that leads to DNA cleavage. 
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Fig. 11. Determination of hydroxyl radical production by compound 63 and Cisplatin 
The compound 63-Cu (II) (Fig. IIA) and Cisplatin-Cu (II) (Fig. 11B) are shown to 
generate the hydroxyl radicals (OH) which react with calf thymus DNA, resulting in strand 
breaks. The assay is based on the fact that degredation of DNA by hydroxyl radical results in 
the release of TBA reactive material, which forms a colored adduct readable at 532 nm.s3 
Increasing concentrations of compound 63 or Cisplatin in presence of Cu (11) showed a 
corresponding increase in the generation of hydroxyl radicals. The results in Fig. 11 confirmed 
the relatively higher rate of formation of hydroxyl radicals and correlated with the rate of DNA 
degredation by the compound 63 as well as Cisplatin. 
Work published; 
Synthesis, molecular docking and biological evaluation of new steroidal 4H-pyrans, Shamsuzzaman, Ayaz 
Mahmood Dar, et al, Spectrochimica Acta Part A: Molecular and Biornolecular Spectroscopy 117 (2014) 493-
501 
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2'-Amino-3'-cyanocholest-6-eno [5, 7- d e] 4H-pyran derivatives (66-68) 
In vitro cytotoxicity: 
The steroidal 4H-pyrans 66-68 (refer to chapter 2 for synthesis) were evaluated for in vitro 
cytotoxicity against cancer cell lines: SW480, A549, HepG2, HeLa, MCF7, DU 145 and HL-
60. The preliminary anticancer screening data given in Table 20 showed that compounds (66-
68) exhibited different levels of cytotoxicity during which compound 67 is found to have 
effective IC50 (<20 pmol L') against given cancer cells; 13.21 µmol L' (MCF7), 14.77 
gmol Li' (DU145), 15.23 gmol L-' (HepG2), 16.56 gmol L-' (SW480) and 19.87 umol L' 
(A549).. The compound 68 showed less cytotoxicity as its inhibition count (ICso) against 
given cancer cells is higher (>20 pmol L'); 26.46 pmol L-' (A549), 25.72 pmol L-' 
(HepG2), 36.80 gmol L' (HeLa) and 33.17 umol Ll (MCF7). The compound 66 also 
showed higher ICso against given cancer cells (>20 µcool L1), 27.45 µcool L-' (SW480), 
31.34 µmol L-' (A549), 36.12 pmol L-' (HeLa), 19.72 pmol L-' (MCF7), 28.16 umol L' 
(DU145). The compound 66 was almost inactive against HepG2 and HL-60 cells while 
compound 68 revealed almost inactive against SW480 due to their IC5o >50 pmol L'. 
IC50 (µmot L') 
Colon Lung Hepatic Cervical Breast Prostate Leukaemia 
Compound SW480 A549 HepG2 HeLa MCF7 DU145 HL-60 
66 27.45 31.34 >50 36.12 19.72 28.16 >50 
67 16.56 19.87 15.23 19.61 13.21 14.77 20.57 
68 >50 26.46 25.72 36.80 33.17 41.48 35.61 
Doxorubicin 10.34 8.28 7.36 11.53 12.41 6.26 9.64 
Cisplatin 3.52 12.1 9.63 9.43 9.3 6.54 7.83 
Table 20. Showing anticancer activity data of compound 66-68 against cancer cell lines 
From the table it is clear that the compound 67 was found to be potentially cytotoxic 
among all the three screened compounds and its IC50 against MCF7 was found to be 13.21 
µmot Lr which is very close to the IC5o of standard drug, Doxorubicin (12.41 µmot L-'). 
Compound 67 also depicted potential cytotoxic behavior against DU145, HepG2 and SW480 
cells by showing IC50=14.77 pmol L-', 15.23 pmol Ll and 16.56 pmol L-1, respectively. 
Since compound 66 and 68 were not found so much potent as their growth inhibition was at 
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higher concentration i.e. >25 pmol L-' against given cancer cells except MCF7 cells against 
which compound 66 expressed a considerable behavior i.e. 1050=19.72 µmol L-1. During 
anticancer screening, none of the synthesized compounds were found as effective as the 
standard anticancer drugs like Doxorubicin or Cisplatin, except compound 67 which showed 
ICso=13.21 µmol L-' which is very close to the ICso of Doxorubicin (12.41 pmoI L-') against 
MCF7 cell line. 
To confirm the cytotoxicity of steroidal pyrans towards normal cells, the compound 
66-68 were screened with some non-cancer cells i.e. NL-20 (lung) and HPC (pulp) during 
which none of the synthesized compounds were found toxic, all the compounds showed 
G15o>55 pmol L 1 .  This also suggests that the steroidal pyran derivatives can be used 
specifically for the treatment of cancer cells. The GI50 of compound 66-68, Doxorubicin and 
Cisplatin are given in Table 21. 
G15o (µML'') 
Lung Pulp Periodontal 
Compounds NL-20 HPC HPLF 
66 >100 >100 >100 
67 >100 >100 93.81 
68 80.58 >100 >100 
Doxorubicin 91.77 >100 >100 
Cisplatin 51-25 63.35 61,17 
Table 21. The GISO of compound 66-68, Doxorubicin and Cisplatin against non-cancer cells 
Microscopic examination of gross morphology of cancer cells and comparison with 
steroid pyran 67-treated cancer cells is shown in Fig. 12. The growth of adenocarcinoma 
colon cells (SW480) treated with 24 mM was inhibited within 24 h (Fig. B) but after 37 h 
cells were completely dead (Fig. C). The hepatic carcinoma cells (HepG2) when treated with 
24 mM also showed same behavior, the growth was inhibited within 24 h (Fig. E) but after 
37 h cells were almost completely dead (Fig. F). The breast cancer cells (MCF7) and prostate 
cancer cells (DU145) also followed the same pattern of growth inhibition, as it is clear that 
after treatment for 24 h with steroidal pyran 67, the growth is inhibited in MCF7 (Fig. H) and 
DU145 (Fig. K) while as after 37 h treatment the MCF7 (Fig. I) and DU145 cells (Fig. L) 
were almost completely dead. 
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Fig. 12. Microscopic examination of the interaction of cancer cells with steroid pyran 67. (A), 
(B) and (C) represent SW480 control and cells treated with 24 mM of steroid pyran 67 for 24 
and 37 h, respectively. (D), (E) and (F) represent HepG2 control and cells treated with 24 mM 
of steroid pyran 67 for 24 and 37 h, respectively. (G), (H) and (I) represent MCF7 control and 
cells treated with 24 mM of steroid pyran 67 for 24 and 37 h, respectively. (J), (K) and (L) 
represent DU145 prostatic cancer cell control and cells that reacted with 24 mM of steroid 
pyran 67 for 24 and 37 h, respectively. 
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Comet assay (Single cell gel electrophoresis): 
To confirm the effect of compounds on DNA damage, cells treated with Cisplatin and 
compound 66-68 showed the formation of comets. There was dose-dependent increase in tail 
length when treated with compound 66-68. Compound 67 presented maximum apoptotic 
DNA damage among the three steroidal pyrans studied, which was in accordance with its 
maximum cytotoxicity as seen in MTT assay. The quantified increase in DNA damage 
suggested that all three pyran derivatives induced dose dependent fragmentation of 
chromosomal DNA leading to apoptosis. The images of comet assay for control, cells treated 
with compound 66-68 (50 pg/mL), Doxorubicin (0.1 µM) are shown in Fig. 13. Slides were 
analyzed for parameter like tail length (TL), using image analyzer CASP software version 
1.2.2. The results of the assay for tail length are shown in Fig. 14. 
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Doxorubicin (50 gg/mL) 	Fig. 14. Comparison of the effect of steroidal pyrans on the tail 
length in comet assay 
Fig. 13. Detection of DNA damage in MCF7 cells. Control cells were treated with DMSO 
alone. The DNA fragmentation resulting in a comet-like appearance in cells treated with 
Doxonibicin and compound 66-68. 
Work published; 
Synthesis and biological studies of steroidal pyran based derivatives, Shamsuzzaman, Ayaz Mahmood Dar, et 
aI., Journal ofPhotochemistry and Photobiology B: Biology 129 (2013) 36-47 
I. 
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5a-Cholestano [6, 7- c] 5'-methyl-1'-carbothioic acid amido pyrazole derivatives (67-69) 
In vitro cytotoxicity: 
The in vitro cytotoxicity of steroidal pyrazoles (67-69) (refer to chapter 3 for synthesis) was 
studied by the MTT assay43' 44 and the data reported in Table 22 indicates that they depicted 
different levels of growth inhibition. The compound 68 showed minimum IC5o=16.21 (HL-
60), 17.38 (SW480), 17.75 (MCF7), 19.61 (HeLa) while compound 69 revealed effective 
IC5o=14.35 (HL-60), 17.41 (A549), 21.42 (MCF7), 19.27 (HeLa). The inhibitions showed by 
compound 67 were > 20 pmol L-' (as shown in Table 22). Thus compound 69 can be 
considered as potential anticancer agent [IC50=14.35 (HL-60)] among compound 67-69. The 
cytotoxicity screening data also suggest that the adjoining of pyrazole scaffold to the steroid 
nucleus may be one of the factors responsible for the cytotoxicity of the compound 67-69. 
From the Table 22 it is clear that compound 68 and 69 showed potential cytotoxicity 
against SW480, HL-60 and MCF7 cell lines by showing IC50 close to that of Doxorubicin, 
thus can be considered as potential cytotoxic agents. Compound 69 even showed IC5o same to 
that of Doxorabicin against HL-60 cell line. 
To confirm the toxicity on normal cells, the compound 67-69 were tested with some 
noncancerous cells i.e. NL-20 (lung) and HPC (pulp) during which none of the synthesized 
compounds were found toxic, all the compounds showed IC5o > 60. This also suggests that 
these steroidal pyrazoles can be used specifically for the treatment of cancer cells without 
being toxic to the non-cancer cells. 
Compound IC50 (µcool) a 
Cancer cells Non-cancer cells 
SW480 A549 HepG2 	HeLa HL60 MCF7 NL20 HPC 
67 24.13 20.37 38.12 	>50 21.26 25.12 >100 72.15 
68 17.38 ' 	>50 32.11 	19.61 16.21 17.75 64.23 82.11 
69 19.52 17.41 22.53 	19.27 14.35 21.42 77.12 66.43 
Doxorubicin 12.45 9.12 13.21 	16.76 14.37 14.21 >100 >100 
Cisplatin 3.52 12.1 9.63 	9.43 7.83 9.3 63.35 61.17 
- "IC50 is the concentration of compound that inhibits 50% of cell growth 
Table 22. Showing IC5o of compound 67-69 against Human cancer and non-cancer cells 
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Microscopic examination of gross morphology of cancer cells and comparison with steroid 
pyrazole treated cancer cells is shown in Fig. 15. The human leukaemia cells (BL-60) when 
treated with compound 69 (20 mM) showed cytotoxic behavior, their growth was inhibited 
within 48 h (Fig. D). The breast cancer cells (MCF7) followed the same pattern of growth 
inhibition, as it is clear that after treatment for 48 h with steroidal pyran 69 (20 mm), the 
growth is inhibited in MCF7 cells (Fig. E). The growth of adenocarcinoma cells (SW480) 
was also greatly inhibited when treated with 20 mM of compound 68 for 48 h (Fig. F). The 
untreated cells (intact nuclei) gave bright green fluorescence whereas treated cells showed 
sharp orange-red fluorescence showing apoptosis. 
(A) HL-60 (B) MCF7 (C) SW480 
(D) HL-60 + 69 after 48 h 	(E) MCF7 + 69 after 48 h 	(F) SW480 + 68 after 48 b 
Fig. 15. Fluorescence microscopic images of untreated (A) HL60, (B) MCF7 and (C) SW480 
cells and compound 68 and 69 treated (D), BL60, (E) MCF7 and (F) SW480 cells. 
Comet assay: 
In the comet assay, the genotoxicity was studied while treating the cells with Cisplatin and 
compound 67-69 and the formation of the comet is the sign of DNA degradation. There was 
again dose-dependent increase in tail length when treated with compound 67-69. Compound 
68 presented maximum apoptotic DNA damage among the three steroidal pyrazoles studied, 
which is in accordance with its maximum cytotoxicity against MCF7 cells as seen in MTT 
k 
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assay. None of the steroidal pyrazole exhibited apoptotic DNA damage to the extent of 
Cisplatin. The quantified increase in DNA damage suggested that all three pyrazole 
derivatives induced dose-dependent fragmentation of chromosomal DNA leading to 
apoptosis. The images of comet assay for control, cells treated with Cisplatin (0.1 PM, 54 
µglmL), 67&69 (50 µg/niL) are shown in Fig. 16. Slides were analysed for tail Iength (TL), as 
shown in Fig. 17 using image analyzer CASP software (1.2.2. version). 
Control (67) 	 (68) 
(69) 	 Cisplatin 
Fig. 16. DNA damage detection in MCF7 cells. Treated cells (24 h) were layered over 
agarose gel, lysed, electrophoresed in alkaline buffer and stained with propidium iodide. 
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Fig. 17. Graphical representation of the effect of steroidal pyrazoles on DNA damage 
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5a-Cholestano [5, 6 - b] benzothiazine derivatives (53-55) 
In vitro cytotoxicity: 
The steroidal benzothiazines 53-55 (refer to chapter 4 for synthesis) were screened for in 
vitro cytotoxicity against human cancer cells; SW480, HeLa, A549 and HepG2 by MTT 
assay43' 44 and the screening data reported in Table 23 suggest that compound 53-55 showed 
different levels of cytotoxicity during which the compound 53 depicted effective IC50 =13.73 
p.mol L'' against HeLa cells. Compound 54 and 55 also showed minimum IC50 value in the 
range of 15.83 pmol L' (HepG2) and 16.89 gmol L 1 (A549), respectively. Next to these, 
compound 54 showed minimum IC50 =22.67 }imol L' against SW480 cell line. The IC50 
shown by the starting ketones (50-52) were found either > 40 or much higher >50 gmol L-1. 
It is clear from the screening data that after the adjoining of benothiazine moiety to the 
steroidal ketone derivatives (50-52), there occurs moderate to good increase in cytotoxicity 
(Table 23). During anticancer screening, only compound 53 showed IC50=13.73 µmol L-1  
which is more effective than 5-fluorouracil (IC50 16.32 pmol L 1 ) against HeLa cell line. 
Compound 
SW4S0 
IC50 (pmol L') a 
A549 HepG2 HeLa 
50 47.28 40.61 >50 >50 
51 39.77 46.13 >50 >50 
52 >50 >50 49.22 >50 
53 27.73 16.89 >50 13.73 
54 22.67 29.85 15.83 31.43 
55 >50 41.52 37.65 49.18 
Doxorubicin 10.9 13.5 11.52 12.52 
5-Fluorouracil 15.71 12.8 33.6 16.32 
Cisplatin 3.52 12.1 9.63 9.43 
Table 23. IC50 of starting compounds 50-52 and products 53-55 against human cancer cells 
To confirm the cytotoxicity of steroidal benzothiazines on normal cells, the compound 
53-55. were tested with some non-cancer cells i.e. MCF1OA (breast), NL-20 (lung), HPC 
(pulp) and HPLF (Periodontal) during which none of the synthesized compounds were found 
toxic, all the compounds showed GI50 > 55 µmol L'. The GI50 of compound 53-55 and 
Cisplatin, Doxorubicin and 5-fluorouracil are given in Table 24. 
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GIso (µML-') 
Breast Lung 	Pulp Periodontal 
Compounds MCF10A NL-20 	HPC HPLF 
53 >100 60.92 	67.78 >100 
54 68.41 90.21 	63.31 >100 
55 72.11 >100 	59.16 66.33 
Doxorubicin >100 91.77 	>100 >100 
Cisplatin 26.17 51.25 	63.35 61.17 
5-FU >100 83.54 	73,62 >100 
Table 24. The GI50 of compound 53-55, Doxorubicin, Cisplatin and 5-fluorouracil against 
non-cancerous cells 
Work published; 
Anticancer and antimicrobial evaluation of newly synthesized steroidal 5, 6 fused benzothiazines. 
Shamsuzzaman, Ayaz Mahmood Dar, et al., Arabia,, Journal of Chemistry, http://dx.doi.org(IO.1016/j. 
arabjc.2013.06.027, in press 
2'-Hydrazinocholest-6-eno [4, 5- a] thiazole derivatives (56-58) 
In vitro anticancer activity: 
The inhibitory effect of steroidal thiazoles 56-58 (refer to chapter 4 for synthesis) on human 
cancer cells was measured by MTT assay.43' 44 The results are expressed as ICso (Table 25) 
which depict that compound 56-58 showed different levels of activity. 
Compound 
SW480 A549 
IC5o (µcool L') 
HepG2 HeLa HL-60 
56 14.03±0.2 13.22±0.7 17.37± 1.5 16.62±0.4 >50 
57 13.04±0.6 11.32±0.2 9.71±1.1 13.171-0.4 14.71±0.3 
58 21.66± 0.4 15.441 1.3 >50 11.74± 0.7 26.27±0.5 
Cisplatin 3.52 ± 0.3 10.51 ± 0.2 9.6 ± 0.9 9.43 ± 0.5 7.8±1.5 
Table 25. Showing the IC50 of compound 56-58 against given human cancer cell lines 
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The compound 57 showed minimum IC50= 9.71 ± 1.1 (HepG2), 11.32 f 0.2 (A549), 13.04 ± 
0.6 (SW480) and 13.17 ± 0.4 µmot L-1  (HeLa) while compound 58 showed minimum 
1050=1 134 ± 0.7 (HeLa) and 15.44 f 1.3 gmol L' (A549). The minimum inhibitions shown 
by compound 56 were 13.22 ± 0.7 (A549), 14.03 ± 0.2 (SW480) and 16.62 ± 0.4 pmol L-1  
(HeLa). 
From these results it is clear that the IC50 for compound 57 against A549 cell line is 
11.32 ± 0.2 which is very close to the IC5o of Cisplatin (10.51 1 0.2) against the same cell 
line. IC50 for compound 58 against HeLa cell line is 11.74 ± 0.7 which is also close to the 
IC50 of Cisplatin (9.43 ± 0.5) against the same cell line. Similarly IC5o for compound 57 
against HepG2 is 9.71 ± 1.1 which is also near to the IC50 of Cisplatin (9.6 ± 0.3) against the 
same cell line. It can be concluded that all the compounds (56-58) showed potential 
anticancer activity against A549, HepG2, HeLa cell lines by depicting IC50 close to that of 
standard drug, Cisplatin thus can be considered as potential anticancer agents. 
Treatment of supercoiled plasmid pBR322 DNA with compound 57: 
It has been observed from gel electrophoresis that alter adding copper (100 p.M), the 
concentration of radicals increase which in presence of different concentrations of compound 
57 showed the nicking of plasmid pBR322 DNA from its supercoiled form (Form I) to open 
circular form (Form II). As shown in Fig. 18, lane 6, 7 and 8, the nicking is quite obvious by 
the appearance of form II and with the increase in concentration of compound 57 (lane 8) the 
band intensity (form II) became maximum, depicting the more pronounced cleavage at high 
concentration. 
Form-H 
Form-I 
1 	2 	3 	4 	5 	6 	7 	8 
Fig. 18. Fragmentation pattern of supercoiled plasmid pBR322, Lane I contains DNA only, 
lane 2 contains DNA and copper, lane 3 and 4 contain DNA and compound 57 (200 and 300 
gM respectively), Lane 5, 6 and 7 contain DNA and compound 57 (200, 300, 400 gM 
respectively) + 100 gM copper added to it and Lane 8 contains DNA+ Cisplatin (20 µM) + 
100 µM copper added to it. 
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Detection of hydroxyl radicals ('OH): 
To determine the hydroxyl radical production and the role of copper ions in DNA cleavage, 
an experiment was performed where progressively increasing concentrations of compound 57 
and Cisplatin (12.5-600 gNl were tested on thiobarbituric acid induced DNA breakage (Fig. 
19) and from these results we may conclude that the DNA cleavage by thiobarbituric acid 
involves endogenous copper ions and also that Cu (I) is an intermediate in the pathway that 
leads to DNA cleavage. 
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Fig. 19: Showing comparative determination of hydroxyl radical production by compund 57 
(A) and Cisplatin (B) by the assay of Thiobarbituric acid 
The compound 57-Cu (II) (Fig. 19A) and Cisplatin-Cu (II) (Fig. 19B) are shown to 
generate the hydroxyl radicals (OH) that react with CT DNA, result in strand breaks. The 
assay is based on the fact that degredation of DNA by hydroxyl radical results in the release 
of TBA reactive material, which forms a colored adduct readable at 532 nm.53 Increasing 
concentrations of compound 57 or Cisplatin in presence of Cu (II) showed a corresponding 
increase in the generation of hydroxyl radicals. However the generation of hydroxyl radical 
being more in case of Cisplatin as shown in Fig. 19(B). The results in Fig. 19 confirmed the 
relatively higher rate of formation of hydroxyl radicals and correlated with the rate of DNA 
degredation by the compound 57 as well as Cisplatin. 
Work accepted; 
Synthesis, characterization and in vitro anticancer activity of newly synthesized steroidal 6, 7-fused thiazoles, 
Shamsuzzaman, Ayaz Mahmood Dar, et al., Journal of Chemistry (accepted) 
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2, 2-Diphenyl-2-picryl-hydrazyl (DPPM assay: 
The 2, 2-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging activity of the heterosteroids 
was measured according to the literature method.6° Drug stock solution (1 nig/mL) was 
diluted to final concentration of 2, 4, 6, 8, 10 and 12 in methanol. Methanolic DPPH solution 
(1 niL, 0.3 mmol) was added to 3.0 mL of drug solution of different concentrations. The tube 
was kept at an ambient temperature for 30 min and the absorbance was measured at 517 nm. 
The scavenging activity was calculated by following formula: [% inhibition = [(Aconuoi - 
ASample/A ontrol x 100] Where Aoonirol  is the absorbance of the ascorbic acid (standard) and 
Asampie is the absorbance of different compounds. The methanolic DPPH solution (I mL, 0.3 
mM) was used as control. 
Hydrogen peroxide (HIO2) scavenging assay: 
Hydrogen peroxide is generated in vivo by several oxidase enzymes. There is increasing 
evidence that hydrogen peroxide, either directly or indirectly via its reduction product 
hydroxyl radical (-OH), causes severe damage to biological systems. In this method, when a 
scavenger is incubated with hydrogen peroxide, the decay or loss of hydrogen peroxide can 
be measured spectrophotometrically at 230 run.61 The method was carried out with minor 
modifications. A solution of hydrogen peroxide (20 mM) was prepared in phosphate buffered 
saline (PBS, pH 7.4). Various concentrations of 1 mL of the steroidal compounds or 
standards in methanol were added to 2 mL of hydrogen peroxide solution in PBS. The 
absorbance was measured at 230 nm after 10 min. 
Scavenging of nitric oxide (SNP) radical assay: 
Aqueous solution of sodium nitroprusside (SNP) at physiological pH spontaneously generates 
nitric oxide (NO) which interacts with oxygen to produce nitrite ions that can be estimated by 
the use of modified Griess Ilosvay reaction with little modifications. Scavengers of NO 
compete with oxygen leading to reduce production of NO. The reaction mixture (6 mL) 
containing SNP (10 mM, 4 mL), phosphate buffer saline (PBS, pH 7.4, 1 mL) and steroidal 
compounds or standard (1 rnL) in DMSO at various concentrations was incubated at 25 °C 
for 150 min. After incubation, 0.5 mL of the reaction mixture containing nitrite ion was 
removed, 1 mL of sulphanilic acid reagent was added, mixed well and allowed to stand for 5 
min. for completion of diazotization. Then 1 mL of NEDD was added, mixed and allowed to 
stand for 30 min. in diffused light. A pink colored chromophore was formed. The absorbance 
was measured at 540 nm.62 
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[4', 6'-Dioxo-2'-thioxo-1H-pyrisnidin-1-y16-imino-5a-cholestane derivatives (94-96) 
Many thiosemicarbazone derivatives with a broad spectrum of effects are known to act as 
free radical inhibitors. 63 The DPP assay6° is widely used for assessing the ability of radical 
scavenging activity of these compounds. Because of the presence of odd electron, DPPH 
shows a strong absorption band at 517 nrn in the visible spectrum. As this electron becomes 
paired off in the presence of a free radical scavenger, this absorption vanishes and the 
resulting decolorization is stoichiometric with respect to the number of electrons taken up. 
The result of DPPH assay of the steroidal pyrimidine (94-96) (refer to chapter 1 for 
synthesis) is shown in Table 26 and it is clear that all the compounds exhibited potential 
antioxidant activity compared to the standard, ascorbic acid. Compound 96 showed 
maximum antioxidant activity by depicting the higher absorbance among all the three 
screened compounds. 
Compound 
25 .tg/mL 
Absorbance value ± S.D. 
50 µg/mL 	75 ug/mL 100 gglmL 
94 17.8±0.2 26.410.4 31.6±0.2 37.5±0.3 
95 21.2±0.5 29.3±0.2 32.4±0.4 38.4±0.2 
96 26.210.3 30.2±0.5 35.7±0.4 39.8±0.6 
Ascorbic acid 35.0±0.4 40.0±0.2 39.0±0.3 46.0±0.5 
Control - - - - 
-Values represent the mean ± standard error mean (SEM) of three experiments. 
Table 26. Showing reducing power of steroidal pyrimidines (94-96) 
2'-Amino-3'-carboethoxycholest-6-eno [5, 7- del 4H-pyran derivatives (63-65) 
Many pyran derivatives with a broad spectrum of biological activity are known to show free 
radical scavenging activity. One of the pyran derivatives, kojic acid is known to have 
potential antioxidant activity. With this intrest, the steroidal pyrans (63-65) were screened for 
DPPH scavenging assay and the results are given in Table 27. But during the antioxidant 
screening by DPPH assay6°, it was found that steroidal pyrans (63-65) (refer to chapter 2 for 
synthesis) were not significantly active compared to the standard, ascorbic acid. The 
antioxidant activity shown by the steroidal pyrans was found to be less than 50% of the 
ascorbic acid. 
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Compound Absorbance value f S.D. 
25 gg/mL 50 p.g/mL 75 pg/mL 100 ug/mL 
63 9.3±0.2 12.5±0.4 13.2±0.6 17.1±0.3 
64 11.2±0.4 13.6±0.2 16.2±0.4 16.9±0.3 
65 10.2±0.3 11.8±0.4 15.2±0.1 19.8±0.6 
Ascorbic acid 35.0±0.4 40.0±0.2 39.0±0.3 46.0±0.5 
Control - - - - 
-Values represent the mean I standard error mean (SEM) of three experiments. 
Table 27. Showing reducing power of steroidal pyrans (63-65) 
Cholestano [6, 7 - c] 5'-methyl-I'-carbothioic acid amido pyrazole derivatives (67-69) 
Since thiosemicarbazones have often depicted the free radical inhibition in a potential 
manner.63 Thus, pyrazole which is the derivative of thiosemicarbazone has also got tendency 
to act as the effective radical scavenger. Hence the H202 scavenging assay61 of steroidal 
pyrazoles (67-69) (refer to chapter 3 for synthesis) has been done and the results are shown 
in Table 28. It is clear that the compound 67-69 were found significantly active in 
antioxidant activity compared to the standard, ascorbic acid. 
Compound Absorbance value ± S.D. 
25 EtglmL 50 pg/mL 75 µg/mL 100 Itg/mL 
67 19.3±0.5 27.4±0.1 33.1±0.3 36.2±0.1 
68 21.5±0.1 28.3±0.6 31.6±0.2 38.3±0.6 
69 18.7±0.2 26.8±0.4 32.4±0.6 40.1±0.3 
Ascorbic acid 35.0±0.4 40.0±0.2 39.0±0.3 46.0±0.5 
Control - - - - 
-Values represent the mean f standard error mean (SEM) of three experiments. 
Table 28. Showing reducing power of steroidal pyrazoles (67-69) 
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2'-Hydrazinocholest-6-eno [4, 5 - d] thiazole derivatives (56-58) 
Among sulfur compounds, thiazole is an important compound with wide number of 
applications. Thus, as per literature, the thiazoles can act as the effective radical scavengers. 
Thus the SNP radical scavenging assay62 of steroidal thiazoles (56-58) (refer to chapter 4 for 
synthesis) has been done and the results are shown in Table 29. It is clear that the compounds 
(56-58) were found significantly active in antioxidant activity compared to the standard, 
ascorbic acid. 
Compound Absorbance value ± S.D. 
25 tg/mL 50 pglmL 75 gg/mL 100 pg/mL 
56 19.6±0.4 26.4±0.3 30.1±0.2 37.4±0.2 
57 20.2±0.3 29.3±0.2 34.6±0.5 39.8±0.6 
58 16.7±0.2 22.2±0.1 27.4±0.5 33.5±0.6 
Ascorbic acid 35.0±0.4 40.0±0.2 39.0}0.3 46.0±0.5 
Control - - - - 
-Values represent the mean E standard error mean (SEM) of three experiments. 
Table 29. Showing reducing power of steroidal thiazoles (56-58) 
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DNA is an important template as it regulates many biochemical processes that occur in the 
cellular system. The different loci present in the DNA are involved in various regulatory 
processes such as gene expression, gene transcription, mutagenesis, carcinogenesis, etc.64 
Many synthetic molecules exert their anticancer activities by binding with DNA, thereby 
altering DNA replication and inhibiting the growth of tumor cells. DNA cleavage reaction is 
also considered of prime importance as it proceeds by targeting various constituents of DNA 
viz., the nucleic bases, deoxyribose moiety and phosphodiester linkage. Therefore, synthetic 
molecules that undergo hydrolytic DNA cleavage are useful in genetic engineering, 
molecular biotechnology and robust anticancer drug design.65, 66 
In the field of molecular biology and drug development, the cleaving agents of nucleic 
acid have attracted extensive attention due to their potential applications. 67 Under uncatalyzed 
physiological conditions, the phosphodiester bonds of DNA are extremely stable and the half 
life of DNA for hydrolysis is estimated to be around 200 million years.68 Metal complexes 
have been widely investigated as cleaving agents of nucleic acids and are found to be 
reasonably efficient,69 but their use in pharmacy is restricted because of serious issues over 
the lability and toxicity, that limits the practical usage of these compounds.70 To overcome 
these limitations, Gobel and co-workers7' put forward the concept of 'metal-free cleaving 
agents' which are being applied to active phosphodiesters like nucleic acid mimic and RNA. 
Since DNA has been identified as the primary molecular target of heterocyclic based 
anticancer drugs, interaction of well tailored heterocycles with DNA ascertains the extent and 
mode of DNA binding and the potential of these compounds to act as chemotherapeutic 
agents. There are various modes of DNA interaction; covalent, non-covalent, intercalation 
etc. DNA targeted metal based drugs which bind to nucleobase moieties has shown low 
degree of selectivity and high toxicity to the normal cells. Recently, non-covalent DNA 
binding organic heterocycles particularly pyrimidine derivatives have received attention in 
the development of efficient anticancer drugs (5-fluorouracil).72 Intercalation and electrostatic 
interactions are well known effects that lead to the hypochromism and hyperchromism shifts, 
respectively in the DNA. 
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Material and equipments: 
Super coiled pBR322 DNA was purchased from GeNei (India) and was used for the agarose 
gel experiment without further purification. Calf thymus DNA (CT DNA) and pUC 19 DNA 
were purchased from Sigma, were dissolved in a 0.1 M Tris-buffer. The purity of DNA was 
verified by monitoring the ratio of absorbance at 260 nm to that of 280 nm, which was in the 
range 1.8-1.9. The concentration of the DNA was determined spectrophotometrically using 
$-760 = 6600 MI cm* 14 DNA ligase enzyme was purchased from CalBioChem and was 
utilized as received. The UV-Vissible measurements were recorded on a Beckman DU 40 
Spectrophotometer (USA) while as fluorescence measurements were recorded on a Shimadzu 
Spectrofluorimeter-5000 (Japan). Cleavage experiments were performed with the help of 
Axygen electrophoresis supported by Genei power supply with a potential range of 50-500 V, 
visualized and photographed by Vilber-INFINITY gel documentation system. 
Gel electrophoresis: 
Two concentrations (100 and 200 pM) of compounds and 3µL of 0.5 pg/iL of pUC19 DNA 
was loaded with 2 µL of EtBr into 1% agarose gel. The final volume of the reaction mixture 
for all the wells of gel was 10 µL. The DNA band was visualized under UV transilluminator. 
Absorption spectroscopy: 
The UV-Vissible measurements of calf thymus DNA were recorded on a Beckman DU 40 
Spectrophotometer (USA) by using a cuvette of 1 cm path length. The absorbance values of 
compounds in the absence and presence of DNA were recorded in the range of 225-350 nm. 
Appropriate blanks corresponding to the DNA solutions and buffer were subtracted to correct 
the base line. 
Fluorescence spectroscopy: 
Fluorescence measurements were recorded on a Shimadzu Spectrofluorimeter-5000 (Japan). r 
The fluorescence quenching with increasing concentration of DNA was recoi!ded after 
exciting the drug solution at 280 nm, using 10/10 nm as slit widths. After subtracting the 
value of the baseline (buffer alone), the uncorrected fluorescence values, Foo, for compounds 
was corrected as follows 
F = Fuc x (3000 + x) / 3000 
r 	 150 
where `x' is the volume of the added DNA solution (in microliters), 3000 is a mixture volume 
(in microliters), before the addition of DNA, and F is a corrected fluorescence value.73' 74 
Molecular Docking: 
The rigid molecular docking studies were performed using HEX 6.1 software.75 The initial 
structure of the compounds was generated by Mercury modeling software. The molecules of 
compounds were optimized for use in the following docking study. The crystal structure of 
the B-DNA dodecamer d(CGCAAATTTCGC)2 (PDB ID: 1BNA) was downloaded from the 
protein data bank. All calculations were carried out on an Intel CORE i5, 2.6 GHz based 
machine running MS Windows 7 as the operating system. Visualization of the docked pose 
have been done using PyMol molecular graphics program.76 
Nuclease or cleavage activity: 
Cleavage experiments of supercoiled pBR322 DNA (300 ng) by new heterosteroids (1.0-5.0 
µM) in (5 mM Tris-HC1/50 mM NaCI), buffer at pH 7.2 were carried out and the reaction 
followed by agarose gel electrophoresis. The sample was incubated for 1 h at 37 °C. A 
Ioading buffer containing 25% bromophenol blue, 0.25% xylene cyanol and 30% glycerol 
was added and electrophoresis was carried out at 60 V for I h in Tris-HC1 buffer using 1% 
agarose gel containing 1.0 gglmL EtBr. The reaction was also monitored upon addition of 
various radical inhibitors and/or activators such as DMSO, tert-butyl alcohol (TBA), sodium 
azide (NaN3), superoxide dismutase (SOD), mercaptopropionic acid (MPA), glutathione 
(GSH) and 11202. 
T4 ligation experiment: 
To support the hydrolytic mechanism of DNA cleavage, the DNA relegation experiments 
were performed using T4 ligase enzyme. The compounds treated with pBR322 plasmid DNA 
(2 mg), ligation buffer of 1.5 mL in 10X, T4 Iigase 1 mL (2 units) and 2.5 mL of H2O were 
mixed and incubated at 4 °C for 1 h. Subsequently the samples were loaded on 1% agaros 
gel and visualized by staining with an ethidium bromide solution. 
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DNA binding studies of [4', 6'-dioxo-2'-thioxo-IH-pyrimidin-1-y1] 6-imino-5a-cholestane 
derivatives (94-96) 
Gel electrophoresis: The steroidal pyrimidines (94-96) (refer to chapter 1 for synthesis) 
were examined for their binding abilities with pUC19 DNA by agarose gel electrophoresis. In 
the Fig. 20, lane 1 contains DNA only, lane 2, 4, 6 contains DNA and 100 µM of compound 
94-96 and lane 3, 5, 7 contain DNA and 200 pM of compound 94-96. At low concentration, 
the compound 94-96 do not show any appreciable change in the band intensity of DNA (lane 
2, 4, 6). However, at higher concentrations band intensity gets diminished in compound 94-
96 (lane 3, 5, 7). Thus electrophoretic pattern demonstrate that all the compounds interact 
with DNA. The loss in the band intensity at higher concentration may be assumed due to the 
intercalation of the compound 94-96 to DNA, which in turn results in the displacement of 
EtBr. In case of lane 2, 4, 6 the concentration of the compounds is not sufficient for the 
displacement of EtBr. This conclusion was further supported from the fluorescence 
quenching, which gave convincing evidence for interaction of the compounds with DNA. 
UV-vis absorption spectroscopy: Absorption spectra of the compound 94-96 showed quite 
similar broad, unstructured lowest-energy bands with maxima in the vicinity of 285 run. Fig. 
21 shows the absorption spectra of the compounds in presence of various concentrations of 
CT DNA. The concentrations of all the compounds were maintained at 100 }iM to make an 
easier comprehension and comparison of the extent of binding interaction of the compound 
94-96 to DNA. It was found that the absorption intensity in the compound 94-96 increased 
with gradual addition of DNA that showed hyperchromism, with slight bathochromic shifts. 
Such type of bathochromic shift suggests an interaction between DNA and compound 94-96. 
An interaction between compound 94-96 and DNA decreases the energy gap between the 
LUMO and HOMO of the compound 94-96 that results in a bathochromic shift. As can be 
seen from the Fig. 21 the isobestic point is not clear, which hinders in calculating the binding 
constant values, suggests that DNA and compound 94-96 does not bind in 1:1 ratio or there 
may be more than one 'mode of binding. 
Fluorescence spectroscopy: To obtain an insight into the binding of compound 94-96 with 
DNA, the fluorescence quenching of compound 94-96 was studied using DNA as a quencher, 
and the degree of the accessibility of each of the molecule to the quencher was examined. 
Fig. 22 depicts change in the emission spectrum of these compounds in presence of DNA. 
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The fluorescence quenching data was analyzed to obtain the quenching constant by using the 
well-known Stern-Volmer equation (1).77 
(.2J_i — k, [Q] 
	 (1 )  
Where F, and F denote the steady-state fluorescence intensities in the absence and in the 
presence of quencher (DNA), respectively, lv is the Stern-Volmer quenching constant 
(which is a measure of quenching efficiency), and [Q] is the concentration of the quencher. 
Hence, eq. 1 was applied to determine Ksv by linear regression of a plot of (FJF)- 1 versus 
concentration of DNA and is represented in Fig. 22. The Stern-Volmer constants (Ksv) 
estimated for compound 94-96 by Stem-Volmer equation were recorded in Table 30. The 
Stern-Volmer plot is linear, indicating that only one type of quenching process occurs, either 
static or dynamic. 
Compounds 	K v(1x10") (M"') 	Kq (1x10') (M-'s-') K(Ix10-3)(M-') 	n 
94 1.54 1.54 4.634 1.124 0.9937 
95 2.44 2.44 2.123 0.988 0.9947 
96 1.83 1.83 2.435 1.027 0.9938 
r ` is the regression in binding equilibrium 
Table 30. Binding parameters obtained from the fluorescence quenching method 
Analysis of quenching mechanism was confirmed from the values of biomolecular quenching 
rate constants, which are evaluated using the equation (2): 
K 
 _y 
K sv  
q 	T O 
	 (2) 
where z° is the lifetime of the biomolecules without the quencher and Kq stands for the 
bimolecular quenching. constant. The value of r° for biopolymers is 10"&s.78 Accordingly the 
values of Kq are calculated (Table 30). In general, the maximum Kq of various kinds of 
biomolecules is 1010 Ms', which is less than the values in our case, indicates the 
fluorescence quenching is initiated by a static quenching process.7S When small molecules 
bind independently to a set of equivalent sites on a biomacromolecule by static quenching, 
the equilibrium between free and bound molecules is given by the equation (3): 
log F°F, 
—F 
 = logK+nlog[Q] 
	
(3) 
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where K and n are the binding constant and the number of binding sites, respectively. From a 
plot of (F0 - F)IF vs. log [Q] (Fig. 21A), K and the n can be obtained from the intercept and 
the slope (Table 30). As seen in Table 30, the values of n were approximately equal to 1, 
which indicated the existence of just one main binding site on DNA for compound 94-96. 
Recently Ruiz et al.79 have reported the incorporation of steroidal moiety in Rhodium and 
Iridium complexes, enhances their antitumor activities. These metal-steroidal complexes also 
have binding constants in a range of 103 M1. Haramane (Hivi), photosensitizer interact with 
DNA through intercalative mechanism and the binding constant (9 x 103 M') is found to be 
on the same order of magnitude as that are in present case.80 
Molecular Docking: In our experiment, rigid molecular docking (two interacting molecules 
were treated as rigid bodies) studies were performed to predict the binding modes of 
compounds with a DNA duplex of sequence d(CGCAAATTTCGC)2 dodecamer (PDB 
ID: IBNA) and provide an energetically favorable docked structures (representative figure of 
DNA-compound 95 complex shown in Fig. 23). It is evident from the figure that these type 
of compounds get attached with DNA through major groove and their pyrimidine moiety 
showed intercalation between the nucleotide base pairs of DNA. In this configuration, the 
group at 3J3-axial position (i.e_, X—moiety) remains inclined towards the phosphodiester bond 
of DNA and the possibility of hydrogen bonding cannot be ruled out. The resulting relative 
binding energy of docked steroidal pyrimidine—DNA complexes was found to be —280 to 
—293 k3 mol-'. This value is consistent with the high binding constant obtained from 
spectroscopic values. Thus there is a mutual complement between spectroscopic techniques 
and molecular modeling, which can provide valuable information about the interaction of the 
compounds with DNA and the conformation constraints for adduct formation. 
;. 20. Agrose gel electrophoresis of reaction mixtures containing pUC19 DNA and 
-pound 94-96. The concentration of DNA was 75 mg/L. Lane 1, DNA; lane 2, 3 DNA + 
100, 200 p M); lane 4, 5 DNA+ 95 (100, 200 p M); lane 6.7 DNA + 96 (100, 200 p M) 
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Fig. 21. Variation of UV-vis absorption for steroidal pyrimidines (94-96) with increase in 
concentration of CT DNA, (A) shows the variation of (F0 — F)/F with log concentratio 
DNA. 
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Fig. 22. Fluorescence titration of compound 94-96 with the CT DNA. Fluorescence intensity 
decreases with subsequent addition of DNA solution. (a), (b) and (c) represent fluorescence 
quenching of compound 94-96 due to the addition of DNA, respectively. (d) Stern-Vohner 
plots for the compound 94-96. 
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Fig. 23. Cartoon representation of DNA-compound 95. The N-, S- and the 0- termini of the 
pyrimidine moiety of the compound are shown as blue, yellow and red sticks, respectively. 
(a), (b) and (c) shows minimum energy poses of DNA-steroidal pyrmidine complex. 
Work published; 
Steroidal pyrimidines: Synthesis, characterization, molecular docking studies with DNA and 
in vitro cytotoxicity, Shamsuzzaman, Ayaz Mahmood Dar, et al., Journal of Molecular 
Structure 1045 (2013) 62-71 
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DNA binding studies of [6'-amino-2'-thioxo-4'-oxo dihydro-1H-pyrimidin-1-yl] 6-imino-
5a-cholestane derivatives (97-99) 
Electronic absorption titration: Electronic absorption spectroscopy is one of the most 
useful techniques for the investigation of mode of the interaction of compounds with DNA. 
The UV-vis spectra of compound 97-99 (refer to chapter 1 for synthesis) exhibited intense 
absorption bands at 290 nm attributed to the nix* or intraligand transitions as shown in Fig. 
24. This intense ligand (r_*n*) absorption band is used to monitor the interaction of the 
compounds with CT DNA. Upon the addition of increasing concentration of CT DNA (0.70 - 
4.24x l0-' M) to the test compounds in 2% DMSO/5mM Tris HC1/50mM NaCl buffer 
solution, the ligand intraligand absorption band exhibited hyperchromism without shift in 
band position. Hyperchromicity and hypochromicity are the spectral features of DNA 
concerning its double helical structure. The hyperchrornic effect reflects the corresponding 
changes of DNA in its conformation and structure and results from the structural damage to 
the secondary structure DNA double helix.' These spectral characteristics suggested that 
compounds have higher binding propensity with CT DNA and interacts presumably by 
electrostatic interaction via the phosphate backbone of DNA double helix together with the 
hydrophobic interaction, since the bulky nature of the compounds is expected to hinder the 
intercalative mode of binding. The hydrophobic interaction with DNA replaces the water 
molecules in the DNA grooves leading to the enhancement in entropy and stabilization of the 
DNA-bound compound. 82 
In order to further compare the binding strength of the compounds, their intrinsic binding 
constant (Kb) were determined from the following equation (4). 83 
[DNA]/I as - Er I = [DNA]/ I sb — c f I + I /Kb I cb — of 1 	 (4) 
where, [DNA] represents the concentration of CT DNA, Ea, Ef and sb are the apparent 
extinction coefficients AQb~I[M], the extinction coefficient for free compound and the 
extinction coefficient for compound in the fully bound form, respectively. In the plots of 
[DNA] / a,-zfversus [DNA], Kb is given by the ratio of the slope to the intercept. 
The intrinsic binding constants for compound 97-99 were found to be 9.34x 103, 6.56 x 103 
and 1.54 x 10 x`, respectively. The results obtained revealed that compound 99 binds more 
strongly with CT DNA as compared to the remaining compounds and the order of binding 
affinity is 99>97>98. 
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Fluorescence spectroscopy: The emission spectra of compound 97-99 displayed intense 
luminescence at 358 nm at room temperature in the absence of DNA, when excited at 290 
nm. On addition of increasing concentration of CT DNA (0.70 x 10"5 to 4.24 x 10-5 M) to the 
fixed amount of compounds (1 x 10-4 M), the emission intensity appreciably increases as 
shown in Fig. 25. The enhancement in the emission intensity is largely due to the change in 
environment around compounds and related to the extent to which the molecule is inserted 
into the hydrophobic environment of DNA minor and major grooves. Since DNA is a 
hydrophobic molecule, it reduces the accessibility of solvent molecules to reach the 
hydrophobic environment inside the DNA and the mobility of the compound is restricted at 
the binding site ultimately leading to decrease in vibrational mode of relaxation.82 
Furthermore, the binding of complex to the DNA helix could decrease the collisional 
frequency of solvent molecules with the compound, leading to the emission enhancement of 
the compound. These results revealed that interaction between CT DNA and compound 
occurs due to the hydrophobicity of both molecules. 
To compare the binding affinity of compounds to DNA quantitatively, the binding constant 
`K' and binding site number `n' were calculated by using Scatchard equation (5) and (6).$a, ss 
CF = CT (FIFO - P) (1- P) 	 (5) 
r/c=K(n-r) 	 (6) 
where, CF is the concentration of free compound, CT is the total concentration of compound; 
F and F,, are fluorescence intensities in the presence and absence of DNA, respectively. P is 
the ratio of observed fluorescence quantum yield of the bound compound to that of the free 
compound. The value P was obtained as the intercept by extrapolating from a plot of F/F0 
versus 1/[DNA], r denotes CB = (CT-CF) / [DNA], `c' is the free compound concentration and 
`n' is the binding site number. 
The binding constants for compound 97-99 were calculated to be 4.6 x 103, 3.5 x 103 and 1.1 
x 104, respectively. The number of binding sites `n' for compound 97-99 were found to be 
1.34, 1.28 and 1.46, respectively indicating that compound 99 has higher DNA binding 
propensity in agreement with the electronic absorption titration experiment. 
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Nuclease or cleavage activity: The DNA cleavage was controlled by the relaxation of 
supercoiled circular form of pBR322 DNA into the nicked and linear form. When a circular 
plasmid DNA is subjected to agarose gel electrophoresis, the fastest migration will be 
observed for supercoiled form (Form I). If one strand is cleaved, the supercoils will relax to 
produce a slower moving open circular form (Form II). If both strands are cleaved, a Iinear 
form (Form III) will be generated that migrates in between Form I and Form II. The DNA 
cleaving ability of compound 99 was investigated using pBR322 DNA. In the absence of an 
activator, the compound 99 cleaved double stranded supercoiled plasmid DNA (SC form: 
Form I) (300 ng) in 5 mM Tris-HCl/50 mM NaCl buffer into nicked circular form (NC form: 
Form II) after 1 h of incubation at physiological pH 7.2 at 25 °C.BG. 87 Keeping the DNA 
concentration constant (300 ng) the concentration of compound 99 was varied (1.0-5.0 pM) 
and the cleavage reaction was monitored by gel electrophoresis. The concentration-dependent 
electrophoretic cleavage pattern exhibited conversion of SC form (Form I) to NC form (Form 
II) with increase in concentration of compound 99. 
At 3 pM concentration, compound 99 exhibited efficient nuclease activity. At still 
higher concentrations there was complete conversion of SC form into NC form with the 
concurrent formation of LC form. Presence of Form I, II and III of pBR322 DNA indicated 
that compound 99 is involved in cleavage of double strand super coiled DNA (Fig. 26). 
The nuclease activity in the presence of activators viz.; MPA, GSH and H202 were 
also observed and the results showed significant enhancement in the cleavage activity. Their 
activating efficacy follows the order of GSH = H202 > MPA. To predict the mechanism of 
pBR322 plasmid DNA cleavage by compound 99, comparative reactions were carried out in 
the presence of various radical inhibitors or trappers such as singlet oxygen scavenger sodium 
azide (NaN3), hydroxyl radical scavengers viz.; dimethylsulfoxide (DMSO) tert-butyl alcohol 
(TBA) and superoxide dismutase (SOD) as superoxide anion inhibitor (Fig. 27). When the 
hydroxyl radical inhibitor DMSO and TBA were added to the reaction mixture, the nuclease 
activity was not inhibited, excluding the role of hydroxyl radical in the cleavage process. In 
the presence of radical scavengers Ike NaN3 and SOD, the cleavage was inhibited under the 
present experimental conditions. The compound 99 seems to follow the mechanistic pathway 
involving singlet oxygen and superoxide anion to generate ROS responsible for initiating 
DNA strand scission.88 
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Molecular Docking: To understand steroidal pyrimidine-DNA interaction, the molecular 
docking technique is an attractive tool to get insight of the mechanistic study, by placing a 
molecule into the binding site of the target specific region of the DNA. In our experiment, 
rigid molecular docking (two interacting molecules were treated as rigid bodies) studies were 
performed to predict the binding modes of compounds with a DNA duplex of sequence 
d(CGCAAATTTCGC)2 dodecamer (PDB ID: 1 BNA), and provide an energetically favorable 
docked structures (DNA-compound 97-99 complexes shown in Fig. 28). Compound 97-99 
are making one hydrogen bond with binding energy -266.22 Kcal, one hydrogen bond with 
binding energy -275.27 Kcal and three hydrogen bonds with binding energy -266.90 Kcal, 
respectively with DNA. The docking score of the compound 97-99 was found to be -6.0, -5.9 
and -6.2, respectively revealing the better docking of compound 99 with DNA among the 
three compounds. It is evident from the docked poses that these types of compounds get 
attached with DNA through electrostatic as well as hydrophobic interaction. The steroid 
moiety due to its stereochemical reasons remains far from the nucleotide base pairs and hence 
it is the pyrimidine moiety with groups like -NH, -CO and -NH2 which show intercalation 
between the nucleotide base pairs of DNA through hydrogen bonding. Thus binding energy 
and docking score values are consistent with the high binding constant obtained from 
spectroscopic values. 
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Fig. 24. Absorption spectra of compound 97-99 in Tris-HC1 buffer upon the addition of CT 
DNA. [Compound] = 6.67x10 M, [DNA] _ (0.70-4.24) x 10'5 M. 
Compound 98 	 Compound 99 	Compound 97 
Fig. 25. The emission spectra of compound 97-99 in Tris-HC1 buffer (pH 7.2) in the presence 
and absence of CT DNA at room temperature. 
Form III 
Form II 
Form I 
1 	2 	3 	4 	5 	6 
Fig. 26. Agarose gel electrophoresis patterns of pBR322 plasmid DNA (300 ng) cleaved by 
compound 99 (1.0-5.0 gM), after I b incubation time (concentration dependent) Lane 1: 
control; Lane 2: 1.0 11M 99 + DNA; Lane 3: 2.0 1rM 99 + DNA; Lane 4: 3.0 pM 99 + DNA. 
Lane 5: 4.0 pM 99 + DNA; Lane 6: 5.0 pM 99 + DNA, in buffer (5 mM Tris-HCU50 mM 
NaCl, pH 7.2 at 25 °C) 
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Fig. 27. Agarose gel electrophoresis pattern for the cleavage of pBR322 supercoiled DNA 
(300 ng) by compound 99 (2.0 µM) in presence of different activating agents and radical 
scavengers. Lane 1: 99 + GSH + DNA, Lane 2: 99 + MPA + DNA, Lane 3: 99 + H202 + 
DNA, Lane 4: 99 + NaN3 + DNA, Lane 5: 99 + DMSO + DNA, Lane 6: 99 + t-butyl alcohol 
+ DNA, Lane 7: 99 + SOD + DNA in buffer (5 mM Tris—HCI150 mM NaCl, pH 7.2 at 25°C) 
(a) Compound 97 	(b) Compound 98 	(c) Compound 99 
Fig. 28. Docked poses of DNA with the compound 97-99. The N, S and 0 termini of 
pyrimidine moiety of the compounds are shown as blue, yellow and red sticks, respectively. 
Work published; 
DNA binding, docking studies, artificial nuclease activity and in vitro cytotoxicity of newly 
synthesized steroidal 1H-pyrimidines, Shamsuzzaman, Ayaz Mahmood Dar, et al., Comptes 
Rendus Chimie, http://dx.doi.org/l0.1016/j.crci.2013.07.001 (in press) 
163 
DNA binding of 2'-amino-3'-carboetboxycho lest-6-eno [5, 7- d e] 4H-pyran derivatives 
(63-65) 
Gel Electrophoresis: The steroidal pyrans 63-65 (refer to chapter 2 for synthesis) were 
examined for their binding abilities with pUC19 DNA by agarose gel electrophoresis. In the 
Fig. 29, lane 1 contains DNA only, lane 2, 4, 6 contains DNA and 100 gM of compound 63-
65 and lane 3, 5, 7 contain DNA and 200 µM of compound 63-65. At low concentration, 
compound 63-65 do not show any appreciable change in the band intensity of DNA (lane 2, 
4, 6). However, at higher concentrations band intensity gets diminished in compound 63-65 
(lane 3, 5, 7). Thus electrophoretic pattern demonstrate that the compound 63-65 interact with 
DNA. The loss in the band intensity at higher concentration may be assumed due to the 
intercalation of compound 63-65 to DNA, which in turn results in the displacement of EtBr. 
In case of lane 2, 4, 6 the concentration of compounds is not sufficient for displacement of 
EtBr. This was further supported from the fluorescence quenching, which gave convincing 
evidence for strong interaction of the compounds with DNA. 
Electronic absorption titration: Absorption spectroscopy is one of the most useful 
techniques to study the mode of binding of any compound to DNA.89 Addition of increasing 
amounts of CT DNA (0.70 x 10-5 - 4.24 x 10-5 M) to steroid pyrans 64 and 65 exhibited 
variation in the intense absorption bands at 210-340 nm as shown in Fig. 30. The absorption 
spectra of compound 64 and 65 reveal strong hyperchromism implying the higher DNA 
binding propensity of steroidal pyrans. Hyperchromicity and hypochrornicity are the typical 
spectral features of DNA associated with its double helical structure. Hypochromic effect is 
attributed to the intercalative binding mode whereas hyperchromic effect is related to the 
electrostatic binding mode or to the partial uncoiling of DNA helix structure, exposing more 
bases of DNA indicative of strong binding of compounds to CT DNA.9° Moreover, 
hyperchromic effect reflects the corresponding changes in the secondary structure of DNA in 
its conformation after the compound-DNA interaction. 
To compare quantatively the effect of binding strength of compounds, the intrinsic 
binding constants Kb of the compound-DNA were determined by monitoring changes in the 
absorbance of m-i* bands with increasing concentration of CT DNA. The intrinsic binding 
constant, Kb for compound 64 and 65. were calculated from Eq. (4), through a plot of [DNA]/ 
Ca - s1 vs. [DNA], where [DNA] represents the concentration of DNA and Ca, ce and sb the 
apparent extinction coefficient (Aobj[M]), the extinction coefficient for free compound (M) 
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and the extinction coefficient for the free steroid pyran .(M) in the fully bound form, 
respectively and were found to be 5.3 x 103 and 3.7 x 103 M, respectively. 
[DNA]/ I sa - aft = [DNA]/I eb — E f + + I /Kb f Eb -- E f ] 	 (4) 
The reason for the higher binding affinity of compound 64 may be due to the presence of 
acetate group at the 3f axial position of the steroid moiety which forms additional 
intercalative force with the base pairs of DNA molecule in addition to the hydrogen bonding 
by the -NH2 of the pyran ring. 
Fluorescence spectral studies: In the absence of CT-DNA, compound 64 and 65 emit 
luminescence in Tris-HCl buffer pH 7.2 at ambient temperature, with a fluorescence 
maximum appearing at 453 and 427 nm, respectively when excited at 270 nm. Upon addition 
of increasing concentration of [DNA] (0-33.3 x 10'6 M) to the fixed amount of compound 
concentration (6.67 x 10-6 M), there was a gradual enhancement in the fluorescence intensity 
of the compounds with no apparent change in the shape and position of the emission bands 
(Fig. 31). This implies that the compounds interacted with CT-DNA due to the inaccessibility 
of the solvent water molecules to reach the hydrophobic environment inside the DNA helix, 
and the mobility of the compound is restricted at the binding site ultimately leading to 
decrease in vibrational mode of relaxation. To compare the binding affinity of compound 64 
and 65, the binding data obtained from the emission spectra was fitted in the Scatchard 
equation to acquire the binding parameters.9 ' A plot of r/Cf vs. r gave the binding constant for 
64 and 65 as 2.85 x 103 and 1.17 x 103 M'', respectively. The number of steroid pyrans 
bound per DNA (n) calculated 92 for 64 and 65 was found to be 1:53 and 1.06, respectively; 
indicating that compound 64 interacted with DNA more strongly as compared to 65. 
Molecular docking: Molecular docking is a way to understand the mechanistic study by 
placing a molecule into the binding site of the target specific region of the DNA mainly in a 
non-covalent fashion,93 which can substantiate the spectroscopic results. In our experiment, 
molecular docking studies of compound with DNA duplex of sequence 
d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA) were performed in order to predict the 
chosen binding site along with preferred orientation of the molecules inside the DNA groove. 
The intercalation between the compounds and base pairs of DNA is mainly by hydrogen 
bonding shown by the NH2 of the pyran ring. In the docked pose (Fig. 32), NH2 of the 
compound forms two hydrogen bonds with the base pairs of DNA; one hydrogen bond is 
with the 2"d nitrogen of 4 h` guanine of DNA while another hydrogen bond is with the 3H 
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nitrogen of 5 h` guanine of DNA. The resulting binding energy of docked steroid pyran DNA 
complex was found to be -339.68 KJ mol"1. Thus, we can conclude that there is a mutual 
complement between spectroscopic techniques and molecular docked model, which can be 
substantiate our spectroscopic results and at the same time provides further evidence of 
groove binding. 
1 	2 	3 	4 	5 	6 	7 
Fig. 29. Agarose gel electrophoresis of reaction mixtures containing pUC19 DNA and 
compound 63-65 Lane 1, DNA only; Lane 2, 3 DNA + compound 63 (100, 200 pM), Lane 4, 
5 DNA + compound 64 (100, 200 pM) and Lane 6, 7 DNA + compound 65 (100, 200 pM) 
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Fig. 30. Absorption spectra of compound 64 and 65 in Tris-HC1 buffer upon the addition of 
calf thymus DNA [complex] = 6.67 x 10 M, [DNA] = (0.70 - 4.24) x 10-5 M. Arrow shows 
change in intensity with increasing concentration of DNA. 
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Fig. 31. Emission spectra of compound 64 and 65 in the presence of DNA in 5 mM Tris-
HCI150 mM NaC1 buffer. Arrows show the intensity changes upon increasing concentration 
of the DNA. 
Fig. 32. Molecular docked model of steroidal pyran (yellow color) with DNA dodecamer 
duplex of sequence d(CGCGAATTCGCG)2 (PDB ID: 1BNA) and the green dashed lines 
showing hydrogen bond interaction between them. 
Work published; 
Synthesis, molecular docking and biological evaluation of new steroidal 4H-pyrans, 
Shamsuzzaman, Ayaz Mahmood Dar, et al, Spectrochimica Acta Part A: Molecular and 
Biomolecular Spectroscopy 117 (2014) 493-501 
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DNA binding of 2'-amino-3'-cyanocholest-6-eno [5, 7- d e] 4H-pyran derivatives (66-68) 
Electronic absorption titration: The covalent or non-covalent interactions are responsible 
for the binding of heterocyclic compounds with DNA. In covalent bonding, the easily leaving 
group of the compound is replaced by a nitrogen base of DNA such as guanine N7 while the 
non-covalent DNA interactions include electrostatic, intercalative and groove binding of 
heterocycles outside of a DNA helix. The absorption spectra of steroid pyrans 66-68 (refer to 
chapter 2 for synthesis) exhibited hyperchromism of 26.11%, 27.51% and 19.63%, 
respectively at intraligand absorption band (267-271 nm) as shown in Fig. 33. The observed 
hyperchromism revealed that compound 66-68 bind to CT DNA electrostatically via non-
covalent bonding with the DNA double helix. Moreover, steroid pyrans 66-68 exhibited a 
higher DNA binding profile due to the incorporation of NH2 into the DNA binding grove. 
Since the hydrogen bonding interactions between -NH2 groups of steroidal pyran and the 
functional groups positioned on the edge of DNA bases feature novelty as it provides 
molecular recognition at the specific site at the cellular target. The intrinsic binding constant 
values (Kb) of these compounds were determined by monitoring the changes in the 
absorbance at the intraligand band with increasing concentration of CT DNA. In order to 
further compare the binding strength of the compounds, their intrinsic binding constant (Kb) 
were determined from the following equation (4). 
[DNA]/ I Ea — cr I = [DNA]! I se — sp I + 1 /Kb I Er,— sr I 	 (4) 
where, [DNA] represents the concentration of DNA, Ea, sf and ab are the apparent extinction 
coefficients Aa5/[M], the extinction coefficient for free compound and the extinction 
coefficient for compound in the fully bound form, respectively. In the plots of [DNA] / ca sF 
versus [DNA], Kb is given by the ratio of the slope to the intercept. 
The binding constants Kb obtained for compound 66-68 are 1.97 x 103 M-', 5.4 x 103 M-1 and 
2.3 x 103 M', respectively. Interestingly, the intrinsic binding K1, value of compound 67 is 
higher in magnitude than other compounds. It may be due to! the additional interaction like 
hydrogen bonding by the carbonyl moiety of acetate group (OCOCH3) with DNA base pair 
which demonstrates the remarkably higher binding propensity of compound 67 towards CT 
DNA. 
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Fluorescence spectral studies: An intense luminescence at 336 nrn in 0.01 Tris-HCU50 mM 
NaC1 buffer was obtained in the emission spectra of compound 66-68 at room temperature 
when excited at 269 nm. The emission intensity to a fixed amount of compounds gradually 
increases with no apparent change in the shape and position of the emission bands (shown in 
Fig. 34) on addition of increasing concentration of CT DNA (0.70 x 10'5 to 4.24 x 10"s M). 
The enhancement in emission intensity is related to the extent to which the compound 
penetrates into the hydrophobic environment inside the DNA helix therefore compound 
mobility is restricted at the binding site leading to a decrease in the vibrational mode of 
relaxation and thus avoids the quenching effect of the solvent molecules. The increase in 
emission intensity revealed that the compound interacts by hydrophobic interaction in the 
DNA major groove. 
To compare the binding affinity of compounds to DNA quantitatively, the binding constant 
`K' and binding site number `n' were calculated by using Scatchard equation (5) and (6). 
CF=CT(F/F0 —P)(1—P) 	 (5) 
r/c=K(n—r) 	 (6) 
Where, CF is the concentration of free compound, CT is the total concentration of compound; 
F and Fo are fluorescence intensities in the presence and absence of DNA, respectively. P is 
the ratio of observed fluorescence quantum yield of the bound compound to that of the free 
compound. The value P was obtained as the intercept by extrapolating from a plot of F/Fo 
versus 1/[DNA], r denotes Cs = (C7—CF) / [DNA], `c' is the free compound concentration and 
`n' is the binding site number. 
The binding constant determined from the Scatchard equation for compound 66-68 was 
calculated to be 2.2 x 103 M-', 5.37 x 103 M"' and 2.51 x 103 M'', respectively. The number 
of binding sites `n' for compound 66-68 were found to be 0.92, 1.36 and 1.04, respectively 
indicating that compound 67 has higher DNA binding propensity in agreement with the 
electronic absorption titration experiment. 
Chemical nuclease activity: Heterocyclic compounds have played an important role in DNA 
endonucleolytic cleavage reactions. DNA cleavage is normally reflected by relaxation of the 
supercoiled circular form (Form I) of pBR322 DNA resulting in nicked circular (Form II) 
and/or linear form (Form III). The DNA cleavage ability of the compound 66-68 was 
performed on pBR322 DNA (300 ng) incubated at 310 K with increasing concentration of 
compounds (5-25 !.LM) in aqueous buffer solution (5 mM Tris-HCV50 mM NaCI, pH 7.2) for 
I h. As shown in Fig. 35, it was observed that all the three compounds are found to exhibit 
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nuclease activity at different concentration. The steroidal pyrans converted supercoiled DNA 
(Form 1) into NC DNA (Form II) without concurrent formation of form III suggesting single 
strand DNA cleavage (Lane 2-16). Compound 67 showed efficient cleavage in comparison to 
66 and 68; with increase in concentration intensified nicked form (Form II) was observed. 
DNA cleavage in presence of recognition elements: The potential interacting site of 
compounds 66-68 with pBR322 DNA were determined in presence of minor groove binding 
agent (DAPI) and the major groove binding agent, methyl green (MG). The supercoiled 
pBR322 DNA was treated with DAPI or methyl green prior to the addition of compounds. 
The cleavage reaction mediated by compound 66-68 was inhibited in presence of DAPI while 
it remained unaffected in the presence of MG (Fig. 36) indicating minor groove-binding 
preference of the compounds. 
DNA cleavage in presence of reactive oxygen species: In order to explore the mechanistic 
pathway of the cleavage activity, comparative DNA cleavage experiments of compound 66-
68 were carried out in presence of some known radical scavengers such as DMSO and ethyl 
alcohol (EtOH) as hydroxyl radical scavenger (HO'), sodium azide (NaN3) as singlet oxygen 
(1 02) quencher and superoxide dismutase (SOD) as superoxide anion radical (O.') scavenger 
were used prior to the addition of compounds to DNA solution (Fig. 37). The addition of 
DMSO (Lane 2), EtOH (Lane 3) to compound 67 diminishes the cleavage activity which is 
indicative of the involvement of hydroxyl radical in the cleavage process. In the case ofNaN3 
and SOD (Lane 4 and 5), the form II of plasmid DNA was converted to linear form III 
indicating two subsequent and proximate single strand breaks of DNA non-randomly. 
Similarly, compound 68 showed inhibition of DNA cleavage in presence of DMSO (Lane 6) 
whereas ethyl alcohol completely quench the formation of band II (Lane 7), suggestive of 
involvement of diffusible (OH) hydroxyl radicals as one of the ROS responsible for DNA 
breakage. On the other hand, addition of NaN3 and SOD did not show significant quenching 
of the cleavage revealing that singlet oxygen and superoxide anion were not involved in the 
cleavage process (Lane 8 and 9). Since, the compound 67 and 68 are able to cleave DNA in 
the absence of any reducing agent, which reveal that DNA might be cleaved by a discernible 
hydrolytic pathway. The compound 66 also showed inhibition of DNA cleavage in presence 
of DMSO (Lane 10) while as ethyl alcohol also quench the formation of band II (Lane 11), 
revealing the fact ( OH) hydroxyl radicals being responsible for DNA breakage. Since, the 
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compounds 66-68 are able to cleave DNA in the absence of any reducing agent, which 
reveals that DNA might be cleaved by a discernible hydrolytic pathway. 
T4 ligation experiment: The standard DNA relegation protocol94was followed to support the 
hydrolytic mechanism of DNA cleavage and the DNA relegation experiments were 
performed using T4 ligase enzyme. The compound 66-68 treated with pBR322 plasmid DNA 
(2 mg), ligation buffer of 1.5 mL in 10X, T4 ligase 1 mL (2 units) and 2.5 mL of H2O were 
mixed and incubated at 4 °C for 1 h. Subsequently, the samples were loaded on 1% agarose 
gel and visualized by staining with an ethidium bromide solution. To confirm the discernible 
hydrolytic DNA cleavage pathway mediated by compound 66-68, DNA relegation 
experiment was performed in which supercoiled pBR322 DNA was treated with T4 ligase 
enzyme and subjected to gel electrophoresis.95 Under present experimental conditions, the 
nicked form (Form II) was relegated to a large extent in the presence of T4 ligase enzyme in 
comparison to control DNA alone in supercoiled form (Fig. 38), providing a direct evidence 
in favour of hydrolytic mechanism. 
Molecular Docking: In our experiment, molecular docking studies of compound 66-68 with 
DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: IBNA) were 
performed in order to predict the chosen binding site along with preferred orientation of the 
molecules inside the DNA groove. The electrostatic interaction between the compounds and 
base pairs of DNA is mainly by hydrogen bonding shown by the NH2 of the pyran ring. In 
Fig. 39a, the NH2 of the compound 66 forms three _hydrogen bonds with the base pairs of 
DNA; one hydrogen bond is with the 3°a oxygen of 15'h cytosine of DNA; second with 51' 
oxygen of 16th guanidine of DNA while third hydrogen bond is with the 4" oxygen of 16th 
guanine of DNA. In the docked pose (Fig. 39b), NH2 of the compound 67 forms two 
hydrogen bonds with the base pairs of DNA; one hydrogen bond is with the 2°d oxygen of 
151h cytosine of DNA while second hydrogen bond is with the 3'h oxygen of 16" guanine of 
DNA. In Fig. 39c, the oxygen of the pyran ring of compound 68 forms one hydrogen bond 
with the first oxygen of 13'h cytosine of DNA, The resulting binding energy of docked 
[steroid 4H-pyrans (66-68)-DNAJ complexes was found to be —308.61 KJ mor', —311.34 KJ 
moi' and —301.42 KJ mol"', respectively. The more negative the relative binding, the more 
potent is the binding between DNA and target molecule. Thus, we can conclude that there is a 
mutual complement between spectroscopic techniques and molecular docked models, which 
can substantiate our spectroscopic results and at the same time provides further evidence of 
groove binding. 
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Fig. 33. Absorption spectra of steroid pyrans 66-68 in Tris—HCI buffer upon the addition of 
CT DNA [complex] = 6.67x 10-' M, [DNA] = (0.70-4.24) x 10"5 M. 
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Fig. 34. Emission spectra of compound 66-68 in Tris—HCI buffer (pH 7.2) in the presence 
and absence of CT DNA at room temperature 
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Fig. 35. Gel electrophoresis diagram showing cleavage of pBR322 supercoiled DNA (300 ng) 
by compound 66-68 at 310 K after incubation for 1 h. Lane 1: DNA control; Lane 2: 5 pM of 
67 + DNA; Lane 3: 10 pM of 67 + DNA; Lane 4: 15 µM of 67 + DNA; Lane 5: 20 µM of 67 + 
DNA; Lane 6: 25 gM of 67 + DNA; Lane 7: 5 pM of 68 + DNA; Lane 8: 10 µ1V1 of 68 + DNA; 
Lane 9: 15 µM of 68 + DNA; Lane 10: 20 µM of 68 + DNA; Lane 11: 25 pM of 68 + DNA. 
Lane 12: 5 µM of 66 + DNA; Lane 13: 10 gM of 66 + DNA; Lane 14: 15 µM of 66 + DNA; 
Lane 15: 20 µM of 66 + DNA; Lane 16: 25 µM of 66 + DNA. 
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Fig. 36. Gel electrophoresis pattern for the cleavage of pBR322 plasmid DNA (300 ng) by 
compound 66-68 in the presence of DNA minor and major groove binding agents; DAPI and 
methyl green at 310 K after incubation for 30 min. Lane 1: DNA; Lane 2: DNA+ 67 + DAFI (8 
ri M); Lane 3: DNA+ 67 + Methyl green (2.5 gL of a 0.01 mg ml-' solution); Lane 4: DNA + 68 
+ DAPI (8pM); Lane 5: DNA + 68 + Methyl green (2.5 gL of a 0.01 mg mi I sol.); Lane 6: 
DNA + 66 + DAPI (8µM); Lane 7: DNA +66+  Methyl green (2.5 .L of a 0.01 mg mI"1  sol.). 
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Fig. 37. Gel electrophoresis pattern for the cleavage pattern of pBR322 plasmid DNA (300 ng) 
by 66-68 (25 mM) in the presence of ROS at 310 K after incubation for 1 h. Lane 1, DNA 
control; Lane 2, DNA+ 67 + DMSO (0.4 µM); Lane 3, DNA+ 67 + ethyl alcohol (0.4 	; 
Lane 4, DNA+ 67 + NaN3 (0.4 µM); Lane 5, DNA+ 67 + SOD (15 Units); Lane 6, DNA +68+  
DMSO (0.4 µM); Lane 7, DNA + 68 + ethyl alcohol (0.4 pM); Lane 8, DNA + 68 + NaN3 (0.4 
"; Lane 9, DNA+ 68 + SOD (15 Units). Lane 10, DNA+ 66 + DMSO (0.4 pM); Lane 11, 
DNA + 66 + ethyl alcohol (0.4 pIvi); Lane 12, DNA + 66 + NaN3 (0.4 pM); Lane 13, DNA + 
66 + SOD (15 Units). 
1 	2 	3 	4 	5 	6 	7 
Fig. 38. Gel electrophoresis pattern for the pBR322 plasmid DNA ligation, linearized by 
compound 66-68; Lane 1, DNA control; Lane 2, pBR322 plasmid DNA cleaved by 66; Lane 
3, ligation of nicked pBR322 plasmid DNA by T4 DNA ligase, Lane 4, pBR322 plasmid 
DNA cleaved by 67, Lane 5, ligation of nicked pBR322 plasmid DNA by T4 DNA ligase. 
Lane 6, pBR322 plasmid DNA cleaved by 68, Lane 7, ligation of nicked pBR322 DNA by 
T4 DNA ligase. 
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Fig. 39. Molecular docked models of steroidal pyrans 66-68 (purple colour) and docked pose 
(A) showing the general intercalation of compounds with DNA dodecamer duplex of 
sequence d(CGCGAATTCGCG)2 (PDB ID: 1BNA) and the yellow dashed lines showing 
hydrogen bond interaction. 
Work published; 
Synthesis and biological studies of steroidal pyran based derivatives, Shamsuzzaman, Ayaz 
Mahmood Dar, et al., Journal of Photochemistry and Photobiology B: Biology 129 (2013) 
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H I G H L I G HTS 
-A synthesis of new series of steroidal pyrimidines has been performed. 
. The interaction of compounds with DNA were evaluated by [1V-vis and fluorescence spectroscopy. 
-The interaction of compounds with DNA was also carried out with Gel electrophoresis and docking studies. 
. The K values for compounds 7-9 indicate higher binding affinity of compounds towards DNA. 
. The new compounds were tested for in vitro cytotoxicity against different cancer and non-cancer cells, 
ARTICLE 	INFO ABSTRACT 
Article history: A series of new steroid pyrimidines (7-9) were synthesized by reacting steroidal thiosernicarbazones (4- 
Received 24 December 2012 6) with diethyl malonate. The new compounds were characterized by 18. 'H NMR, "C NMR. MS and aria- 
Received in revised form 8 April 2013 lyrical data. The interaction studies of compounds (7-9) with DNA were carried out by employing gel Accepted 8 April 2013 electrophoresis, W-vis and fluorescence spectroscopy. The acting force between the compounds (7-9) Available online 23 April 2013 and DNA was mainly hydrophobic while the other interactions like van der Waals, hydrogen bonding 
cannot be ruled out. The gel electrophoresis pattern also demonstrated that the compound 7 alone or Keywords: in presence of Cu (1I) causes the nicking of supercoiled pBR322 and it seems to follow the mechanistic 
uv-vl
dine 
UV-vis pathway involving generation of hydroxyl radicals that are responsible for initiating DNA strand scission. 
Fluorescence The docking study of compounds (7-9) suggested that the intercalation of compounds in between the 
Gel electrophoresis nucleotide base pairs might be due to the presence of pyrimidine moiety in steroid molecule. MT T assay 
Cytotoxicity was carried out to check the toxicity of new compounds (7-9) against the different human cancer as well 
as non-cancer cell lines A545, MCC'-7. HeLa, HL-60. SW480, HepG2, HT-29, A549, 1$4B5, MCF70A, NL-20, 
HPC and HPLF. Apoptotic degradation of DNA in presence of steroidal pyrimidines (7-9) was analyzed by 
agarose gel electrophoresis and visualized by ethidium bromide staining (comet assay). 
0 2013 Elsevier B.V. All rights reserved. 
1. Introduction 
Heterosteroids have been accredited with a great amount of 
attention over the years by medicinal chemists for drug discovery. 
The interesting structural and stereochemical features of the 
steroid nucleus provide additional fascination to the researchers. 
and thereby alterations in the steroidal skeleton have been envis-
aged to discover new chemical entities with a potential to afford 
some promising drugs of the future. The incorporation of a hetero-
cyclic ring or a heteroatom in the steroid backbone affects the 
chemical properties of a steroid and often results in useful 
Corresponding author. Tel.: +91 9411003465. 
E-mail address: shamsuzzaman90gmaii.com ( Shamsuzzaman). 
0022-2850J5 - see front matter 0 2013 Elsevier BY. All rights reserved. 
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alterations in its biological activities [1]. Therefore, researchers 
are on a continuous pursuit to design and produce better heteros-
teroids, by following natural models. 
From last few years, numerous molecules possessing pyrimi-
dine moiety have been reported to exhibit a broad spectrum of bio-
Iogical activities such as anticancer [2,3], antiviral [4], antibacterial 
]5], antioxidant [6,7], anxiolytic [8] and antidepressant [9]. Fur-
thermore, they possess anti-inflammatory [10] and analgesic activ-
ities which are well documented in the literature [11.12]. Besides 
this, pyrimidine derivatives have been explored for use as hista-
mine and adenosine receptor antagonists as well as among several 
other biological receptors and modulators [13,14]. 
In the field of molecular biology and drug development, the 
cleaving agents of nucleic acid have attracted extensive attention 
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ABSTRACT 
A new series of steroidal pyrimidines (7-9) has been synthesized by reacting steroidal 
thiosernicacbazones (4-6) with ethyl cyanoacetate. The compounds were characterized by 
IR,'H NMR, 13C NMR. MS and analytical data. The interaction studies of compounds 7-9 
with DNA were carried out by UV-vis and luminescence spectroscopy. Compounds (7-9) 
bind to DNA preferentially through electrostatic and hydrophobic interactions, with Kb 
values found to be 6.56 x 103 M-', I.54 x 104M and 934 x I Oa M-1. respectively, 
indicating the higher binding affinity of compound 8 towards DNA. Gel electrophoresis 
pattern demonstrated that compound 8 shows strong interaction with DNA and that, 
during its cleavage activity with pBR322 DNA, it seems to fallow the mechanistic pathway 
involving the generation of singlet oxygen and a superoxide anion, which are responsible 
for initiating DNA strand scission. The docking study suggested that the intercalation of 
compounds in between the nucleotide base pairs is due to the presence of a pyrimidine 
moiety in the steroid molecule. MlT assay was carried out to check the toxicity of new 
compounds 7-9 against the different human cancer as well as non-cancer cell lines A545, 
MCF-7, HeLa, HL-60, 5W480, HepG2, HT-29, A549,184B5, MCFI OA, NL-20, HPC. and HP F. 
Apoptotic degradation of DNA in the presence of steroidal pyrimidines 7-9 was analysed 
by agarose gel electrophoresis and visualized by ethidium bromide staining (comet assay). 
® 2013 Academie des sciences. Published by Elsevier Masson SAS. All rights reserved. 
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1. Introduction 
Steroids have been the focus of important research 
throughout the scientific history. But the recent past has 
seen an exhaustive interest of research being diverted 
towards these biologically important molecules. It is 
probably because of the various advantages associated 
with steroid-based chemotherapeutics, as these corn- 
Corresponding author. 
E-mail address: sharnsuzzaman9Fgnmil.com (Shamsuzzaman).  
pounds turn out to be non-toxic, less vulnerable to 
multidrug resistance and highly bioavailable because they 
are capable of penetrating the cell wall [1]. AIthough 
various modifications of steroids, including derivatization, 
cyclization, lieterocyclization, etc., have been tried, as far 
as the literature precedents are concerned, little efforts 
have been made towards the efficient synthesis of steroidal 
based pyrimidines derivatives and simultaneous studies of 
in vitro DNA binding or of nuclease. 
Pyrimidine moiety containing molecules have been 
shown to exhibit a broad spectrum of biological activities 
like anticancer [2,3], antiviral [4], antibacterial [5], 
1631-0748/5 — see front matter ® 2013 Academie des sciences. Published by Elsevier Masson SAS, All rights reserved. 
h ttp: j Jdx. d o l.0 rg!l O.l 016ll.erci.2 o f 3.07.001 
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j.crci.2013.07.001 
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GRAPH] CAL ABSTRACT 
A convenient synthesis of new series of steroidal 4H-pyrans has been performed. After characterization, 
the interaction of compounds 4 and 5 with DNA was evaluated by gel electrophoresis, docking studies 
and UV-vis and fluorescence spectroscopy. MIT assay and comet assay has been performed to check 
the in vitro cytotoxicity of new compounds. 
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HIGHLIGHTS 
• A convenient synthesis of new series 
of steroidal 4H-pyrans has been 
performed. 
• The interaction of compounds 4 and 5 
with DNA was evaluated by different 
biophysical techniques. 
.The K values for compounds 4 and 5 
indicate their higher binding affinity 
towards DNA. 
x 
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d (2) 
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ARTICLE INFO 	ABSTRACT 
Article hisrory: A series of new steroidal 4H-pyran5 (4-6) have been synthesized from steroidal a, n-unsaturated ketones 
Received 25 May 2013 (1-3). The products (4-6) were characterized by IR. 1H NMR. 13C NMR. MS and analytical data. The inter- 
Received in revised form 27 July 2013 action studies of compounds (4-6) with DNA were carried out by employing gel electrophoresis, UV-vis 
Accepted 3 August 2013 
Available online 16 August 2013 and fluorescence spectroscopy. The gel electrophoresis pattern revealed that compounds (4-6) bind to DNA and also demonstrated that the compound 6 alone or in presence of Cu (11) causes the nicking of 
supercoiled pBR322. The compounds 4 and 5 bind to DNA preferentially through electrostatic and hydro- 
Keywords: phobic interactions with Ke values found to be 5.3 x 103 and 3.7 x 103 M-', respectively, indicating the 4H
-pin 
Ethylcyapoacetate  
higher binding affinity of compound 4 towards DNA. The docking study suggested the intercalation of 
Anticancer compounds in between the nucleotide base pairs. The cytotoxicity and genotoxicity of the newly synthe- 
Docking sized compounds were checked by MTT and comet assay, respectively during which compound 6 showed 
Comet assay potential behaviour. 
© 2013 Elsevier B.V. All rights reserved. 
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ARTICLE INFO 	 ABSTRACT 
Steroid based cancer chemotherapeutic agents of the type 2'-amino-3'-cyanocholest-6-eno[5,7-de]4H-
pyrans (lc-3e) have been synthesized and characterized by the various spectroscopic and analytical 
techniques. The DNA binding studies of compounds (lc-3c) with Cr DNA were carried out by UV-vis 
and fluorescence spectroscopy and gel electrophoresis. The compounds (11c-3c) bind to DNA preferen-
tially through electrostatic and hydrophobic interactions with Kb values found to be 5.4 x 103, 
2.3 x 103 M-t and 1.97 x 103 M-'. respectively indicating the higher binding affinity of compound (1c) 
towards DNA. The molecular docking study suggested that the electrostatic interaction of compounds 
(lc-3c) in between the nucleotide base pairs is due to the presence of pyran moiety in steroid molecule. 
All the compounds (lc-3c) cleave supercoiled pBR322 DNA via hydrolytic pathway, as validated by 14 
DNA ligase assay. The compounds (lc-3c) were screened for in vitro cytotoxicity against the cancer 
and non-cancer cells 5W480. A549. HepG2, HeLa, MCF-7, HL-60. DU-145, NL-20, HPC and HPLF by MTT 
assay. The compounds (lc-3c) were tested for genotoxicity (comet assay) involving apoptotic degrada-
tion of DNA and was analyzed by agarose gel electrophoresis and visualized by ethidium bromide stain-
ing. The results revealed that compound (1c) has better prospectus to act as cancer chemotherapeutic 
candidate which warrants further in vivo anticancer investigations. 
v 2013 Elsevier 13.V. All rights reserved. 
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1. Introduction 
Steroids are a class of important polycyclic compounds which 
exhibit diverse biological activities. Except for the naturally occur-
ring substances, most of steroidal pharmaceuticals are semi-syn-
thetic compounds [1]. Several steroidal derivatives have been 
investigated as new curative agents for cancers and other diseases. 
It is proved that a number of biologically important properties of 
modified steroids are dependent upon structural features of the 
steroid ring system or side chain so this chemical modification of 
the steroid provides a way to alter the functional groups and 
numerous structure-activity relationships have been established 
by such synthetic alterations [2]. 
Pyran derivatives are of considerable interest in industry as well 
as in academia owing to their potential biological and medicinal 
activities, such as analgesic, anticancer, anti-inflammatory. 
antibacterial and also serve as potential inhibitors of human Chk-
1 kinase (Fig. 1) [3]. Furthermore, the applications of pyran deriv-
atives are not only found in pharmaceutical ingredients and biolog-
ical agrochemicais [4] but they also constitute a structural unit of 
number of natural products [5]. 
Corresponding author. Tel,: +91 9411003465. 
E-mail address: shamsuzzaman9@gmail.com (Shamsuzzaman). 
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DNA cleaving agents have attracted extensive attention in the 
field of molecular biology due to their potential applications ]6]. 
Under uncatalyzed physiological conditions, the phosphodiester 
bonds of DNA are extremely stable and the half life of DNA hydro-
lysis is estimated to be around 200 million years [7[. Some of the 
metal complexes have been widely investigated as efficient cleav-
ing agents of nucleic acids [8] but the serious issues over their 
]ability and toxicity restricted the practical usage of these com-
pounds in pharmacy [9]. To overcome these limitations, Gobel 
and co-workers [ 10] put forward the concept of 'metal free cleav-
ing agents' which are being applied to active phosphodiesters like 
'nucleic acid mimic' and RNA. 
Although various modifications of steroids have been tried 
including derivatization, cyclization, and heterocyclization, very 
few efforts have been made towards the efficient synthesis and 
the study of DNA binding, cleavage, cytotoxic and genotoxic activ-
ity of steroid based 4H-pyrans. So in continuation of our previous 
work [11 ] herein, we report the synthesis of new steroidal 4H-pyr-
ans as metal free DNA binding agents. The presence of —NH and 
—CO groups in the molecules can cooperatively participate in the 
interaction with DNA via hydrogen bonding. A computer aided 
molecular docking study was carried out to validate the specific 
binding mode of the compounds. Furthermore, these compounds 
JTUSCI39;_No.ofPagesl5_,_.~.. 	~' ' r 	i ie I  
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Abstract 
A convenient synthesis of a new series of nano steroidal pyrazolones is reported. They were characterized by X-ray diffraction, 
scanning electron microscopy, UV—vis light, Fourier transform-infrared spectroscopy, tH and 13C nuclear magnetic resonance, 
mass spectroscopy and analytical data. The X-ray diffraction patterns at room temperature showed that two nano steroids, 7 and 8, 
are formed in single phase with hexagonal crystal symmetry, while nano steroid 9 is formed with orthorhombic crystal symmetry. 
Compounds 1-3 are forted withhexagonal, monoclinic and tetragonal crystal symmetry, respectively. Scanning electron microscopy 
showed that the crystals of nano steroids 7-9 are brick-shaped agglomerates with less sharp edges and a rough surface with a few 
microcrystals, while the homogeneous crystal of nano steroid 3 has an approximate spherical morphology of nano particles conjoined 
to the chains. UV—vis absorption analysis showed that the band gap energy of nano steroids 7 and 8 was 3.70 eV and 4.61 eV, while 
that of 2 and 3 was 4.38 eV and 4.27 eV, respectively. Nano steroids 2,3 and 7-9 were screened for antimicrobial activity against 
various strains; nano compound 7 showed potential antimicrobial activity. 
® 2013 Taibah University. Production and hosting by Elsevier B.V. All rights reserved. 
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1. Introduction 
Self-assembly of organic compounds with cholesterol 
groups has proved to be an attractive field in nanotech-
nology research. Some steroid derivatives are known to 
form ordered structures, whichindicate thermotropic and 
lyotropic liquid crystalline, monolayers, multilayers and 
micelles [1]. As steroids are important constituents of 
most eukaroytic cell membranes, a great deal is known 
about certain aspects of their function. In model sys-
tems, cholesterol is distributed evenly on both sides of 
the bilayer, with its polar hydroxyl group held in the 
vicinity of the phosphate groups of phospholipids [2,3 J. 
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KEYWORDS 	 Abstract A series of new 5a-cholestano [5,6-b] benzothiazines (4-6) has been synthesized by the 
Benzothiazine; reaction of 5x-cholestan-6-one (1-3) with 2-aminothiophenol in the presence of iodine. The struc- 
5a-Cholestan-6-one; 	 tures of newly synthesized compounds have been established on the basis of spectral and analytical 
Antibacterial; 	 data. Compounds (1-6) were screened for in vitro anticancer activity against the human cancer cell 
Antifungal; lines; SW480 (colon adenocarcinoma cells), A549 (lung carcinoma cells), HepG2 (hepatic carci- 
Anticancer 	 noma cells) and HeLa (cervical cancer cells) using MTT assay during which the products (4-6) 
showed marked increase in anticancer activity and in particular, compound 6 showed 
IC sp = 13.73 iimol L-' against HeLa cells, being more effective than Doxorubicin against the same 
cells. Compounds 4 and 6 also showed minimum ICSO of 15.83 itmol L-t and 16.89 pmol L-1 
against HepG2 and A549 cells, respectively. Compounds (1-6) were also tested for in vitro antimi-
crobial activity against different bacterial as well as fungal strains during which newly synthesized 
compounds (4-6) were found more potent than starting compounds (1-3). Compound 4 was found 
to be more potent than the reference drug, Chloramphenicol, in the case of Escherichia coli while 
compound 5 was found almost equally potential antifungal agent against P. marneffei in compar-
ison with the reference drug, Nystatin. 
© 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. 
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1. Introduction 
Steroids have been the important focus of research throughout 
the scientific history. But the recent past has seen an exhaustive 
focus of research being diverted towards these biologically 
important molecules. This is pertinently true of the rational 
semi-synthetic modifications of steroidal molecules. Probably, 
it is because of the various advantages associated with steroid 
based chemotherapeutics. These compounds turn out to be 
non-toxic, less vulnerable to multi-drug resistance (MDR) 
1878-5352 © 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. 
http://dx.doi.org/IG.IO16/j.arabjc.20 13.06.027 
Please cite this article in press as Shamsuzzaman, et al., Anticancer and -antimicrobial 'evaluation of newly. synthesized steroidal 
5,6 fused benzothiazines. Arabian Journal of Chemistry (2013); http://dx doi.orgl10 1016/j.arabic 2013,06'027 
Med Chem Res 	 MEDICINAL CHEMISTRY DOI 14.1007/s00044-013-0636-y 	 ~5EAR1"Y 
ORI'GiNAL RESEARCH 
Synthesis, evaluation and docking studies on steroidal pyrazolones 
as anticancer and antimicrobial agents 
Shamsuzzantan • Ashraf Mashrai • Anis Ahmad 
Ayaz Mahmood Dar • Hena Khanam '  
Mohd Danishuddin • Asad U. Khan 
Received: 15 February 2013/Accepted: 20 May 2013 
O Springer Science+Business Media New York 2013 
Abstract A series of new steroidal pyrazolones have been 
synthesized, characterised and evaluated for their in vitro 
anticancer activity. They were tested against five cancer 
(SW480, HepG2, A549, HeLa and HL-60) cell lines. The 
synthesized compounds showed high selectivity and com-
pound 4 showed the strongest inhibitory activity against 
human SW480 (ICso = 11.67 µmol L— '). In addition, the 
synthesized compounds were tested for their antimicrobial 
activity by disc diffusion assay and MIC by broth micro 
dilution method against Gram-positive, Gram-negative 
strains of bacteria as well as fungus strains and we found a 
correlation between the observed and predicted antimicro-
bial activities. Docking studies were performed to investi-
gate the hypothetical binding mode of the target compounds. 
This study provided a new molecular scaffold for the further 
development of anticancer as well as antimicrobial agents. 
Keywords Steroid - Pyrazolone - Anticancer 
Antimicrobial. Docking 
Introduction 
Steroids attract much attention in cell biology and patho-
physiology because of the wide range of biological 
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phenomena in which they are involved (Vejux and Lizard, 
2009). The involvement of steroids in anticancer promotion 
and suppression has been known for a long time. This 
involvement goes far beyond the steroidal sex hormones 
(Salvador at al., 2013). Many anticancer steroids are 
enzyme inhibitors, such as aromatase and sulfatase inhib-
itors for breast cancer, 5 a-reductase inhibitors for the 
treatment of benign prostatic hyperplasia and CYP 17 
inhibitors for advanced prostate cancer therapy (Handratta 
er al., 2005). A variety of steroids with unusual and 
interesting structures have been synthesized and evaluated 
for their antitumor activity (Krstic'a et al., 2007; Poza 
et al., 2007; Bansal and Guleria, 2008; Koutsourea et al., 
2008; Thibeault et at., 2008). Among these steroids, 
nitrogen containing steroid derivatives have been shown to 
be more potent and have been used clinically for the 
treatment of cancer (Guarna et al., 1999; Ling et al., 1997). 
Among all the numerous antibiotics developed to date, few 
compounds possessing a steroid nucleus have been studied 
and the results clearly showed that these compounds 
exhibited a good antibacterial activity against several 
human pathogenic bacteria (Jayasinghe at al., 1998; Atta 
at al-, 1998). The potent mechanism of action of these 
compounds described by the interactions of amine groups 
with the negative phosphate groups of LPS displacing 
divalent cations such as Cat+ and Mg2 (Nikaido, 1996; 
Vaara. 1993). Pyrazolones are important structural cores in 
many drug substances of medicinal fields. Heterocyclic 
nucleus containing pyrazolones are useful antipyretic and 
analgesic drugs (Himly at al., 2003), whilst edaravone 
(MCI-186) has been used for treating the brain (Kawai 
at al., 1997) and myocardial ischemia (Wu et al., 2002). In 
addition, pyrazolones possess kinase inhibitory properties, 
particularly of enzymes which catalyze the phosphoryla-
tion of serine and threonine in proteins and also used for 
Published online: 31 May 2013 ] Springer 
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KEYWORDS 	 Abstract A convenient synthesis of 2'-(2",4"-dinitrophenyl)-Sa-cholestano [5,7-c dJ pyrazolines 4-6 
Cholest-5-en-7-one; 	 from cholest-5-en-7-one 1-3 was performed and structural assignment of the products was confirmed 
2.4-Dinitrophenylhydrazine; 	on the basis of IR,'H NMR, 13C NMR, MS and analytical data. The synthesized compounds were 
Pyrazoline; 	 screened for in vitro antimicrobial activity against different strains during which compound 6 showed 
Antimicrobial; potent antimicrobial behaviour against Corynebacteriwn xerosis and Staphylococcus epidermidrs. 
Anticancer 	 The synthesized compounds were also screened for in vitro anticancer activity against human cancer 
cell lines during which compound 5 exhibited significant anticancer activity. 
© 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved. 
1. Introduction 
In the last few decades there has been an extensive focus of re-
search towards the rational modification of steroid molecules. 
This is due to the fact that such type of compounds are less 
toxic, less vulnerable to multi-drug resistance (MDR) and 
highly bioavailable because of being capable of penetrating 
the cell wall. Recent studies reveal that incorporation of het-
eroatom (NCO/S) enhances the biological activities of steroid 
molecules. This is proved by various activities shown by these 
systems like antimicrobial. anti-inflammatory, hypotensive, 
hypocholesterolemic and diuretic activities (Manson et al., 
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1963; Hirschmann et al., (963, 1964; Wang et al., 1993; Gupta 
et al.. 1996). As a result, a number of different heterocyclic sys-
tems have been introduced into the core structure of steroids 
with pyrazoles, pyrazolines, isoxazoles, isoxazolines, thiazoles. 
thiadiazoles, pyridines, pyrimidines, imidazoles, etc. as the 
notable ones. Among these heterocycles, pyrazolines occupy 
a unique place in the realm of natural and synthetic organic 
chemistry (Jung et al., 2005). 
Pyrazoline derivatives are synthetic targets of utmost 
importance for the researchers, since such type of compounds 
have a wide range of biological and pharmaceutical properties 
such as analgesic, antipyretic and antiandrogenic activities 
(Jung et al., 2005; Amr et al., 2005). Pyrazolines also possess 
antidepressant, anti-inflammatory and antirheumatic activities 
(Palaska et al., 2001; Bansal et al., 2001). Besides this pyrazo-
lines are also used as potent antidiabetic agents (Villhauer 
et al., 2002; Ahn et al., 2004). Recently, pyrazolines were re-
ported as a DP-IV inhibitors and antitumor agents (Amr, 
2000; Hammam et al., 2000; 2003). 
1319-6103 © 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved. 
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KEYWORDS 	 Abstract In the present study steroidal derivatives, 3 [3-[5'-rnercapto-1',3',4'-oxadiazole-2-yl]methoxy 
Hydrazide cholest-5-ene 2, 30-[2',5'-dimethylpyrrole-1-yl]axninoc-arbonylntethoxycholest-5•ene 3 and 3I -[3',5'- 
Oxudiazole; 	 dimethyl pyrazole-l-yl]carbonylmethoxycholest-5-ene 4 have been synthesized from cholest-5-en- 
Pyrrole; 3--O-acetyl hydrazide 1 using CS2JKOH, acetonyl acetone and acetyl acetone, respectively as 
Pyrazole; 	 reagents and are characterized by IR, 1 H NMR,11C NMR, MS and elemental analysis. Compounds 
Anticancer; 2-4 were also evaluated for anticancer activity against human leukemia cell line (HL-60) by MTT 
M~ 	y 	 assay and compound 4 displayed the promising behavior by showing better anticancer activity. 
O 2012 King Saud University. Production and hosting by Elsevier aN. All rights reserved, 
1. Introduction 
1,3,4-Oxadiazc les, pyrroles, pyrazoles and their derivatives rep-
resent an important class of heterocyclic compounds with 
broad spectrum of biological activity. 1,3,4-Oxadiazoles have 
been reported to possess insecticidal (Zheag et al., 2003), herbi-
cidal (Chavan et al., 2006), antibacterial (Shivarama Hollaa 
et al., 2000), antifungal (Liu et al., 2008), analgesic (Narayana 
et al., 2005), anti-inflammatory (Koksal et al., 2008), antimalar-
ial (Zareef et al., 2007a), antiviral (Farghaly and El-Kashef, 
2006), anti-HBV (El-Essawy et al., 2007), antianxiety (Amr 
et al., 2008), anticancer (Kumar et al., 2008), anti-HIV (Zareef 
et al., 2007b), antitubercular (Macaev et al., 2005) and anticon-
vulsant activities (Zarghi et al., 2005). Substituted pyrroles have 
been used as intermediates in the synthesis of mitomycin anti- 
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tumor antibiotics possessing antibacterial activity (De Leon 
and Ganem, 1997; Gilchrist, 1998; Luly and Rapoport, 1983). 
Functionalized pyrroles are building blocks of natural tetrapyr-
role pigments (Dutton et al., 1983) such as porpbobilinogen or 
bilirubin and various other natural products and their analogs 
(Shen et al., 1993). PyrazoIes and their derivatives are of much 
importance on account of their use in therapy in different dis-
eases (El-Hawash et al., 2006; Salgin-Goksen et al., 2007; Savel-
li and Alessandro, 1996). They are also reported to possess 
antibacterial (Abdallah et al., 20(35), fungicidal (Devasia 
et al., 2006), antidiuretic (Vicini et al., 2002), anticancer (Ros-
tom, 2006; Ibrahim et al., 2007), anti-HIV (Rida et al., 2005; 
Salib, 2008), antitumor (Salgin-Goksen et al., 2007), analge-
sic-anti-inflammatory (Gulcan et al., 2003; Onkol et al., 2008) 
and anticonvulsant (Onkol et al., 2004) properties. This gave 
a great impetus to the search for potential pharmacologically 
active drugs carrying such moieties. 
Taking into consideration the existing cancer therapies, 
chemotherapy has turned out to be one of the most significant 
treatments in cancer management (Harrison et al., 2009). The 
natural product based drugs, Paclitaxel and Docetaxel, are 
extensively used in the treatment of a wide variety of cancers 
1319-6103 O 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved. 
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A preparation of new series of 2'-hydrazinocholest-6-eno [4, 5-d] thiazoles 4-6 from 5a-cholestan-6-one 1-3 is herein reported. 
After characterization by IR, H NMR,' }C NMR, MS, and analytical data, the synthesized compounds 4-6 were tested for anticancer 
activity in vitro against the human cancer cell lines A549, HepG2, HeLa, SW480, and HL-60 by MTT as well as sulforhodarnine 
B assay during which compounds 4-6 showed significant anticancer behaviour. The gel electrophoresis pattern demonstrated that 
the compound 4 alone or in presence of Cu (1I) causes the nicking of supercoiled pBR322. Further the compound 4 is also able to 
generate reactive oxygen species (hydroxyl radical) in a dose-dependent manner, which correlates its ability to cause DNA breakage. 
1. Introduction 
Steroids have always attracted considerable attention because 
of being a fundamental class of biologically signalling 
molecules. In addition to their profound physiological and 
clinical importance [1], they have the potential to be devel-
oped as drugs for the treatment of a large number of diseases 
including cardiovascular, autoimmune, and brain tumours, 
breast cancer, prostate cancer, and osteoarthritis [2-4]. 
Most of the steroid-based pharmaceuticals are semisynthetic 
compounds prepared by connecting a special functionality 
to the core structure of a steroid [5]. Most important of 
such functionalities are the heterocyclic systems because 
of their potent receptor binding properties. The advantage 
of employing hydrophobic steroid units is their ability to 
interact with cell membranes and thus pave the way for 
biological activity of such hybrid molecules [4]. 
Ihiazoles and their derivatives have attracted continuing 
interest over the years because of their varied biological 
activities. They have been reported as antiallergic [6], anti-
hypertensive [7], anti-inflammatory [8], antischizophrenic 
191, antibacterial [10], anti-HIV [11], hypnotics [12], and 
selective COX-2 inhibitors [13], fibrinogen receptor antago-
nists with antithrombotic activity [ 14], and new inhibitors of 
bacterial DNA gyrase B [15]. The substituted thiazoles have 
a number of other characteristic pharmacological features 
such as relative stability and ease of starting materials built 
in biocidal unit, enhanced lipid solubility with hydrophilicity, 
and easy metabolism of compounds [16]. 
In view of the pharmacological importance of heteros-
teroids particularly thiazoles and in continuation of our 
previous work on developing new bioactive modified steroids 
with heterocyclic moiety attached at ring B of tetracyclic 
core [ 17-19], our aim here is to synthesize the new steroid 
derivatives with a substituted thiazole ring attached at ring 
B of tetracyclic core and to study their in vitro anticancer 
activity, 
2. Experimental 
2.1. Materials and Instruments; All the reagents and solvents 
were obtained from the best known commercial sources 
and were freshly distilled. Melting points were determined 
on a Kofler apparatus and are uncorrected. The IR spectra 
were recorded on KBr pellets with Pye Unicam SP3-100 
spectrophotometer and values are given in cm'. 1H and 
13C NMR spectra were run in CDC13 on a JEOL Eclipse 
